gamma-aminobutyric acid has been researched along with Neuralgia in 582 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to explore the efficacy and feasibility of cognitive behavioral therapy (CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of messenger RNA (mRNA) expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients." | 9.41 | Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. ( Bajaj, M; Banerjee, A; Banerjee, BD; Bhardwaj, N; Chilkoti, GT; Malik, A; Saxena, AK; Singal, A; Thakur, GK, 2021) |
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 9.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| " Neuropathic pain (NP) may facilitate ED, because it is frequently associated with anxiety, depression, and its drug, pregabalin, may also contribute ED." | 9.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The objective of this study was to determine whether pregabalin treatment for patients with neuropathic pain promotes erectile dysfunction." | 9.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The purpose of this study was to evaluate the therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis." | 9.19 | Therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis. ( Arai, I; Fukuda, H; Ichiji, K; Kaga, T; Kayama, S; Konno, S; Takahashi, N, 2014) |
| "The objective of this study was to evaluate the effect of pregabalin in painful cervical or lumbosacral radiculopathy treated in Primary Care settings under routine clinical practice." | 9.14 | Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. ( Masramón, X; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2010) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 9.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 9.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 9.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 9.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 9.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years." | 9.10 | Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. ( Beck, M; Birklein, F; Kim, KS; Krummenauer, F; Kutschke, G; Mengel, E; Ries, M, 2003) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 9.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "The aim of this systematic review was to determine the efficacy of gabapentin (GBP) in the treatment of pain of idiopathic trigeminal neuralgia (TN)." | 9.01 | Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials. ( Ariyawardana, A; Dinh, HQ; Lin, S; Nguyen, K; Ong, YL; Ta, PCP, 2019) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 8.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "Data from the MEDLINE database were searched using algorithms to identify relevant economic evaluations published in English or Spanish on pregabalin for the management of neuropathic pain, generalized anxiety disorder (GAD), and epilepsy in Spanish patients over the last 10 years." | 8.90 | Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. ( Álvarez, E; Darbà, J; Kaskens, L; Navarro-Artieda, R; Pérez, C; Sicras-Mainar, A, 2014) |
| "The majority of published evidence supports the possibility that pregabalin could be a cost-effective and/or cost-saving alternative for the treatment of refractory epilepsy, GAD, and neuropathic pain, in both treatment-naïve patients and in those who have demonstrated inadequate response or intolerance to previous therapy." | 8.90 | Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. ( Álvarez, E; Darbà, J; Kaskens, L; Navarro-Artieda, R; Pérez, C; Sicras-Mainar, A, 2014) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 8.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "The US Food and Drug Administration (FDA) approved pregabalin in December 2004 for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia." | 8.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| " The search terms included pregabalin, Lyrica, S-(+)-3 isobutyl-gaba, PN, DPN, diabetic peripheral neuropathy, PHN, postherpetic neuralgia, partial seizures, epilepsy, generalized anxiety disorder, and CI-1008." | 8.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| "Pregabalin appears to be an effective therapy in patients with diabetic peripheral neuropathy, postherpetic neuralgia, and adults with refractory partial-onset seizures." | 8.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin and pregabalin are efficacious treatments for neuropathic and postsurgical pain." | 8.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 8.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 8.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 8.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 8.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 8.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "In a 5-year follow-up study in a hospital in southern China, it was shown that intervertebral foramen (IVF) injection of ozone at the involved segmental levels could significantly alleviate paroxysmal spontaneous pain and mechanical allodynia in patients with chronic, intractable postherpetic neuralgia (PHN) and improve the quality of life." | 7.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "(1) IVF injection of ozone at L4-5 was only effective in suppression of mechanical allodynia in rats with neuropathic pain but not with inflammatory pain; (2) the analgesic effects of IVF ozone lasted much longer (> 14 days) than other selective molecular target drugs (< 48 hours) inhibiting or antagonizing at Nav1." | 7.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| " The effects of genistein were compared with those of gabapentin, which is widely used in clinical practice for peripheral nerve injury." | 7.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Genistein and gabapentin exhibit positive effects on histopathology, inflammation, and clinical findings of peripheral nerve injury." | 7.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Topical application of gabapentin gel ipsilaterally but not contralaterally alleviated CCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodynia (days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action." | 7.85 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Pregabalin was mainly used as a second-line drug for the treatment of GAD or neuropathic pain and to a lesser extent as add-on therapy in epilepsy." | 7.80 | Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. ( Bodén, R; Brandt, L; Kieler, H; Wettermark, B, 2014) |
| "This paper aimed to discuss the curative effect and safety of curing intercostal neuralgia through paravertebral nerve block combined with pregabalin." | 7.80 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| "A 28-year-old female patient developed an increased temperature and neuropsychiatric symptoms after receiving 75 mg pregabalin therapy for neuralgia." | 7.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Clinicians should be alert to the serious neuropsychiatric symptoms and thrombocytopenia associated with the use of pregabalin." | 7.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Nonsteroidal anti-inflammatory drug and pregabalin combination therapy may result in a lower incidence of spinal surgery during the first year of treatment or a delayed period before undergoing spinal surgery if necessary compared with nonsteroidal anti-inflammatory drug monotherapy in patients with leg symptoms caused by lumbar spinal stenosis." | 7.80 | One-year follow-up for the therapeutic efficacy of pregabalin in patients with leg symptoms caused by lumbar spinal stenosis. ( Arai, I; Fukuda, H; Ichiji, K; Kayama, S; Konno, S; Takahashi, N, 2014) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 7.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 7.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 7.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To report a case of paraplegia with limb edema caused by pregabalin." | 7.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Pregabalin, which is one of medications used for neuropathic pain, might cause limb edema, that is, a condition needs differential diagnosis." | 7.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| " We compared the efficacy of orally administered morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia with that on neuroma pain using the tibial neuroma transposition (TNT) model." | 7.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "Morphine, pregabalin, gabapentin, and duloxetine attenuated the level of mechanical allodynia in a dose-dependent manner." | 7.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "These data indicate that the potency of morphine and the efficacy of pregabalin, gabapentin, and duloxetine on mechanical allodynia are different from those on neuroma pain and that combination therapy is one of different therapeutic choices for the treatment of neuropathic pain." | 7.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| " The von Frey filaments, acetone drop, and radiant heat test were performed to assess the degree of mechanical allodynia, thermal allodynia and thermal hyperalgesia respectively, at different time intervals, i." | 7.78 | Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats. ( Amin, B; Hosseinzadeh, H, 2012) |
| "The aim of this study was to evaluate the effect of topical treatment with pregabalin and diclofenac on neuropathic orofacial pain induced by infraorbital nerve injury in the rat." | 7.78 | Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. ( Benoliel, R; Eliav, E; Heir, G; Khan, J; Markman, S; Noma, N; Patel, J; Plaza-Villegas, F, 2012) |
| "Topical treatment with pregabalin or diclofenac can reduce neuropathic orofacial pain induced by nerve injury." | 7.78 | Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. ( Benoliel, R; Eliav, E; Heir, G; Khan, J; Markman, S; Noma, N; Patel, J; Plaza-Villegas, F, 2012) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 7.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 7.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 7.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| " Right hemichorea developed and was related to adjunctive therapy with gabapentin." | 7.74 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "To systematically establish the pain relieving efficacies of venlafaxine and gabapentin alone and in combination." | 7.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety." | 7.01 | Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature. ( Juba, KM; Kenney, AE; Masri, S; Scigliano, D, 2023) |
| "Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge." | 6.84 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Taking pregabalin for the treatment of neuropathic pain poses an increased risk for developing ED in male patients." | 6.79 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "Pruritus is common in dialysis patients." | 6.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly." | 6.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch." | 6.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 6.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "After observing improvement of restless legs symptoms in seven patients treated with pregabalin for neuropathic pain, we extended the clinical observation to a total of 16 patients with secondary RLS, in most of them due to neuropathy, and to three patients with idiopathic RLS." | 6.73 | Pregabalin in restless legs syndrome with and without neuropathic pain. ( Bachmann, CG; Liebetanz, KM; Paulus, W; Schindehütte, J; Sommer, M; Tings, T, 2007) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 6.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 6.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 6.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Each gabapentin-naive subject was allocated to receive either 200 mg (100 mg, twice daily), 400 mg (100 mg, four times daily), or 600 mg (200 mg, three times daily) of gabapentin for three days." | 6.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 6.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 6.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 6.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| "Neuropathic pain is more severe, with significant disability." | 6.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited." | 6.50 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 6.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 6.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin displays nonlinear absorption kinetics, is minimally protein bound (< 3%), has a high mean (SD) volume of distribution (50." | 6.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| " The recommended dosage in adults is 300 mg at bedtime on day 1,300 mg BID on day 2, and 300 mg TID on day 3, titrating up as needed to 2400 to 3600 mg/d." | 6.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 6.42 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " We report on a case of a 31 year old female who presented to the emergency department with unilateral leg pain, weakness, and swelling after increasingly titrating her Gabapentin dosage over three weeks." | 5.46 | Radiologic Findings in Gabapentin-Induced Myositis. ( Chang, DR; Coupal, TM; Munk, PL; Ouellette, HA; Pennycooke, K, 2017) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma-1 antagonists." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Chronic pain, neuropathic pain, inflammatory pain, ozone therapy, interventional therapy, gabapentin, spared nerve injury, bee venom, complete Freud's adjuvant." | 5.46 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to generating unwanted side-effects." | 5.46 | Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. ( Ahmad, N; Islam, NU; Rahman, FU; Sewell, RDE; Shahid, M; Subhan, F, 2017) |
| "Gabapentin gel (10% w/w) was applied three times daily on the ipsilateral or contralateral plantar surface of the hind-paw, whereas in a concurrent systemic study, gabapentin was intraperitoneally administered daily (75 mg/kg) for 30 days." | 5.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Tests for static- and dynamic-mechano-allodynia [paw withdrawal threshold (PWT) to von Frey filament application and latency (PWL) to light brushing], cold-allodynia [paw withdrawal duration (PWD) to acetone], heat- (PWL and PWD) and mechano-hyperalgesia (PWD to pin prick) were utilized to assess pain, whereas effects on locomotion (open field) and motor balance (rotarod and footprint analysis) were measured on days 5-30 post surgery." | 5.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Systemic gabapentin neuropathic pain management carries side-effects ostensibly preventable by localized therapy." | 5.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 5.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 5.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
| "Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models." | 5.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Mechanical allodynia was assessed using von Frey hairs." | 5.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 5.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "This study was designed to explore the efficacy and feasibility of cognitive behavioral therapy (CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of messenger RNA (mRNA) expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients." | 5.41 | Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. ( Bajaj, M; Banerjee, A; Banerjee, BD; Bhardwaj, N; Chilkoti, GT; Malik, A; Saxena, AK; Singal, A; Thakur, GK, 2021) |
| "This paper aimed to discuss the curative effect and safety of curing intercostal neuralgia through paravertebral nerve block combined with pregabalin." | 5.40 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| " The result showed that: visual analogue scale (VAS) and quality of sleep (QS) of three groups of patients after treatment all decreased obviously; group A had slow work, large amount of dosage and many adverse effects; group B had quick work, but the improvement on pain and sleep was not satisfactory; the curative effect of group C was higher than group A and B (p<0." | 5.40 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| "The edema was considered to be caused by pregabalin and the medicine was ceased gradually." | 5.38 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Morphine was less potent in neuroma pain than in mechanical allodynia." | 5.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "After TNT injury, mechanical allodynia and neuroma pain are observed." | 5.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "It has been reported that <50% of neuropathic pain patients are satisfactorily treated with drugs." | 5.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "The gabapentin has beneficial effect in the FBSS associated neuropathic pain." | 5.37 | Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome. ( Chang, ST; Lai, MH; Lu, SC; Wu, YT, 2011) |
| "In both neuropathic pain models, rats exhibited mechanical hypersensitivity, whereas a significant increase in anxiety-like behaviour was observed only in CCI rats (time spent in open arms decreased significantly from 99+/-15." | 5.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "Neuropathic pain was induced in rats by partial sciatic nerve ligation (PNL) and chronic constriction injury (CCI)." | 5.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "Neuropathic pain is commonly associated with affective disorders such as anxiety and depression." | 5.35 | Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. ( Blackbeard, J; Pheby, T; Rice, AS; Segerdahl, AR; Wallace, VC, 2008) |
| "Gabapentin did not produce an anti-allodynic effect, whereas the morphine and gabapentin combination completely decreased allodynia behavior at 30 min post-injection, an effect that persisted until 120 min." | 5.35 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action." | 5.35 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "Our patient is the first patient with neuropathic pain, treated with gabapentin who developed hemichorea, in the absence of brain lesions." | 5.35 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "Neuropathic pain is associated with a number of disease states of diverse aetiology that can share common pathophysiological mechanisms." | 5.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 5.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 5.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
| "Gabapentin was concluded to be an effective therapeutic option for neuralgia of the IXth cranial nerve before surgery." | 5.30 | [Use of gabapentin in glossopharyngeal neuralgia]. ( Esparcia Navarro, M; García Callejo, FJ; Marco Algarra, J; Martínez Beneyto, MP; Morant Ventura, A; Talamantes Escribá, F, 1999) |
| "Gabapentin is an effective treatment for chronic neuropathic pain but may cause dizziness, drowsiness, and confusion in some older adults." | 5.27 | Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. ( Burneo, J; Dev, VK; Dixon, SN; Fleet, JL; Garg, AX; Kuwornu, PJ; Montero-Odasso, M, 2018) |
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 5.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| " Neuropathic pain (NP) may facilitate ED, because it is frequently associated with anxiety, depression, and its drug, pregabalin, may also contribute ED." | 5.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The objective of this study was to determine whether pregabalin treatment for patients with neuropathic pain promotes erectile dysfunction." | 5.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The purpose of this study was to evaluate the therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis." | 5.19 | Therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis. ( Arai, I; Fukuda, H; Ichiji, K; Kaga, T; Kayama, S; Konno, S; Takahashi, N, 2014) |
| "The objective of this study was to evaluate the effect of pregabalin in painful cervical or lumbosacral radiculopathy treated in Primary Care settings under routine clinical practice." | 5.14 | Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. ( Masramón, X; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2010) |
| "The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN)." | 5.14 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 5.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "A double-blind, randomized, placebo-controlled cross-over multi-center study was conducted to evaluate the efficacy and safety of gabapentin in the treatment of neuropathic pain caused by traumatic or postsurgical peripheral nerve injury, using doses up to 2400 mg/day." | 5.13 | Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. ( Arnèr, S; Biber, B; Boivie, J; Gordh, TE; Jensen, TS; Kalliomäki, J; Kalso, E; Mannheimer, C; Stubhaug, A, 2008) |
| "Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury." | 5.12 | Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. ( Chambers, R; Cousins, MJ; Griesing, T; Murphy, TK; Otte, A; Siddall, PJ, 2006) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 5.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| " Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN has been reported anecdotally." | 5.11 | A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. ( Arendt, G; Braun, JS; Hahn, K; Husstedt, IW; Maschke, M; Schielke, E; Straube, ME; von Giesen, HJ, 2004) |
| " We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia." | 5.11 | Morphine, gabapentin, or their combination for neuropathic pain. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Tu, D; Weaver, DF, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 5.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 5.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years." | 5.10 | Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. ( Beck, M; Birklein, F; Kim, KS; Krummenauer, F; Kutschke, G; Mengel, E; Ries, M, 2003) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| " Data on 2724 subjects from 10 recently completed placebo-controlled clinical trials of pregabalin in diabetic neuropathy, postherpetic neuralgia, chronic low back pain, fibromyalgia, and osteoarthritis were used." | 5.09 | Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. ( Farrar, JT; LaMoreaux, L; Poole, MR; Werth, JL; Young, JP, 2001) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 5.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "The aim of this systematic review was to determine the efficacy of gabapentin (GBP) in the treatment of pain of idiopathic trigeminal neuralgia (TN)." | 5.01 | Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials. ( Ariyawardana, A; Dinh, HQ; Lin, S; Nguyen, K; Ong, YL; Ta, PCP, 2019) |
| " Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| " Effective interventions were described for painful diabetic neuropathy (pregabalin, gabapentin, certain tricyclic antidepressants [TCAs], opioids, antidepressants, and anticonvulsants), postherpetic neuralgia (gabapentin, pregabalin, certain TCAs, antidepressants and anticonvulsants, opioids, sodium valproate, topical capsaicin, and lidocaine), lumbar radicular pain (epidural corticosteroids, repetitive transcranial magnetic stimulation [rTMS], and discectomy), cervical radicular pain (rTMS), carpal tunnel syndrome (carpal tunnel release), cubital tunnel syndrome (simple decompression and ulnar nerve transposition), trigeminal neuralgia (carbamazepine, lamotrigine, and pimozide for refractory cases, rTMS), HIV-related neuropathy (topical capsaicin), and central NeuP (certain TCAs, pregabalin, cannabinoids, and rTMS)." | 4.95 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "We know from adult randomised controlled trials that some antiepileptics, such as gabapentin and pregabalin, can be effective in certain chronic pain conditions." | 4.95 | Antiepileptic drugs for chronic non-cancer pain in children and adolescents. ( Clinch, J; Cooper, TE; Heathcote, LC; Howard, R; Krane, E; Lord, SM; Schechter, N; Sethna, N; Wiffen, PJ; Wood, C, 2017) |
| "This was a pooled analysis of 19 randomized placebo-controlled trials of pregabalin for peripheral neuropathic pain conditions, including diabetic peripheral neuropathy, postherpetic neuralgia, and post-traumatic/postsurgical pain." | 4.95 | Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin? ( Almas, M; Clair, A; Latymer, M; Ortiz, M; Parsons, B; Pérez, C; Varvara, R, 2017) |
| "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear." | 4.93 | Pregabalin and gabapentin for the treatment of sciatica. ( Marshman, LA; Plummer, D; Robertson, K, 2016) |
| "With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (FM)." | 4.91 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Data from the MEDLINE database were searched using algorithms to identify relevant economic evaluations published in English or Spanish on pregabalin for the management of neuropathic pain, generalized anxiety disorder (GAD), and epilepsy in Spanish patients over the last 10 years." | 4.90 | Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. ( Álvarez, E; Darbà, J; Kaskens, L; Navarro-Artieda, R; Pérez, C; Sicras-Mainar, A, 2014) |
| "The majority of published evidence supports the possibility that pregabalin could be a cost-effective and/or cost-saving alternative for the treatment of refractory epilepsy, GAD, and neuropathic pain, in both treatment-naïve patients and in those who have demonstrated inadequate response or intolerance to previous therapy." | 4.90 | Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. ( Álvarez, E; Darbà, J; Kaskens, L; Navarro-Artieda, R; Pérez, C; Sicras-Mainar, A, 2014) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Gabapentin is an anti-epileptic agent but now it is also recommended as first line agent in neuropathic pain, particularly in diabetic neuropathy and post herpetic neuralgia." | 4.89 | Implications and mechanism of action of gabapentin in neuropathic pain. ( Bali, A; Jaggi, AS; Kukkar, A; Singh, N, 2013) |
| "Clinical trial evidence supported the use of only gabapentin and pregabalin in some neuropathic pain conditions (painful diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain) and fibromyalgia." | 4.89 | Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. ( Aldington, D; Cole, P; Derry, S; Haanpaa, M; Hamunen, K; Kalso, EA; Lunn, MP; Moore, RA; Rice, AS; Wiffen, PJ, 2013) |
| "For gabapentin and pregabalin only we found reasonably good second tier evidence for efficacy in painful diabetic neuropathy and postherpetic neuralgia." | 4.89 | Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. ( Aldington, D; Cole, P; Derry, S; Haanpaa, M; Hamunen, K; Kalso, EA; Lunn, MP; Moore, RA; Rice, AS; Wiffen, PJ, 2013) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 4.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| " A post hoc analysis of multiple clinical studies of pregabalin in patients with painful diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) was conducted to evaluate the efficacy and safety of pregabalin in older patients." | 4.86 | Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. ( Cheung, R; Emir, B; Murphy, TK; Semel, D; Zlateva, G, 2010) |
| "The US Food and Drug Administration (FDA) approved pregabalin in December 2004 for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia." | 4.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| " The search terms included pregabalin, Lyrica, S-(+)-3 isobutyl-gaba, PN, DPN, diabetic peripheral neuropathy, PHN, postherpetic neuralgia, partial seizures, epilepsy, generalized anxiety disorder, and CI-1008." | 4.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| "Pregabalin appears to be an effective therapy in patients with diabetic peripheral neuropathy, postherpetic neuralgia, and adults with refractory partial-onset seizures." | 4.84 | Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ( Boyce, E; Guyer, J; Nuzum, D; Tassone, DM, 2007) |
| " Finally, we consider the link between alpha2delta subunits and disease, both in terms of spontaneous and engineered mouse mutants that show cerebellar ataxia and spike-wave epilepsy, and in terms of neuropathic pain and the mechanism of action of the gabapentinoid drugs - small-molecule ligands of the alpha2delta-1 and alpha2delta-2 subunits." | 4.84 | Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. ( Davies, A; Dolphin, AC; Douglas, L; Hendrich, J; Van Minh, AT; Wratten, J, 2007) |
| " Multiple multicentre randomised controlled trials have shown clear efficacy of gabapentin and pregabalin for postherpetic neuralgia and painful diabetic neuropathy." | 4.84 | Antiepileptic drugs in the treatment of neuropathic pain. ( Eisenberg, E; Krivoy, N; River, Y; Shifrin, A, 2007) |
| "Multiple, large, high-quality trials have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| "Gabapentin and pregabalin are efficacious treatments for neuropathic and postsurgical pain." | 4.84 | Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. ( Gilron, I, 2007) |
| " However, two randomised placebo-controlled studies have recently emerged demonstrating efficacy of pregabalin in reducing central neuropathic pain due to spinal cord injury and central poststroke pain." | 4.84 | Pregabalin in the management of central neuropathic pain. ( Gray, P, 2007) |
| " Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain." | 4.82 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 4.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 4.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 4.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 4.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " In the New Drug Application for gabapentin, data from two adequate and well-controlled clinical trials was submitted to the Food and Drug Administration (FDA) in support of the approval of the indication for the treatment of post-herpetic neuralgia." | 4.82 | How modeling and simulation have enhanced decision making in new drug development. ( Corrigan, BW; Donevan, S; El-Kattan, A; Ewy, W; Feltner, DE; Hermann, D; Koup, JR; Kowalski, KG; Lalonde, RL; Li, CS; Lockwood, P; Miller, R; Ouellet, D; Werth, JL, 2005) |
| "To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures." | 4.82 | Pregabalin: a new neuromodulator with broad therapeutic indications. ( McAuley, JW; Shneker, BF, 2005) |
| " The meta-analysis of the 2 high-quality, placebo-controlled RCTs showed positive effect of gabapentin in diabetic neuropathy and post-herpetic neuralgia." | 4.81 | Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. ( Furlan, AD; Mailis, A; Mellegers, MA, 2001) |
| " Mechanical allodynia and thermal hyperalgesia were measured to confirm neuropathic pain induction following before and after gabapentin (GBP) treatment." | 3.88 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "Prior work applied hierarchical clustering, coarsened exact matching (CEM), time series regressions with lagged variables as inputs, and microsimulation to data from three randomized clinical trials (RCTs) and a large German observational study (OS) to predict pregabalin pain reduction outcomes for patients with painful diabetic peripheral neuropathy." | 3.88 | Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. ( Alexander, J; Bonfanti, G; Brodsky, M; Edwards, RA; Emir, B; Grugni, R; Manca, L; Parsons, B; Savoldelli, A; Watt, S; Whalen, E, 2018) |
| "In a 5-year follow-up study in a hospital in southern China, it was shown that intervertebral foramen (IVF) injection of ozone at the involved segmental levels could significantly alleviate paroxysmal spontaneous pain and mechanical allodynia in patients with chronic, intractable postherpetic neuralgia (PHN) and improve the quality of life." | 3.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "(1) IVF injection of ozone at L4-5 was only effective in suppression of mechanical allodynia in rats with neuropathic pain but not with inflammatory pain; (2) the analgesic effects of IVF ozone lasted much longer (> 14 days) than other selective molecular target drugs (< 48 hours) inhibiting or antagonizing at Nav1." | 3.85 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "The combination of low-dose KML29:gabapentin additively attenuated mechanical allodynia and synergistically reduced cold allodynia." | 3.85 | The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. ( Banks, ML; Bradshaw, HB; Crowe, MS; Kinsey, SG; Leishman, E; Prather, PL; Wilson, CD, 2017) |
| "Gabapentin is commonly prescribed for nerve pain but may also cause dizziness, sedation and gait disturbances." | 3.85 | The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. ( Banks, ML; Bradshaw, HB; Crowe, MS; Kinsey, SG; Leishman, E; Prather, PL; Wilson, CD, 2017) |
| "Pregabalin (PGB) is extensively prescribed to treat neurological and neuropsychiatrical conditions such as neuropathic pain, anxiety disorders, and epilepsy." | 3.85 | Chronic pregabalin treatment decreases excitability of dentate gyrus and accelerates maturation of adult-born granule cells. ( Coll, L; Lempel, AA; Piriz, J; Schinder, AF; Uchitel, OD, 2017) |
| " The effects of genistein were compared with those of gabapentin, which is widely used in clinical practice for peripheral nerve injury." | 3.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Genistein and gabapentin exhibit positive effects on histopathology, inflammation, and clinical findings of peripheral nerve injury." | 3.85 | Neuroprotective Effect of Genistein in Peripheral Nerve Injury. ( Arslantas, A; Aydin, HE; Baycu, C; Bektur, E; Kocman, AE; Kose, A; Ozbek, Z; Ozkara, E; Sahin, E; Vural, M, 2017) |
| "Topical application of gabapentin gel ipsilaterally but not contralaterally alleviated CCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodynia (days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action." | 3.85 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| " Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 3.85 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Gabapentin and pregabalin are antiepileptic drugs (AEDs) with epilepsy and neuropathic pain indications." | 3.81 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "Anonymous data from routine TDM-service at the National Center for Epilepsy regarding serum concentration measurements of gabapentin and pregabalin, 2009-2013, were utilised." | 3.81 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "Gabapentin and pregabalin are more used in women than in men, and routine use of TDM is most common in patients with epilepsy." | 3.81 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "To evaluate the antinociceptive and hypnotic effects of pregabalin, we established a neuropathic pain-like model in mice using partial sciatic nerve ligation (PSNL), and examined thermal hyperalgesia, mechanical allodynia, electroencephalogram, rota-rod testing, and c-Fos expression in the anterior cingulate cortex." | 3.81 | Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice. ( Guo, W; Han, WJ; Hong, ZY; Huang, ZL; Li, YD; Liu, YY; Qu, WM; Wang, TX; Yin, D, 2015) |
| "Mechanical allodynia in SNL rats was attenuated by gabapentin (100 mg/kg) and AQU-118 (in a dose-dependent manner)." | 3.81 | Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain. ( Davis, SF; Fairchild, DD; Hain, HS; Hanania, T; Henry, MA; Hu, A; Malekiani, SA; Nix, D; Patil, MJ; Sucholeiki, I; Sucholeiki, R, 2015) |
| "The results demonstrated that oral AQU-118 attenuates mechanical allodynia in both neuropathic pain models and with efficacies that mirror gabapentin at the 40 mg/kg dose used in the CCI-IoN model but without effect on basal sensitivity to mechanical stimulation/locomotive activity." | 3.81 | Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain. ( Davis, SF; Fairchild, DD; Hain, HS; Hanania, T; Henry, MA; Hu, A; Malekiani, SA; Nix, D; Patil, MJ; Sucholeiki, I; Sucholeiki, R, 2015) |
| "Pregabalin was mainly used as a second-line drug for the treatment of GAD or neuropathic pain and to a lesser extent as add-on therapy in epilepsy." | 3.80 | Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. ( Bodén, R; Brandt, L; Kieler, H; Wettermark, B, 2014) |
| "Pregabalin was highly effective for neuralgia associated with intercostal damage after thoracotomy." | 3.80 | Successful management of postoperative pain with pregabalin after thoracotomy. ( Kawamura, M; Matsutani, N, 2014) |
| "In OXPT-treated mice LPP1 and pregabalin dose-dependently reduced tactile allodynia (41-106% and 6-122%, respectively, p<0." | 3.80 | Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. ( Cios, A; Filipek, B; Malawska, B; Mogilski, S; Sałat, K; Sałat, R; Więckowski, K; Wyska, E, 2014) |
| " To address this issue, we obtained clinical trial data from the Food and Drug Administration (FDA) through the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, and harmonized patient level data from 12 clinical trials (4 gabapentin and 8 pregabalin) in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN)." | 3.80 | Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. ( Dworkin, RH; Farrar, JT; Gilron, I; Haynes, K; Katz, NP; Kerns, RD; Rappaport, BA; Rowbotham, MC; Tierney, AM; Troxel, AB; Turk, DC, 2014) |
| "This paper aimed to discuss the curative effect and safety of curing intercostal neuralgia through paravertebral nerve block combined with pregabalin." | 3.80 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| "A 28-year-old female patient developed an increased temperature and neuropsychiatric symptoms after receiving 75 mg pregabalin therapy for neuralgia." | 3.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Clinicians should be alert to the serious neuropsychiatric symptoms and thrombocytopenia associated with the use of pregabalin." | 3.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Nonsteroidal anti-inflammatory drug and pregabalin combination therapy may result in a lower incidence of spinal surgery during the first year of treatment or a delayed period before undergoing spinal surgery if necessary compared with nonsteroidal anti-inflammatory drug monotherapy in patients with leg symptoms caused by lumbar spinal stenosis." | 3.80 | One-year follow-up for the therapeutic efficacy of pregabalin in patients with leg symptoms caused by lumbar spinal stenosis. ( Arai, I; Fukuda, H; Ichiji, K; Kayama, S; Konno, S; Takahashi, N, 2014) |
| "The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model." | 3.79 | Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium. ( Annemans, L; Chevalier, P; Eyckerman, R; Lamotte, M; Van Campenhout, H, 2013) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 3.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "Pregabalin was a very efficacious antiallodynic and analgesic drug capable of increasing the pain thresholds for tactile allodynia and thermal hyperalgesia in diabetic mice." | 3.79 | Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. ( Gluch-Lutwin, M; Librowski, T; Nawiesniak, B; Sałat, K, 2013) |
| "The involvement of voltage-dependent calcium channels and reactive oxygen species in the pathophysiology of neuropathic pain might justify the preventative administration of antioxidant enzymes, at low doses, in combination with gabapentin (GaP) to maximize its analgesic effect in an experimental model of neuropathic pain in rats." | 3.79 | Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model. ( Arcos, M; Barrios, C; Montes, F; Palanca, JM, 2013) |
| "The frequency of PHN after untreated zoster varies widely." | 3.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To report a case of paraplegia with limb edema caused by pregabalin." | 3.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Pregabalin, which is one of medications used for neuropathic pain, might cause limb edema, that is, a condition needs differential diagnosis." | 3.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Lysophosphatidic acid (LPA), an initiator of neuropathic pain, causes allodynia." | 3.78 | Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs. ( Kato, A; Ogawa, K; Shinohara, S; Takasu, K; Yoneda, Y, 2012) |
| " We compared the efficacy of orally administered morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia with that on neuroma pain using the tibial neuroma transposition (TNT) model." | 3.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "Morphine, pregabalin, gabapentin, and duloxetine attenuated the level of mechanical allodynia in a dose-dependent manner." | 3.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "These data indicate that the potency of morphine and the efficacy of pregabalin, gabapentin, and duloxetine on mechanical allodynia are different from those on neuroma pain and that combination therapy is one of different therapeutic choices for the treatment of neuropathic pain." | 3.78 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| " The von Frey filaments, acetone drop, and radiant heat test were performed to assess the degree of mechanical allodynia, thermal allodynia and thermal hyperalgesia respectively, at different time intervals, i." | 3.78 | Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats. ( Amin, B; Hosseinzadeh, H, 2012) |
| "The aim of this study was to evaluate the effect of topical treatment with pregabalin and diclofenac on neuropathic orofacial pain induced by infraorbital nerve injury in the rat." | 3.78 | Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. ( Benoliel, R; Eliav, E; Heir, G; Khan, J; Markman, S; Noma, N; Patel, J; Plaza-Villegas, F, 2012) |
| "Topical treatment with pregabalin or diclofenac can reduce neuropathic orofacial pain induced by nerve injury." | 3.78 | Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. ( Benoliel, R; Eliav, E; Heir, G; Khan, J; Markman, S; Noma, N; Patel, J; Plaza-Villegas, F, 2012) |
| " The aim of this study was to determine the pharmacokinetics of pregabalin in a patient with malabsorption secondary to celiac disease and compare the findings with the data available from pre-existing studies in healthy volunteer controls." | 3.77 | Pregabalin assay in a patient with widespread neuropathic pain and late onset gluten intolerance. ( Hanu-Cernat, DE; Phipps, AN; Raphael, JH, 2011) |
| "In order to detect an anti-nociceptive interaction between morphine and gabapentin, the anti-allodynic and anti-hyperalgesic effects of these drugs, administered either separately or in combination, were determined using the von Frey and acetone tests in a rat model of neuropathic pain (Bennett model)." | 3.75 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 3.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "To explore the effect of a prior authorization (PA) policy restricting access to pregabalin for the management of diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) on the overall utilization of pharmacologic therapy and healthcare services among fee-for-service Medicaid plan beneficiaries." | 3.75 | Effects of a Medicaid prior authorization policy for pregabalin. ( Alvir, J; Chu, BC; Hvidsten, K; Johnston, SS; Margolis, JM; Mullins, CD; Onukwugha, E; Rossi, JG, 2009) |
| " Based on the need for new approaches in that field the effect of systemic administration of lacosamide (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037), a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsive drug candidates, was examined in rats in a tumor-induced bone cancer pain model and in a chemotherapy-induced neuropathic pain model." | 3.74 | Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. ( Bain, SC; Beyreuther, BK; Brot, MD; Callizot, N; Feldman, R; Stöhr, T, 2007) |
| "Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed." | 3.74 | Pregabalin and duloxetine for the treatment of neuropathic pain disorders. ( Terneus, W, 2007) |
| " Right hemichorea developed and was related to adjunctive therapy with gabapentin." | 3.74 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| "A 44-year-old female with gabapentin-responsive supraorbital neuralgia is presented." | 3.73 | Abnormal blink reflex studies in a patient with supraorbital neuralgia. ( Cohen, AS; Gantenbein, AR; Goadsby, PJ, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "To systematically establish the pain relieving efficacies of venlafaxine and gabapentin alone and in combination." | 3.73 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Case report on a patient with SUNCT-syndrome (short lasting, unilateral neuralgiform headache attacks with conjunctival injection, sweating, and rhinorrhoea) who was successfully treated with gabapentin." | 3.72 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| " Oxcarbazepine and carbamazepine (3-100 mg x kg(-1)) did not affect mechanical hyperalgesia or tactile allodynia induced by partial sciatic nerve ligation in the rat following oral administration." | 3.72 | Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. ( Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003) |
| "Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months." | 3.30 | Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial. ( Ahmadi, SA; Bagheri, S; Dolatkhah, H; Hassanzadeh, S; Majid Ahmadi, S; Moradishibany, I; Reisi, S, 2023) |
| "Diabetic peripheral neuropathic pain (DPNP) is common and often distressing." | 3.11 | Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise ( Ahmed, SH; Alam, U; Bennett, DL; Bouhassira, D; Bradburn, M; Cooper, C; Devers, M; Gandhi, R; Glover, R; Gouni, R; Hariman, C; Horspool, M; Johnson, M; Jude, EB; Julious, S; Loban, A; Maguire, D; McDougall, C; Petrie, J; Rajbhandari, S; Rayman, G; Rice, ASC; Selvarajah, D; Sharma, S; Sloan, G; Sutherland, K; Tesfaye, S; Tsatlidis, V; Turton, E; Vas, P; Waterhouse, S; White, D, 2022) |
| "Gabapentin (GBP) is a structural analog of gamma-aminobutyric acid (GABA) that is commonly used in palliative care for symptom management indications including neuropathic pain syndromes, hiccups, cough, and anxiety." | 3.01 | Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature. ( Juba, KM; Kenney, AE; Masri, S; Scigliano, D, 2023) |
| " The majority of adverse events pertained to the nervous system (7 effects) or psychiatric (3 effects) disorders." | 3.01 | The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. ( Eldabe, S; Meaadi, J; Nazar, H; Obara, I, 2023) |
| "Despite RCTs documenting the adverse events of gabapentionoids on the nervous system, there was no evidence of gabapentinoid use leading to addiction, suggesting an urgent need to design studies investigating their abusive potential." | 3.01 | The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. ( Eldabe, S; Meaadi, J; Nazar, H; Obara, I, 2023) |
| "The study did not provide any evidence of clinical efficacy for AZD5213 when combined with pregabalin in the treatment of painful diabetic neuropathy." | 3.01 | A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability. ( Alexander, RC; Katz, N; Raudibaugh, K; Spierings, ELH, 2021) |
| "In this study, patients with painful diabetic neuropathy were trained using an experimental pain paradigm in an attempt to enroll a subset of patients who are "pain connoisseurs" and therefore more able to discriminate between active and placebo treatments." | 3.01 | A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability. ( Alexander, RC; Katz, N; Raudibaugh, K; Spierings, ELH, 2021) |
| "Gabapentin is an effective treatment for chronic neuropathic pain but may cause dizziness, drowsiness, and confusion in some older adults." | 2.87 | Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. ( Burneo, J; Dev, VK; Dixon, SN; Fleet, JL; Garg, AX; Kuwornu, PJ; Montero-Odasso, M, 2018) |
| " The goal of this study was to assess the association between gabapentin dosing and adverse outcomes by obtaining estimates of the 30-day risk of hospitalization with altered mental status and mortality in older adults (mean age 76 years) in Ontario, Canada initiated on high dose (>600 mg/day; n = 34,159) compared to low dose (≤600 mg/day; n = 76,025) oral gabapentin in routine outpatient care." | 2.87 | Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. ( Burneo, J; Dev, VK; Dixon, SN; Fleet, JL; Garg, AX; Kuwornu, PJ; Montero-Odasso, M, 2018) |
| "Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge." | 2.84 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Treatment of neuropathic pain in children is challenging, and requires a multimodal approach of pharmacologic, physical, and psychological therapies; however there is little evidence to guide practice." | 2.82 | A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. ( Amaria, K; Brown, S; Campbell, F; Johnston, B; McGrath, P; Pehora, C; Watkins, J, 2016) |
| "Nabilone or placebo was titrated over 4 weeks (0." | 2.80 | Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. ( Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D, 2015) |
| "Nabilone was well tolerated, with dizziness/drowsiness most frequently reported." | 2.80 | Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. ( Doupe, M; Esfahani, F; Ethans, K; Galloway, K; Gomori, A; Namaka, M; Torabi, M; Turcotte, D, 2015) |
| "Neuropathic cancer pain (NCP) is a common manifestation of cancer and/or its treatment." | 2.79 | Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. ( Argyra, E; Melemeni, A; Raptis, E; Siafaka, I; Stavropoulou, E; Vadalouca, A, 2014) |
| "Prompt use of a neuropathic pain-specific adjuvant, such as pregabalin, in NCP may lead to better control of the neuropathic component, with opioid-sparing effects." | 2.79 | Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. ( Argyra, E; Melemeni, A; Raptis, E; Siafaka, I; Stavropoulou, E; Vadalouca, A, 2014) |
| "Taking pregabalin for the treatment of neuropathic pain poses an increased risk for developing ED in male patients." | 2.79 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| " Discontinuation because of adverse events was significantly greater in the duloxetine (19." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| "Duloxetine, pregabalin and duloxetine plus gabapentin were generally safe and tolerable for the treatment of DPNP." | 2.79 | Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. ( Irving, G; Malcolm, S; Raskin, J; Risser, RC; Tanenberg, RJ, 2014) |
| "Those patients who reported neuropathic pain were randomly treated with gabapentin or pregabalin." | 2.79 | Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial. ( Comoglu, SS; Dolgun, H; Gurer, B; Kertmen, H; Sekerci, Z; Turkoglu, E; Yilmaz, ER, 2014) |
| "Many patients may suffer from neuropathic pain in the early post-surgical period after lumbar discectomy." | 2.79 | Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial. ( Comoglu, SS; Dolgun, H; Gurer, B; Kertmen, H; Sekerci, Z; Turkoglu, E; Yilmaz, ER, 2014) |
| " Safety assessments included adverse events (AEs), clinical laboratory tests, and electrocardiograms." | 2.79 | Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. ( Feins, K; Hsu, C; Merante, D; Rosenstock, J; Sharma, U; Vinik, A, 2014) |
| " The primary endpoint was a ≥1/3 reduction in pain (NRS); secondary endpoints included the time to analgesia and adverse effects." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Patients (N = 75) with oncological neuropathic pain, previously untreated with pregabalin, were recruited in 5 Italian institutions between 2007 and 2010." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Both strategies effectively controlled neuropathic pain, but according to the adopted selection design arm A is preferable to arm B for pain control." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Neuropathic pain is commonly associated with cancer." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| " Adverse events (AEs) were also compared between treatment groups." | 2.78 | Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. ( Emir, B; Juhn, M; Parsons, B; Sanin, L; Yang, R, 2013) |
| "Pregabalin reduced neuropathic pain due to SCI over a 12 to 16 week treatment period." | 2.78 | Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. ( Emir, B; Juhn, M; Parsons, B; Sanin, L; Yang, R, 2013) |
| "Patients with chronic, below-level, neuropathic pain due to SCI were randomized to receive 150 to 600 mg/d pregabalin (n = 108) or matching placebo (n = 112) for 17 weeks." | 2.78 | A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. ( Cardenas, DD; Goto, S; Kaneko, T; Knapp, LE; Nieshoff, EC; Parsons, B; Sanin, L; Scavone, JM; Soulsby, M; Sporn, J; Suda, K; Suzuki, MM; Whalen, E; Yang, R, 2013) |
| "Oral morphine was used for rescue analgesic for continued pain." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "A total of 120 patients with cancer having severe neuropathic cancer pain were enrolled in the study after taking approval from Institutional Ethics Committee and divided in to 4 groups: group AT-amitriptyline, group GB-gabapentin, group PG-pregabalin, and group PL-placebo." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic pain is difficult to diagnose and difficult to treat with certainty." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic pain frequently occurs in cancer patients, but no drug therapy has been established for this type of disorder." | 2.77 | Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. ( Fujisaka, Y; Kaneda, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Okamoto, W; Otsuka, M; Tsurutani, J, 2012) |
| "The subjects of the study were 15 cancer patients with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital and met the International Association for the Study of Pain diagnostic criteria for neuropathic pain." | 2.77 | Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. ( Fujisaka, Y; Kaneda, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Okamoto, W; Otsuka, M; Tsurutani, J, 2012) |
| "Pruritus is common in dialysis patients." | 2.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly." | 2.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch." | 2.77 | Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. ( Atalay, H; Biyik, Z; Covic, A; Gaipov, A; Goldsmith, D; Guney, F; Kanbay, M; Solak, Y; Turk, S, 2012) |
| "We hypothesized that an antineuropathic pain drug like pregabalin could be helpful to optimize postoperative analgesia by reducing the requirement for opioids and their associated side effects." | 2.75 | Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy. ( Cabrera Schulmeyer, MC; de la Maza, J; Farias, C; Ovalle, C; Vives, I, 2010) |
| " Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| "Peripheral neuropathic pain presents commonly in clinical practice, and 2 of its most prevalent types are PHN and PDN." | 2.75 | A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. ( Duffull, SB; Moore, BJ; Nissen, LM; O'Callaghan, JP; Smith, MT; Zin, CS, 2010) |
| " Pregabalin average daily dosage (SD) was 385." | 2.75 | Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. ( Clifford, DB; Durso-De Cruz, E; Emir, B; Freeman, R; Glue, P; Murphy, TK; Schifitto, G; Scott, GN; Simpson, DM; Whalen, E, 2010) |
| "Pregabalin is effective in several neuropathic pain syndromes." | 2.75 | Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. ( Clifford, DB; Durso-De Cruz, E; Emir, B; Freeman, R; Glue, P; Murphy, TK; Schifitto, G; Scott, GN; Simpson, DM; Whalen, E, 2010) |
| " Adverse events caused the discontinuation of 9." | 2.75 | The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. ( Baron, R; Cloutier, C; Freynhagen, R; Leon, T; Murphy, KT; Phillips, K; Tölle, TR, 2010) |
| "Patients with moderate to severe neuropathic pain, despite the use of various pharmacologic treatments prior to study entry, were enrolled (n = 409) and treated with CR oxycodone plus pregabalin (n = 169), CR oxycodone (n = 106), and pregabalin (n = 134)." | 2.74 | Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. ( Colini Baldeschi, G; Gatti, A; Occhioni, R; Reale, C; Sabato, AF, 2009) |
| "Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy." | 2.74 | Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Jackson, AC; Tu, D, 2009) |
| "After observing improvement of restless legs symptoms in seven patients treated with pregabalin for neuropathic pain, we extended the clinical observation to a total of 16 patients with secondary RLS, in most of them due to neuropathy, and to three patients with idiopathic RLS." | 2.73 | Pregabalin in restless legs syndrome with and without neuropathic pain. ( Bachmann, CG; Liebetanz, KM; Paulus, W; Schindehütte, J; Sommer, M; Tings, T, 2007) |
| "Neuropathic cancer pain represents a major challenge." | 2.73 | Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2007) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 2.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "Gabapentin was well tolerated." | 2.73 | Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. ( Arnèr, S; Biber, B; Boivie, J; Gordh, TE; Jensen, TS; Kalliomäki, J; Kalso, E; Mannheimer, C; Stubhaug, A, 2008) |
| "They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e." | 2.73 | Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. ( Dworkin, RH; Emir, B; Griesing, T; Murphy, K; Sharma, U; Stacey, BR, 2008) |
| "Fourty six patients with neuropathic pain which was burning, stabbing and shooting in quality were allocated to take gabapentin (group GBP) and amitriptyline (group AMI) monotherapy." | 2.72 | [Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain]. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2006) |
| "Chronic neuropathic pain was associated with motor cortex disinhibition, suggesting impaired GABAergic neurotransmission related to some aspects of pain or to underlying sensory or motor disturbances." | 2.72 | Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain. ( Drouot, X; Keravel, Y; Lefaucheur, JP; Ménard-Lefaucheur, I; Nguyen, JP, 2006) |
| "To evaluate pregabalin in central neuropathic pain associated with spinal cord injury." | 2.72 | Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. ( Chambers, R; Cousins, MJ; Griesing, T; Murphy, TK; Otte, A; Siddall, PJ, 2006) |
| "Gabapentin is a new antiepileptic drug that may additionally have a role in the treatment of neuropathic pain." | 2.71 | Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. ( Ahn, SH; Bae, JH; Jang, SH; Lee, BS; Moon, HW; Park, HW; Sakong, J, 2003) |
| " In this study, conventional analgesics were continued at a therapeutic level, and gabapentin was administrated for an 18-day titration period followed by a 5-week maintenance period at a dosage of 1800 mg/day or the maximum tolerable dosage." | 2.71 | Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. ( Ahn, SH; Bae, JH; Jang, SH; Lee, BS; Moon, HW; Park, HW; Sakong, J, 2003) |
| "To compare the effect of gabapentin on neuropathic pain refractory to conventional analgesics in patients with spinal cord injury and different durations of symptoms." | 2.71 | Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. ( Ahn, SH; Bae, JH; Jang, SH; Lee, BS; Moon, HW; Park, HW; Sakong, J, 2003) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 2.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 2.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| " This was followed by a 4-week stable dosing period when the patients continued to receive maximum tolerated doses, a 2-week washout period, then a crossover of 4 weeks of medication/placebo titration, and another 4 weeks of stable dosing period." | 2.71 | Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. ( Levendoglu, F; Ogün, CO; Ogün, TC; Ozerbil, O; Ugurlu, H, 2004) |
| "Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system." | 2.71 | Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. ( Levendoglu, F; Ogün, CO; Ogün, TC; Ozerbil, O; Ugurlu, H, 2004) |
| "The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects." | 2.71 | Morphine, gabapentin, or their combination for neuropathic pain. ( Bailey, JM; Gilron, I; Holden, RR; Houlden, RL; Tu, D; Weaver, DF, 2005) |
| " Pregabalin dosing aimed at optimal balance of efficacy and tolerability provides significant pain relief and may reduce risks for AEs and therapy discontinuation." | 2.71 | Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. ( Balkenohl, M; Freynhagen, R; Griesing, T; Strojek, K; Whalen, E, 2005) |
| "Each gabapentin-naive subject was allocated to receive either 200 mg (100 mg, twice daily), 400 mg (100 mg, four times daily), or 600 mg (200 mg, three times daily) of gabapentin for three days." | 2.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 2.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Chronic neuropathic pain occurs in 10-15% of patients with neuroborreliosis and is difficult to treat." | 2.71 | Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. ( Hofmann, H; Ring, J; Weissenbacher, S, 2005) |
| "Gabapentin has some beneficial effects on certain types of neuropathic pain." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| " No significant difference was found among other pain descriptors during the gabapentin and placebo treatment, although this may have been limited by the small sample size and low maximum dosage of gabapentin." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Seven subjects with neuropathic pain, who were more than 30 days post-SCI, completed the study." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Gabapentin reduces certain types of neuropathic pain in the SCI population." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Neuropathic pain is a common complaint after traumatic spinal cord injury (SCI)." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Gabapentin was administered orally in gradually increasing doses up to a maximum of 2,400 mg/day." | 2.69 | Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Parker, F, 1998) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 2.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| "Tonic SCS concurrently initiates neuropathic pain modulation through a supraspinal-spinal feedback loop and serotonergic descending fibers." | 2.66 | Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain. ( Heijmans, L; Joosten, EA, 2020) |
| "Neuropathic pain is a critical burdensome problem due to the complex interplay of several pathological mechanisms and lack of availability of effective therapeutic interventions." | 2.66 | Adenosine receptor signalling: Probing the potential pathways for the ministration of neuropathic pain. ( Belinskaia, DA; Deb, PK; Gadepalli, A; Shaw, S; Shestakova, NN; Tiwari, V; Uniyal, A; Venugopala, KN, 2020) |
| "Efficacy of current treatments for painful diabetic neuropathy is limited to an unpredictable subset of patients, possibly reflecting diversity of pain generator mechanisms, and there is a lack of targeted treatments for individual patients." | 2.58 | The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy. ( Calcutt, NA; Lee-Kubli, C; Malik, RA; Marshall, AG, 2018) |
| "The analgesic effect in neuropathic pain is well evidenced but the role in postoperative pain is less certain." | 2.58 | Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. ( Chincholkar, M, 2018) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2017) |
| "Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage)." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Evidence for other types of neuropathic pain is very limited." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Indomethacin is the best treatment both for HC and PH." | 2.55 | Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. ( Baraldi, C; Cainazzo, MM; Guerzoni, S; Pellesi, L; Pini, LA, 2017) |
| "Numerous interventions for neuropathic pain (NeuP) are available, but its treatment remains unsatisfactory." | 2.55 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "Eligible RCTs examined gabapentin for neuropathic pain and quetiapine for bipolar depression, reported in public (e." | 2.55 | Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. ( Bertizzolo, L; Canner, JK; Cowley, T; Dickersin, K; Doshi, P; Ehmsen, J; Fusco, N; Gresham, G; Guo, N; Haythornthwaite, JA; Heyward, J; Hong, H; Li, T; Mayo-Wilson, E; Payne, JL; Pham, D; Rosman, L; Stuart, EA; Suarez-Cuervo, C; Tolbert, E; Twose, C; Vedula, S, 2017) |
| "Patients with neuropathic pain may experience anxiety, depression, insomnia, disability, and reduced quality of life." | 2.55 | An update on the pharmacologic management and treatment of neuropathic pain. ( Rizzolo, D; Wright, ME, 2017) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "In some respects, neuropathic pain can be considered a "disease" of the nervous system, with features in common with trauma-induced seizures." | 2.53 | Cell transplants to treat the "disease" of neuropathic pain and itch. ( Basbaum, AI; Bráz, JM, 2016) |
| "Neuropathic pain is one of the key features of (classical) Fabry disease (FD)." | 2.53 | Pain management strategies for neuropathic pain in Fabry disease--a systematic review. ( Biegstraaten, M; Hollak, CE; Linthorst, GE; Schuller, Y; Van Schaik, IN, 2016) |
| "Various neuropathic pain models provide considerable evidence that changes in the glutamatergic, GABAergic, and monoaminergic systems." | 2.53 | The Role of Regulatory Transporters in Neuropathic Pain. ( Kerr, BJ; Yousuf, MS, 2016) |
| "The comorbidity of chronic pain and psychiatric disorders, which is well recognized, suggests that the effective therapeutic relief for neuropathic pain induced by SCI can be achieved in conjunction with the management of the sensory and psychiatric aspects of patient." | 2.53 | Combined approaches for the relief of spinal cord injury-induced neuropathic pain. ( Gwak, YS; Kim, HY; Lee, BH; Yang, CH, 2016) |
| "The recommended pharmacotherapy for neuropathic pain includes the use of some antidepressants, such as tricyclic antidepressants (TCAs) (amitriptyline…) or serotonin and noradrenaline re-uptake inhibitors (duloxetine…), and/or anticonvulsants such as the gabapentinoids gabapentin or pregabalin." | 2.53 | Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. ( Barrot, M; Kremer, M; Muller, A; Salvat, E; Yalcin, I, 2016) |
| "Neuropathic pain is more severe, with significant disability." | 2.53 | Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016) |
| "In contrast, medical costs for neuropathic pain did not significantly differ after initiation of pregabalin vs." | 2.52 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Economic studies of pregabalin in neuropathic pain and FM indicate some results favorable to other forms of care, but heterogeneity among study designs and populations hinder comparisons." | 2.52 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Neuropathic pain is considered as a special type of different pain conditions." | 2.52 | [DRUG THERAPY OF NEUROPATHIC PAIN BASED ON THE LATEST RECOMMENDATIONS]. ( Kiss, G, 2015) |
| "Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Whereas most pain due to cancer can be relieved with relatively simple methods using oral analgesics, as suggested by WHO guidelines, some patients may have difficult pain situations that require more complex approaches." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited." | 2.50 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Gabapentin is an anti-epileptic agent but now it is also recommended as first line agent in neuropathic pain, particularly in diabetic neuropathy and post herpetic neuralgia." | 2.49 | Implications and mechanism of action of gabapentin in neuropathic pain. ( Bali, A; Jaggi, AS; Kukkar, A; Singh, N, 2013) |
| "Gabapentin has also been shown to induce modulate other targets including transient receptor potential channels, NMDA receptors, protein kinase C and inflammatory cytokines." | 2.49 | Implications and mechanism of action of gabapentin in neuropathic pain. ( Bali, A; Jaggi, AS; Kukkar, A; Singh, N, 2013) |
| "Neuropathic pain is a debilitating chronic pain condition, which remains difficult to treat." | 2.49 | Update on neuropathic pain treatment: ion channel blockers and gabapentinoids. ( Chen, L; Mao, J, 2013) |
| "This overview now covers the neuropathic pain aspect of that original review, which was withdrawn in 2009." | 2.49 | Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. ( Aldington, D; Cole, P; Derry, S; Haanpaa, M; Hamunen, K; Kalso, EA; Lunn, MP; Moore, RA; Rice, AS; Wiffen, PJ, 2013) |
| "In a recent meta-analysis of 38 double-blind randomized controlled trials (RCTs) comparing pregabalin (PGB) to placebo, we found 20 adverse events (AEs) to be significantly associated with PGB treatment." | 2.48 | The adverse event profile of pregabalin across different disorders: a meta-analysis. ( Gangemi, PF; Perucca, P; Zaccara, G, 2012) |
| "Ataxia was more common in drug-resistant partial epilepsy compared to fibromyalgia." | 2.48 | The adverse event profile of pregabalin across different disorders: a meta-analysis. ( Gangemi, PF; Perucca, P; Zaccara, G, 2012) |
| "Although drug-resistant partial epilepsy is associated with a higher probability of developing vestibulo-cerebellar AEs, the risk for PGB toxicity does not differ across distinct disorders." | 2.48 | The adverse event profile of pregabalin across different disorders: a meta-analysis. ( Gangemi, PF; Perucca, P; Zaccara, G, 2012) |
| "Chronic neuropathic pain can significantly reduce quality of life and place an economic burden on individuals and society." | 2.48 | Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action. ( Guan, Y, 2012) |
| " Descriptive safety data from the original trials were reviewed and the most commonly reported adverse events (AEs; dizziness, somnolence, peripheral oedema and weight gain) were identified to be of primary interest." | 2.48 | Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. ( Arakawa, A; Ogawa, S; Satoh, J; Suzuki, M; Yoshiyama, T, 2012) |
| " We aimed at identifying treatment emergent adverse events (AEs) associated with pregabalin through a systematic review and meta-analysis of all available RCTs." | 2.47 | The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. ( Gangemi, P; Perucca, P; Specchio, L; Zaccara, G, 2011) |
| " We also assessed the association between serious AEs and pregabalin, and investigated whether pregabalin AEs display a dose-response relationship." | 2.47 | The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. ( Gangemi, P; Perucca, P; Specchio, L; Zaccara, G, 2011) |
| " We used relative risks (RRs) to assess the association of any [99% confidence intervals (CIs)] or serious AEs (95% CIs) with pregabalin, and risk differences (RDs, 95% CIs) to investigate dose-response relationships of pregabalin AEs." | 2.47 | The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. ( Gangemi, P; Perucca, P; Specchio, L; Zaccara, G, 2011) |
| " There was a selective dose-response pattern in the onset of pregabalin AEs, with certain AEs appearing at lower doses than others." | 2.47 | The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. ( Gangemi, P; Perucca, P; Specchio, L; Zaccara, G, 2011) |
| " Pregabalin AEs appear according to a selective dose-response pattern, possibly reflecting the severity of dysfunction of distinct anatomic structures." | 2.47 | The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. ( Gangemi, P; Perucca, P; Specchio, L; Zaccara, G, 2011) |
| "Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments." | 2.47 | [Neuropathic pain in oncology. Novel evidence for clinical practice]. ( Carloni, F; Castellani, C; Drudi, F; Possenti, C; Santelmo, C; Tassinari, D, 2011) |
| "Neuropathic pain is caused by lesion or dysfunction of the peripheral sensory nervous system." | 2.46 | The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo. ( Bauer, CS; Dickenson, AH; Dolphin, AC; Lujan, R; Rahman, W; Tran-van-Minh, A, 2010) |
| "Multimodal postoperative pain management targeted at diminishing harmful outcomes should include pregabalin in cases that need opioid reduction and when the risk of developing chronic neuropathic postsurgical pain is present." | 2.46 | Pregabalin for the treatment of postsurgical pain. ( Durkin, B; Glass, P; Page, C, 2010) |
| " Safety was based on adverse events (AEs)." | 2.46 | Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. ( Cheung, R; Emir, B; Murphy, TK; Semel, D; Zlateva, G, 2010) |
| "0009), except for the lowest dosage (150 mg/day) in the youngest age group." | 2.46 | Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. ( Cheung, R; Emir, B; Murphy, TK; Semel, D; Zlateva, G, 2010) |
| "A number of different treatments for neuropathic pain have been studied, but the literature is sizable, rapidly evolving, and lacks important information about practical aspects of patient management." | 2.45 | Treatment of neuropathic pain: an overview of recent guidelines. ( Dworkin, RH; O'Connor, AB, 2009) |
| "Neuropathic pain is a debilitating pain that occurs after nerve injury and is generally resistant to currently available treatments including morphine." | 2.45 | [The mechanism and control of neuropathic pain]. ( Inoue, K, 2009) |
| "The search term "neuropathic pain" was used along with each of the agents outlined in this review: pregabalin, paroxetine CR, duloxetine, tramadol XL, Tramacet, Sativex, and nabilone." | 2.45 | A treatment algorithm for neuropathic pain: an update. ( Esfahani, F; Gomori, A; Grossberndt, A; Intrater, H; Klowak, M; Leong, C; Namaka, M; Turcotte, D, 2009) |
| " On the other hand, for GP a maximum dosage of 3,600 mg/day reduced VAS score (P = 0." | 2.44 | Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. ( Amaniti, E; Kouvelas, D; Papazisis, G; Tzellos, TG, 2008) |
| " Recommendations for future research to inform clinical practice should include cost-effectiveness studies and dose-response analysis in order to determine the schema employed and the duration of treatment." | 2.44 | Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. ( Amaniti, E; Kouvelas, D; Papazisis, G; Tzellos, TG, 2008) |
| "Some mechanisms of the development of neuropathic pain have been proposed; 1) sprouting of A beta fibers to the superficial layer of the dorsal horn, 2) ectopic discharge in the dorsal root ganglion and/or in neuroma at the nerve stump, 3) spinal sensitization." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Neuropathic pain has been known to be refractory to traditional analgesics, such as opioids and non-steroidal anti-inflammatoy drugs." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Central neuropathic pain is a painful condition, often severe, that occurs in a person who is already affected by an injury or disease of the brain or spinal cord." | 2.44 | Pregabalin in the management of central neuropathic pain. ( Gray, P, 2007) |
| " The most common treatment-emergent adverse events were dizziness, somnolence, and peripheral edema." | 2.44 | Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. ( Durso-Decruz, E; Emir, B; Freeman, R, 2008) |
| "To evaluate the efficacy, safety, and tolerability of pregabalin across the effective dosing range, to determine differences in the efficacy of three times daily (TID) versus twice daily (BID) dosage schedules, and to use time-to-event analysis to determine the time to onset of a sustained therapeutic effect using data from seven trials of pregabalin in painful diabetic peripheral neuropathy (DPN)." | 2.44 | Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. ( Durso-Decruz, E; Emir, B; Freeman, R, 2008) |
| " Only one trial included all three of these dosages, and TID dosing was used in four." | 2.44 | Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. ( Durso-Decruz, E; Emir, B; Freeman, R, 2008) |
| " Only the 600 mg/day dosage showed efficacy when administered BID (P < or = 0." | 2.44 | Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. ( Durso-Decruz, E; Emir, B; Freeman, R, 2008) |
| "Treatment with pregabalin across its effective dosing range is associated with significant, dose-related improvement in pain in patients with DPN." | 2.44 | Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. ( Durso-Decruz, E; Emir, B; Freeman, R, 2008) |
| " It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily." | 2.43 | Pregabalin for neuropathic pain based on recent clinical trials. ( Stacey, BR; Swift, JN, 2006) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 2.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| " Thus, monitoring and dosage adjustment are required, without discontinuation of the drug." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Treatment decisions for patients with neuropathic pain can be difficult." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Neuropathic pain is defined as pain caused by a lesion in the nervous system and is common in clinical practice." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia." | 2.42 | Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. ( Backonja, M; Glanzman, RL, 2003) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin displays nonlinear absorption kinetics, is minimally protein bound (< 3%), has a high mean (SD) volume of distribution (50." | 2.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| " The recommended dosage in adults is 300 mg at bedtime on day 1,300 mg BID on day 2, and 300 mg TID on day 3, titrating up as needed to 2400 to 3600 mg/d." | 2.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 2.42 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Diagnosis and management of neuropathic pain syndromes is challenging." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin is a newer generation antiepileptic drug that is commonly used in treatment of neuropathic pain." | 2.41 | Use of gabapentin in the treatment of neuropathic pain. ( Gidal, BE; Laird, MA, 2000) |
| "Gabapentin is a recently introduced anti-epileptic drug used as an adjuvant in partial and secondarily generalised tonic-clonic seizures." | 2.41 | [Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?]. ( Kamp-Jensen, M; Werner, MU, 2001) |
| "Two large, controlled clinical trials of painful diabetic neuropathy and postherpetic neuralgia have demonstrated its analgesic efficacy." | 2.41 | [Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?]. ( Kamp-Jensen, M; Werner, MU, 2001) |
| "Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| " Also, the dosing of the drug in children has been complicated by negative behavioral adverse effects." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 2.41 | [Gabapentin for therapy of neuropathic pain]. ( Block, F, 2001) |
| "Gabapentin proved to be a significantly better analgesic than placebo, was well tolerated in the elderly population, and had a significant positive impact on several subjective and objective outcome measures." | 2.40 | Gabapentin: a new tool in the treatment of neuropathic pain. ( Harden, RN, 1999) |
| "Gabapentin has emerged as a useful new tool based on the results of two large multicenter trials in models of human neuropathy." | 2.40 | Gabapentin: a new tool in the treatment of neuropathic pain. ( Harden, RN, 1999) |
| "Human neuropathic pain remains a prevalent and pervasive problem in our society." | 2.40 | Gabapentin: a new tool in the treatment of neuropathic pain. ( Harden, RN, 1999) |
| "127 patients, aged 18-70 years, who had neuropathic pain related to spinal cord injury (SCI) and disease duration of at least 12 months." | 1.91 | Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury. ( Akıncı, MG; Altas, EU; Konak, HE; Onat, SS; Polat, CS, 2023) |
| "The test groups that demonstrated anti-neuropathic pain activity were further tested in combination with pregabalin, followed by mechanistic studies." | 1.91 | Anti-neuropathic Pain Mechanistic Study on ( Adnyana, IK; Anggadiredja, K; Sukmawan, YP, 2023) |
| "Neuropathic pain has become a contributor to the global burden of illness." | 1.91 | Anti-neuropathic Pain Mechanistic Study on ( Adnyana, IK; Anggadiredja, K; Sukmawan, YP, 2023) |
| "Emodin treatment evoked the expression alteration of 402 proteins (153 up-regulated and 249 down-regulated) in the CCI models, which were primarily involved in PI3K/AKT signaling pathway, gamma-aminobutyric acid (GABA) receptor signaling, complement and coagulation cascades, cGMP/PKG signaling pathway, MAPK signaling pathway, and calcium signaling pathway." | 1.91 | Proteomic and metabolomic approaches elucidate the molecular mechanism of emodin against neuropathic pain through modulating the gamma-aminobutyric acid (GABA)-ergic pathway and PI3K/AKT/NF-κB pathway. ( Chen, P; Gong, Q; Huang, NY; Liu, C; Luo, RX; Pang, B; Wang, C; Wang, L; Ye, ZJ, 2023) |
| " They were also excluded if they lacked sufficient information about how long or at what dosage they had been using the drug." | 1.91 | Abuse and addiction in gabapentinoid drug users for neuropathic pain. ( Aydin Özaslan, E; Kiliç, Z, 2023) |
| "Chronic neuropathic pain often leads to cognitive impairment, but the exact mechanism remains unclear." | 1.72 | Hippocampal Inhibitory Synapsis Deficits Induced by α5-Containing GABA ( Cai, W; Cai, X; Mao, M; Qiu, L; Sun, J; Wang, C; Wen, Y; Yang, H; Zhou, Z; Zhu, W; Zhu, Y, 2022) |
| "A cardinal, intractable symptom of neuropathic pain is mechanical allodynia, pain caused by innocuous stimuli via low-threshold mechanoreceptors such as Aβ fibers." | 1.62 | A subset of spinal dorsal horn interneurons crucial for gating touch-evoked pain-like behavior. ( Furue, H; Koga, K; Sekine, M; Tashima, R; Tozaki-Saitoh, H; Tsuda, M; Watanabe, M; Yasaka, T; Yoshikawa, Y, 2021) |
| "Sensory dysfunctions such as allodynia and hyperalgesia are only part of the symptoms associated with neuropathic pain that extend to memory and affectivity deficits." | 1.62 | 2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors. ( Amodeo, P; Belardo, C; Boccella, S; Calignano, A; Cristiano, C; de Novellis, V; Di Marzo, V; Guida, F; Iannotta, M; Iannotti, FA; Infantino, R; Luongo, L; Maione, S; Marabese, I; Paino, S; Palazzo, E; Ricciardi, F; Vitale, RM, 2021) |
| "Here we report that neuropathic pain-like hypersensitivity induced by common peroneal nerve (CPN) ligation increases nociceptive stimulation-induced responses in glutamatergic LPBN neurons." | 1.56 | Parabrachial nucleus circuit governs neuropathic pain-like behavior. ( Chen, Z; Duan, S; Guo, F; Li, KY; Li, XJ; Li, XY; Li, YY; Liu, R; Ma, XL; Sun, H; Sun, L; Wen, MQ; Wu, MY; Xu, CL; Yu, YQ; Zhu, ZG, 2020) |
| "A rat model of neuropathic pain at 6 weeks after spinal nerve ligation (SNL6w) exhibits both mechanical hypersensitivity and impaired noxious stimuli-induced analgesia (NSIA)." | 1.51 | Tropomyosin Receptor Kinase B Receptor Activation in the Locus Coeruleus Restores Impairment of Endogenous Analgesia at a Late Stage Following Nerve Injury in Rats. ( Kato, D; Obata, H; Saito, S; Suto, T, 2019) |
| "MCS reversed the hyperalgesia induced by peripheral neuropathy in the rats with chronic sciatic nerve constriction and induced a significant increase in the glycine and GABA levels in the PAG in comparison with the naive and sham-treated rats." | 1.51 | Neurochemical effects of motor cortex stimulation in the periaqueductal gray during neuropathic pain. ( Antunes, GF; Assis, DV; Auada, AVV; de Andrade, EM; Fonoff, ET; Gouveia, FV; Lebrun, I; Lopes, PSS; Martinez, RCR; Pagano, RL, 2019) |
| "Mechanical allodynia and thermal hyperalgesia were measured to confirm neuropathic pain induction following before and after gabapentin (GBP) treatment." | 1.48 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "The brain regions relating SNL-induced neuropathic pain were as follows: the posterior association area of the parietal region, superior colliculus, inferior colliculus, primary somatosensory area, cingulate cortex, and cingulum bundle." | 1.48 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "SNL induced- neuropathic pain is transmitted to the primary somatosensory area and parietal region through the cingulum bundle and limbic system." | 1.48 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "Neuropathic pain was severely induced by SNL on the postoperative day 14, excepting the sham group." | 1.48 | Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI. ( Jeong, KY; Kang, JH, 2018) |
| "While S 38093 did not change vocalization thresholds to paw pressure in healthy rats, it exhibited a significant antihyperalgesic effect in the Streptozocin-induced diabetic (STZ) neuropathy model after acute and chronic administration and, in the chronic constriction injury (CCI) model only after chronic administration, submitted to the paw-pressure test." | 1.48 | Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats. ( Ardid, D; Berrocoso, E; Bravo, L; Chalus, M; Chapuy, E; Chaumette, T; Eschalier, A; Llorca-Torralba, M; Marchand, F; Mico, JA; Sors, A, 2018) |
| "This effect of S 38093 in neuropathic pain could be partly mediated by α2 receptors desensitization in the locus coeruleus." | 1.48 | Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats. ( Ardid, D; Berrocoso, E; Bravo, L; Chalus, M; Chapuy, E; Chaumette, T; Eschalier, A; Llorca-Torralba, M; Marchand, F; Mico, JA; Sors, A, 2018) |
| "Neuropathic pain is among the most common and difficult-to-treat types of chronic pain and is associated with sodium channel malfunction." | 1.48 | Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. ( Liang, X; Su, R; Yu, G, 2018) |
| "Left sciatic nerve ligation was used as neuropathic pain model." | 1.48 | Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats. ( Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR, 2018) |
| "Neuropathic pain is a worldwide health problem with no consensus regarding its optimal therapy." | 1.48 | Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats. ( Abdelwahab, S; Abdelzaher, WY; Ibrahim, MA; Rofaeil, RR, 2018) |
| "Von Frey filaments were used to assess tactile allodynia." | 1.48 | Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain. ( Barragán-Iglesias, P; Delgado-Lezama, R; Granados-Soto, V; Hong, E; Loeza-Alcocer, E; Oidor-Chan, VH; Pineda-Farias, JB; Price, TJ; Salinas-Abarca, AB; Sánchez-Mendoza, A; Velazquez-Lagunas, I, 2018) |
| "Neuropathic pain is a debilitating pathological condition that is poorly understood." | 1.46 | Neuropathic pain-induced enhancement of spontaneous and pain-evoked neuronal activity in the periaqueductal gray that is attenuated by gabapentin. ( Faingold, CL; Premkumar, LS; Samineni, VK, 2017) |
| "Neuropathic pain was induced by a chronic constriction injury of the sciatic nerve (CCI) and mechanical allodynia and the spatial memory was assessed using the Von Frey filaments and Morris water maze respectively." | 1.46 | In vivo evaluation of the hippocampal glutamate, GABA and the BDNF levels associated with spatial memory performance in a rodent model of neuropathic pain. ( Farahmandfar, M; Janzadeh, A; Naghdi, N; Nasirinezhad, F; Saffarpour, S; Shaabani, M, 2017) |
| "A distinct acute, severe form of neuropathic pain, called insulin neuritis or treatment-induced painful neuropathy of diabetes (TIND), may also occur shortly after initiation of intensive glycemic control, with an incidence rate of up to 10." | 1.46 | Murine model and mechanisms of treatment-induced painful diabetic neuropathy. ( Anaya, CJ; Enriquez, C; Jolivalt, CG; Marquez, A; Nicodemus, JM, 2017) |
| " Patients' demographic and clinical characteristics, resource utilization data and adverse drug reactions (ADRs) as described in the leaflet were extracted." | 1.46 | Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. ( Katz, P; Liedgens, H; Pegoraro, V, 2017) |
| " We report on a case of a 31 year old female who presented to the emergency department with unilateral leg pain, weakness, and swelling after increasingly titrating her Gabapentin dosage over three weeks." | 1.46 | Radiologic Findings in Gabapentin-Induced Myositis. ( Chang, DR; Coupal, TM; Munk, PL; Ouellette, HA; Pennycooke, K, 2017) |
| "Compared with nociceptive pain, neuropathic pain is a challenging diagnosis to make and successfully treat in children with cancer." | 1.46 | Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer. ( Bruera, E; Madden, K, 2017) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma-1 antagonists." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Chronic pain, neuropathic pain, inflammatory pain, ozone therapy, interventional therapy, gabapentin, spared nerve injury, bee venom, complete Freud's adjuvant." | 1.46 | Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain. ( Chen, J; Guan, SM; Luo, WJ; Sun, W; Wang, JL; Wang, JS; Wang, XL; Wu, FF; Yang, F; Zheng, W, 2017) |
| "Gabapentin (GBP) is a first-line therapy for neuropathic pain, but its mechanisms and sites of action remain uncertain." | 1.46 | Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. ( Bannister, K; Dickenson, AH; King, T; Navratilova, E; Oyarzo, J; Porreca, F; Qu, C; Xie, JY, 2017) |
| "Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to generating unwanted side-effects." | 1.46 | Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model. ( Ahmad, N; Islam, NU; Rahman, FU; Sewell, RDE; Shahid, M; Subhan, F, 2017) |
| "Here we report a case of possible small fiber neuropathy associated with hantavirus infection, in a patient who survived HCPS." | 1.46 | A neuropathic pain syndrome associated with hantavirus infection. ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017) |
| "Persistent and treatment-resistant neuropathic pain may be a prominent feature in hantavirus-associated peripheral neuropathy." | 1.46 | A neuropathic pain syndrome associated with hantavirus infection. ( Anderson, D; Beecher, G; Bridgland, L; Power, C; Zochodne, DW, 2017) |
| "The rat model of neuropathic pain was successfully established." | 1.46 | [Effects of HCN2 in the development of peripheral neuropathic pain in rats]. ( Fu, B; Huang, T; Liu, SJ; Wang, B; Wang, J; Weng, XC, 2017) |
| "Treatment with gabapentin, but not amitriptyline, was associated with a complete attenuation of hind paw mechanical hypersensitivity observed with indinavir treatment." | 1.46 | A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy. ( Bennett, DLH; Calvo, M; Huang, W; Pheby, T; Rice, ASC, 2017) |
| "It often presents with significant neuropathic pain and is associated with previous exposure to neurotoxic nucleoside reverse transcriptase inhibitors." | 1.46 | A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy. ( Bennett, DLH; Calvo, M; Huang, W; Pheby, T; Rice, ASC, 2017) |
| "CFA-induced hyperalgesia and sensitivity to morphine (0." | 1.46 | Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter? ( Bjerrum, OJ; Heegaard, AM; Hestehave, S; Jeggo, RD; Kristensen, PJ; Munro, G, 2017) |
| "Gabapentin gel (10% w/w) was applied three times daily on the ipsilateral or contralateral plantar surface of the hind-paw, whereas in a concurrent systemic study, gabapentin was intraperitoneally administered daily (75 mg/kg) for 30 days." | 1.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Tests for static- and dynamic-mechano-allodynia [paw withdrawal threshold (PWT) to von Frey filament application and latency (PWL) to light brushing], cold-allodynia [paw withdrawal duration (PWD) to acetone], heat- (PWL and PWD) and mechano-hyperalgesia (PWD to pin prick) were utilized to assess pain, whereas effects on locomotion (open field) and motor balance (rotarod and footprint analysis) were measured on days 5-30 post surgery." | 1.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Systemic gabapentin neuropathic pain management carries side-effects ostensibly preventable by localized therapy." | 1.46 | Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model. ( Ahmad, N; Akbar, S; Ali, G; Fawad, K; Sewell, RD; Shahid, M; Subhan, F, 2017) |
| "Chronic pain is a multifactorial disease comprised of both inflammatory and neuropathic components that affect ∼20% of the world's population." | 1.46 | sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. ( Bialer, M; Brennan, KC; Devor, M; Kaufmann, D; Smith, MD; West, PJ; White, HS; Yagen, B, 2017) |
| "Using 3 rat models of neuropathic pain of toxic (oxaliplatin/OXA), metabolic (streptozocin/STZ), and traumatic (sciatic nerve ligation/CCI [chronic constriction nerve injury]) etiologies, we investigated the antihypersensitivity effect of acute and repeated agomelatine administration." | 1.46 | Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence. ( Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E, 2017) |
| "Daily gabapentin treatment attenuated mechanical allodynia and reduced face-grooming episodes in dIoN-CCI rats." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "A rodent model of trigeminal neuropathic pain was first developed in 1994, in which chronic constriction injury (CCI) is induced by ligation of the infraorbital nerve (IoN)." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "However, studies on trigeminal neuropathic pain remain limited." | 1.46 | An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve. ( Chen, L; Ding, W; Doheny, JT; Lim, G; Mao, J; Shen, S; Yang, J; You, Z; Zhu, S, 2017) |
| "Donepezil was started at 3-5 mg/day upon experiencing gabapentinoid-induced somnolence." | 1.46 | Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review. ( Abe, H; Hozumi, J; Ikegami, K; Inoue, R; Kawahara, K; Kogure, T; Sumitani, M; Yamada, Y, 2017) |
| "Neuropathic pain is often treated with gabapentinoids (pregabalin, gabapentin), but gabapentinoid-induced somnolence sometimes prevents patients from using these agents." | 1.46 | Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review. ( Abe, H; Hozumi, J; Ikegami, K; Inoue, R; Kawahara, K; Kogure, T; Sumitani, M; Yamada, Y, 2017) |
| "The Dunning rat model of prostate cancer was used." | 1.43 | Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model. ( Altun, S; Bugan, I; Djamgoz, MB; Karagoz, Z, 2016) |
| "Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain." | 1.43 | A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016) |
| "The pharmacotherapy for neuropathic pain includes gabapentin and tramadol, but these are only partially effective when given alone." | 1.43 | Antinociceptive Interaction of Tramadol with Gabapentin in Experimental Mononeuropathic Pain. ( Aranda, N; Castillo, R; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Zanetta, P, 2016) |
| "Neuropathic pain is the result of injury to the nervous system, and different animal models have been established to meet the manifestations of neuropathy." | 1.43 | Antinociceptive Interaction of Tramadol with Gabapentin in Experimental Mononeuropathic Pain. ( Aranda, N; Castillo, R; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Zanetta, P, 2016) |
| "Gabapentin is a good alternative therapeutic option to anesthetic blockade." | 1.43 | Auriculotemporal Neuralgia: Eight New Cases Report. ( Cuadrado, ML; de la Cruz, C; Garcia-Ptacek, S; Guerrero, AL; Porta-Etessam, J; Ruiz, M, 2016) |
| "The treatment with gabapentin at an average dose of 1,135 mg for 14 weeks reduced pain in 80% of the patients (p < 0." | 1.43 | [Postmastectomy pain syndrome in our region: characteristics, treatment, and experience with gabapentin]. ( de Miguel-Jimeno, JM; Forner-Cordero, I; Matute-Tobias, B; Zabalza-Azparren, M, 2016) |
| "In the nerve injury model of neuropathic pain, WNK1/HSN2 contributed to a maladaptive decrease in the activity of the K(+)-Cl(-)cotransporter KCC2 by increasing its inhibitory phosphorylation at Thr(906)and Thr(1007), resulting in an associated loss of GABA (γ-aminobutyric acid)-mediated inhibition of spinal pain-transmitting nerves." | 1.43 | Inhibition of the kinase WNK1/HSN2 ameliorates neuropathic pain by restoring GABA inhibition. ( Andrews, N; Castonguay, G; Dion, PA; Duan, J; Gaudet, R; Hince, P; Inquimbert, P; Kahle, KT; Khanna, AR; Laganière, J; Latremoliere, A; Lavastre, V; Mapplebeck, JC; Mogil, JS; Omura, T; Rochefort, D; Rouleau, GA; Schmouth, JF; Sotocinal, SG; Ward, C; Woolf, CJ; Zhang, J, 2016) |
| "Preclinical Research Neuropathic pain is particularly difficult to treat because of its diverse etiologies and underlying pathophysiological mechanisms." | 1.43 | Antinociceptive Interactions Between Meloxicam and Gabapentin in Neuropathic Pain Depend on the Ratio used in Combination in Rats. ( Corona-Ramos, JN; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Medina-López, JR, 2016) |
| "The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test." | 1.43 | Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016) |
| "The mechanical allodynia was significantly increased on day 3 after BCAO compared with that during the pre-BCAO assessment." | 1.43 | Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016) |
| "Chronic neuropathic pain is a debilitating condition that remains difficult to treat." | 1.43 | Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain. ( Chen, H; Chen, SR; Hittelman, WN; Li, L; Pan, HL; Wen, L; Xie, JD, 2016) |
| "After MPNL, mechanical allodynia was established, and mice quickly recovered from the surgery without any significant motor impairment." | 1.43 | Medial plantar nerve ligation as a novel model of neuropathic pain in mice: pharmacological and molecular characterization. ( Alves-Filho, JC; Bassi, GS; Bozzo, TA; Cunha, FQ; Cunha, TM; Ferreira, SH; Kusuda, R; Sant'Anna, MB; Souza, GR, 2016) |
| "Peripheral neuropathic pain is a consequence of an injury/disease of the peripheral nerves." | 1.43 | Medial plantar nerve ligation as a novel model of neuropathic pain in mice: pharmacological and molecular characterization. ( Alves-Filho, JC; Bassi, GS; Bozzo, TA; Cunha, FQ; Cunha, TM; Ferreira, SH; Kusuda, R; Sant'Anna, MB; Souza, GR, 2016) |
| "Gabapentin (Gap) relieves neuropathic pain, but it has several adverse effects as well." | 1.43 | Vitamin C enhances the analgesic effect of gabapentin on rats with neuropathic pain. ( Huang, Y; Li, R; Ma, C; Shen, L; Yu, X, 2016) |
| "In the present study, we found that neuropathic pain induced by the chemotherapeutic drug paclitaxel or L5 ventral root transection significantly impaired the function of GABAergic synapses of spinal dorsal horn neurons via the reduction of the GAD67 expression." | 1.43 | mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain. ( Huang, ZZ; Li, D; Liu, CC; Ma, C; Ou-Yang, HD; Wei, JY; Wu, SL; Xin, WJ; Xu, T; Zhang, XL, 2016) |
| "Neuropathic pain is a common neurobiological disease involving multifaceted maladaptations ranging from gene modulation to synaptic dysfunction, but the interactions between synaptic dysfunction and the genes that are involved in persistent pain remain elusive." | 1.43 | mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain. ( Huang, ZZ; Li, D; Liu, CC; Ma, C; Ou-Yang, HD; Wei, JY; Wu, SL; Xin, WJ; Xu, T; Zhang, XL, 2016) |
| "Neuropathic pain is a common neurobiological disease involving multifaceted maladaptations ranging from gene modulation to synaptic dysfunction, but the underlying molecular mechanisms remain elusive." | 1.43 | mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain. ( Huang, ZZ; Li, D; Liu, CC; Ma, C; Ou-Yang, HD; Wei, JY; Wu, SL; Xin, WJ; Xu, T; Zhang, XL, 2016) |
| " Dose-response curves (DRC) and isobolographic analysis were used to confirm their synergistic antihyperalgesic and anti-allodynic responses in a rat neuropathic pain model involving chronic constriction injury of the sciatic nerve and in von Frey and acetone tests." | 1.43 | The Antinociceptive Effects of Tramadol and/or Gabapentin on Rat Neuropathic Pain Induced by a Chronic Constriction Injury. ( Corona-Ramos, JN; De la O-Arciniega, M; Déciga-Campos, M; Domínguez-Ramírez, AM; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Medina-López, JR, 2016) |
| "Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models." | 1.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Mechanical allodynia was assessed using von Frey hairs." | 1.43 | Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain. ( Classon, B; Edenius, C; Grabowska, U; Henderson, I; Hewitt, E; Lindström, E; Malcangio, M; Pitcher, T; Rizoska, B; Sahlberg, BL; Tunblad, K, 2016) |
| "Neuropathic pain is a severe and unbearable condition which arises due to activation of peripheral nociceptors after tissue damage, neuropathic pain is caused from anomalous physiology of central or peripheral nervous system and it may not be related to the ongoing tissue damage or inflammation." | 1.43 | Potential Contribution of Antioxidant Mechanism in the Defensive Effect of Lycopene Against Partial Sciatic Nerve Ligation Induced Behavioral, Biochemical and Histopathological Modification in Wistar Rats. ( Goel, R; Tyagi, N, 2016) |
| "Neuropathic pain was induced in wistar rats by partial sciatic nerve ligation." | 1.43 | Potential Contribution of Antioxidant Mechanism in the Defensive Effect of Lycopene Against Partial Sciatic Nerve Ligation Induced Behavioral, Biochemical and Histopathological Modification in Wistar Rats. ( Goel, R; Tyagi, N, 2016) |
| "The muscimol treated, hemisection-SCI rats also exhibited increased hindpaw withdrawal thresholds and latencies." | 1.43 | Suppressed GABAergic signaling in the zona incerta causes neuropathic pain in a thoracic hemisection spinal cord injury rat model. ( Cho, CB; Lee, YJ; Moon, HC; Park, YS, 2016) |
| "These data provide evidence that neuropathic pain after SCI is caused by decreased GABAergic signaling in the ZI." | 1.43 | Suppressed GABAergic signaling in the zona incerta causes neuropathic pain in a thoracic hemisection spinal cord injury rat model. ( Cho, CB; Lee, YJ; Moon, HC; Park, YS, 2016) |
| "Robust allodynia was observed in all three ligation groups." | 1.42 | Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit. ( Baker, KB; Lanthorn, TH; Mason, S; Rajan, I; Savelieva, KV; Vogel, P; Ye, GL, 2015) |
| "The ongoing use of gabapentin for neuropathic pain was primarily driven by the perception that it was a safe, non-addictive drug with few drug interactions, by possible similarities between the physiology of chronic pain and other neurological conditions, by the well-established clinical precedent of using antiepileptic drugs in pain management, and by the lack of alternative options available in the market." | 1.42 | Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain. ( Ghinea, N; Kerridge, I; Lipworth, W, 2015) |
| "Burst and tonic SCS both reduce allodynia." | 1.42 | Burst and Tonic Spinal Cord Stimulation Differentially Activate GABAergic Mechanisms to Attenuate Pain in a Rat Model of Cervical Radiculopathy. ( Crosby, ND; Goodman-Keiser, MD; Smith, JR; Weisshaar, CL; Winkelstein, BA; Zeeman, ME, 2015) |
| "Paclitaxel treatment resulted in thermal hyperalgesia and in increased GABA transporter-1 (GAT-1) mRNA expression, but not that of other GABA transporters or GABA(A) ergic enzymes in the ACC compared to vehicle treatment." | 1.42 | Comprehensive analysis of the GABAergic system gene expression profile in the anterior cingulate cortex of mice with Paclitaxel-induced neuropathic pain. ( Masocha, W, 2015) |
| "Gabapentin was effective in transiently reversing mechanical allodynia in those mice with lowered thresholds." | 1.42 | Differences in cisplatin-induced mechanical allodynia in male and female mice. ( Corr, M; Woller, SA; Yaksh, TL, 2015) |
| "Male WT mice develop a persistent tactile allodynia resulting from cisplatin administration." | 1.42 | Differences in cisplatin-induced mechanical allodynia in male and female mice. ( Corr, M; Woller, SA; Yaksh, TL, 2015) |
| "Epilepsy was assumed as indication when other AEDs were also measured (50% of patients)." | 1.42 | Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. ( Baftiu, A; Beiske, G; Burns, ML; Johannessen Landmark, C; Johannessen, SI, 2015) |
| "A hallmark of peripheral neuropathic pain (PNP) is chronic spontaneous pain and/or hypersensitivity to normally painful stimuli (hyperalgesia) or normally nonpainful stimuli (allodynia)." | 1.42 | Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats. ( Al Otaibi, M; Djouhri, L; Sathish, J; Smith, T, 2015) |
| "Paclitaxel is a chemotherapeutic agent widely used for treating carcinomas." | 1.42 | Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel. ( Gao, M; Maixner, DW; Weng, HR; Yadav, R; Yan, X, 2015) |
| "In rats with paclitaxel-induced neuropathic pain, the protein expression of GAT-1 was increased while GAT-3 was decreased." | 1.42 | Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel. ( Gao, M; Maixner, DW; Weng, HR; Yadav, R; Yan, X, 2015) |
| "Intrathecal tianeptine reduces neuropathic pain." | 1.42 | Antiallodynic effect of tianeptine via modulation of the 5-HT7 receptor of GABAergic interneurons in the spinal cord of neuropathic rats. ( Heo, BH; Kim, WM; Kim, YC; Lin, H; Yoon, MH, 2015) |
| "Neuropathic pain was induced by spinal nerve ligation (SNL)." | 1.42 | Antiallodynic effect of tianeptine via modulation of the 5-HT7 receptor of GABAergic interneurons in the spinal cord of neuropathic rats. ( Heo, BH; Kim, WM; Kim, YC; Lin, H; Yoon, MH, 2015) |
| "Gabapentin was used as a reference drug in the study." | 1.42 | Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice. ( Guo, W; Han, WJ; Hong, ZY; Huang, ZL; Li, YD; Liu, YY; Qu, WM; Wang, TX; Yin, D, 2015) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 1.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "OMT had analgesic effect on neuropathic pain, which might be probably related to HVDDCs." | 1.42 | [The Analgesia of Oxymatrine Affecting Calcium Channel and GABA Release]. ( Deng, YO; Liu, YG; Lu, XQ; Wu, SX; Yang, L, 2015) |
| "Neuropathic pain is a prevalent and distressing problem faced by people with life-limiting illness that is often difficult to palliate." | 1.42 | Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population? ( Clark, K; Currow, DC; Doogue, M; Lovell, M; Quinn, SJ; Sanderson, C, 2015) |
| "Mechanical allodynia in SNL rats was attenuated by gabapentin (100 mg/kg) and AQU-118 (in a dose-dependent manner)." | 1.42 | Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain. ( Davis, SF; Fairchild, DD; Hain, HS; Hanania, T; Henry, MA; Hu, A; Malekiani, SA; Nix, D; Patil, MJ; Sucholeiki, I; Sucholeiki, R, 2015) |
| "Gabapentin (GBP) is an anti-convulsive drug often used as analgesic to control neuropathic pain." | 1.42 | Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats. ( Araújo, CV; Brito, GAC; Câmara, CC; de Sousa, KKO; Martinez, AMB; Mendonça, FE; Mietto, BS; Oriá, RB; Raposo, RDS; Vale, ML, 2015) |
| " Since, 5-HT6 antagonists improved the effectiveness of gabapentinoids, reduction in the dosage and frequency of gabapentinoids treatment may reduce the side effects." | 1.42 | 5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids. ( Babu, VA; Bhyrapuneni, G; Goura, V; Jayarajan, P; Nirogi, R; Shinde, A; Yathavakilla, S, 2015) |
| "Ambroxol acts as a strong local anaesthetic and preferentially inhibits the nociceptively relevant sodium channel subtype Nav 1." | 1.42 | Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. ( Kern, KU; Weiser, T, 2015) |
| "The reasons for neuropathic pain were postherpetic neuralgia (2 ×), mononeuropathy multiplex, phantom pain, deafferentation pain, postoperative neuralgia and foot neuropathy of unknown origin." | 1.42 | Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. ( Kern, KU; Weiser, T, 2015) |
| "Neuropathic pain is difficult to treat, and the available options are often inadequate." | 1.42 | Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. ( Kern, KU; Weiser, T, 2015) |
| "In addition, PLSN-induced mechanical and thermal hyperalgesia was prevented by systemic (i." | 1.40 | The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice. ( Calixto, JB; Costa, R; Manjavachi, MN; Quintão, NL, 2014) |
| " Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test." | 1.40 | Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats. ( Hashimoto, R; Hosokawa, K; Mashimo, T; Nakae, A; Nakai, K, 2014) |
| "Gabapentin has shown to be effective in animals and humans with acute postoperative and chronic pain." | 1.40 | Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms. ( Eisenach, JC; Hayashida, K; Severino, AL; Suto, T, 2014) |
| " The objective of the present study was to evaluate the efficacy and safety of OROS® hydromorphone combined with pregabalin in patients with chronic non-cancer neuropathic pain." | 1.40 | Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| " Dosage and side effects were recorded at each visit." | 1.40 | Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| " Initial mean dosage was 6." | 1.40 | Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| "Treatment for chronic non-cancer neuropathic pain can be complicated by side effects and drug interactions." | 1.40 | Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| "Seventeen percent (n = 224) had purely neuropathic pain." | 1.40 | Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014) |
| "Both drugs did not affect cold allodynia, whereas pregabalin (30 mg/kg) attenuated heat hyperalgesia (80% vs." | 1.40 | Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. ( Cios, A; Filipek, B; Malawska, B; Mogilski, S; Sałat, K; Sałat, R; Więckowski, K; Wyska, E, 2014) |
| "Tramadol was active against all four endpoints in the Chung model with similar effects in the CCI model, apart from tactile allodynia." | 1.40 | Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine. ( Castagné, V; Le Cudennec, C, 2014) |
| "The selected endpoints were tactile allodynia, tactile hyperalgesia, heat hyperalgesia and cold allodynia." | 1.40 | Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine. ( Castagné, V; Le Cudennec, C, 2014) |
| "Neuropathic pain is a chronic condition resulting from neuronal damage." | 1.40 | Silicon-containing GABA derivatives, silagaba compounds, as orally effective agents for treating neuropathic pain without central-nervous-system-related side effects. ( Amano, Y; Fukasawa, H; Ito, A; Muratake, H; Nagae, M; Shudo, K; Sugiyama, K; Suzuki, H, 2014) |
| "Koumine treatment of diabetic rats decreased neuropathic pain behavior as early as after the first administration." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Koumine was given at a dose range of 0." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Diabetic rats developed mechanical hyperalgesia within 3 weeks after streptozocin injection and exhibited reduced SNCV and impaired myelin/axonal structure." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Gabapentin, commonly used to treat neuropathic pain, produced increased NAc DA in rats with SNL but not in animals with incisional, injury." | 1.40 | Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. ( Becerra, L; Borsook, D; Navratilova, E; Ossipov, MH; Patwardhan, A; Porreca, F; Qu, C; Xie, JY, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | 1.40 | Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| "It may be associated with allodynia and increased pain sensitivity." | 1.40 | Nerve regenerative effects of GABA-B ligands in a model of neuropathic pain. ( Caffino, L; Castelnovo, LF; Cavalli, E; Colciago, A; Faroni, A; Magnaghi, V; Pajardi, G; Procacci, P, 2014) |
| "Few studies correlated neuropathic pain with nerve morphology and myelin proteins expression." | 1.40 | Nerve regenerative effects of GABA-B ligands in a model of neuropathic pain. ( Caffino, L; Castelnovo, LF; Cavalli, E; Colciago, A; Faroni, A; Magnaghi, V; Pajardi, G; Procacci, P, 2014) |
| "Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
| "Mechanical allodynia was fully developed by 28-30days post-immunization (p." | 1.40 | Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. ( Khan, N; Smith, MT; Woodruff, TM, 2014) |
| "This paper aimed to discuss the curative effect and safety of curing intercostal neuralgia through paravertebral nerve block combined with pregabalin." | 1.40 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| " The result showed that: visual analogue scale (VAS) and quality of sleep (QS) of three groups of patients after treatment all decreased obviously; group A had slow work, large amount of dosage and many adverse effects; group B had quick work, but the improvement on pain and sleep was not satisfactory; the curative effect of group C was higher than group A and B (p<0." | 1.40 | Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin. ( Wu, X; Xiao, P; Zhu, X, 2014) |
| "After establishment of neuropathic pain model with the lumbar 5 spinal nerve ligation (L5 SNL), the GABA-evoked currents were recorded in the acutely dissociated L4 DRG neurons using whole-cell patch clamp." | 1.40 | The role of the GABA-A receptor of the adjacent intact dorsal root ganglion neurons in rats with neuropathic pain. ( Fu, J; Gu, J; Gu, Y; Li, G; Ran, R; Wang, L; Wang, Q; Zhang, A; Zhao, Y; Zhong, H, 2014) |
| "Neuropathic pain is a debilitating condition that is often resistant to common analgesics, such as opioids, but is sensitive to some antidepressants, an effect that seems to be mediated by spinal cord 5-HT3 receptors." | 1.39 | The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model. ( Bonacorso, HG; Fachinetto, R; Ferreira, J; Machado, P; Martins, MA; Oliveira, SM; Pinheiro, Fde V; Pinheiro, Kde V; Villarinho, JG; Zanatta, N, 2013) |
| "The selected neuropathic pain model was the spared nerve injury (SNI) model and the endpoints were burrowing and measures of paw posture in Sprague Dawley rats." | 1.39 | A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain. ( de Lannoy, IA; Dykstra, C; Higgins, GA; Lau, W; Lee, DK; Silenieks, LB; Thevarkunnel, S, 2013) |
| "One feature of neuropathic pain is a reduced spinal gamma-aminobutyric acid (GABA)-ergic inhibitory function." | 1.39 | Effect of antioxidant treatment on spinal GABA neurons in a neuropathic pain model in the mouse. ( Chung, JM; Chung, K; Kim, HY; Lu, Y; Wang, J; Yowtak, J, 2013) |
| "Shorter disease progression and neuralgia and PCS etiologies are favorable factors for pregabalin treatment response." | 1.39 | Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting. ( Blanco Tarrio, E; Gálvez Mateos, R; López Gómez, V; Pérez Páramo, M; Zamorano Bayarri, E, 2013) |
| "Patients from a previous study of neuropathic pain (NP) in the Spanish primary care setting still had symptoms despite treatment." | 1.39 | Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting. ( Blanco Tarrio, E; Gálvez Mateos, R; López Gómez, V; Pérez Páramo, M; Zamorano Bayarri, E, 2013) |
| "Occipital neuralgia is a pain in the distribution of the occipital nerves, accompanied by hypersensitivity to touch in the corresponding territory." | 1.39 | [Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients]. ( Barón, J; Guerrero-Peral, ÁL; Herrero-Velázquez, S; Mulero, P; Muñoz, I; Pedraza, MI; Rodríguez, C; Ruiz, M, 2013) |
| "Lacosamide is a third-generation antiepileptic drug that has been proven to be effective, safe and with few side effects." | 1.39 | [Lacosamide as an alternative in the treatment of post-surgery neuropathic pain in an allergic patient]. ( Márquez-Rivas, J; Mayorga-Buiza, MJ; Monge-Márquez, ME; Rivero-Garvía, M, 2013) |
| "Neuropathic pain is a condition that is still not well understood, although it affects a significantly high percentage of the population." | 1.39 | [Lacosamide as an alternative in the treatment of post-surgery neuropathic pain in an allergic patient]. ( Márquez-Rivas, J; Mayorga-Buiza, MJ; Monge-Márquez, ME; Rivero-Garvía, M, 2013) |
| "A rat model of neuropathic pain was used by compressing the right L4 and L5 dorsal root ganglia." | 1.39 | Pregabalin alters nociceptive behavior and expression level of P2X3 receptor in the spinal dorsal horn in a rat model induced by chronic compression of the dorsal root ganglion. ( Cui, D; Fu, P; Liu, S; Yu, J; Zhang, Y, 2013) |
| "Gabapentin (GBP) is an anti-convulsive drug often used as analgesic to control neuropathic pain." | 1.39 | Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats. ( Araújo, CV; Barbosa, AL; Brito, GA; Câmara, CC; Costa, CM; da Silva, AP; Gomes, AS; Oriá, RB; Ramos, HF; Ribeiro, RA; Vale, ML, 2013) |
| "Mechanical allodynia in paclitaxel-treated Sprague Dawley (SD) rats was measured using a dynamic plantar aesthesiometer before and after treatment with E139 (10 and 20 mg/kg) or its vehicle for four consecutive days from day 7 after first administration of paclitaxel (16 mg/kg on two alternate days)." | 1.39 | The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents. ( Edafiogho, IO; Masocha, W; Thangamani, D, 2013) |
| "Neuropathic pain is a chronic neurodegenerative disease." | 1.39 | Antinociceptive effect of Butea monosperma on vincristine-induced neuropathic pain model in rats. ( Krishnan, UM; Muthuraman, A; Shanmugam, P; Singh, N; Thiagarajan, VR, 2013) |
| "Although trigeminal neuropathic pain is one of the most common chronic pain syndromes, the etiology is still unknown." | 1.39 | Pre- and post-synaptic switches of GABA actions associated with Cl- homeostatic changes are induced in the spinal nucleus of the trigeminal nerve in a rat model of trigeminal neuropathic pain. ( Fukuda, A; Furukawa, T; Inoue, K; Kumada, T; Sato, K; Watanabe, M; Wei, B, 2013) |
| "co-treatment with ketamine and pregabalin at sub-effect low doses may be a useful therapeutic method for the treatment of neuropathic pain patients." | 1.39 | Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice. ( Choi, JG; Jeon, BH; Kim, HW; Kim, JM; Ko, YK; Lee, JH; Lim, HS; Park, JB; Shin, YS, 2013) |
| "pregabalin (10, 30, 100 µg) on mechanical allodynia and thermal hyperalgesia were measured." | 1.39 | Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice. ( Choi, JG; Jeon, BH; Kim, HW; Kim, JM; Ko, YK; Lee, JH; Lim, HS; Park, JB; Shin, YS, 2013) |
| "Peripheral neuropathic pain (PNP) is associated with significant economic burden." | 1.39 | Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain. ( Figueras-Balsells, M; Muñoz-Tudurí, M; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2013) |
| "Thiopental sodium was intravenously administered in mice and sleeping time was measured." | 1.39 | Combined antiallodynic effect of Neurotropin® and pregabalin in rats with L5-spinal nerve ligation. ( Kawamura, M; Namba, H; Okai, H; Okazaki, R; Taguchi, K; Yoshida, H, 2013) |
| "Its use to treat lingual neuralgia has not to our knowledge been described previously, and we report a case." | 1.38 | Pulsed radiofrequency modulation for lingual neuralgia. ( Hussain, R; Jamshed, A; Khan, MZ; Rehman, SU, 2012) |
| "The edema was considered to be caused by pregabalin and the medicine was ceased gradually." | 1.38 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Morphine was less potent in neuroma pain than in mechanical allodynia." | 1.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "After TNT injury, mechanical allodynia and neuroma pain are observed." | 1.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "It has been reported that <50% of neuropathic pain patients are satisfactorily treated with drugs." | 1.38 | The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. ( Miyazaki, R; Yamamoto, T, 2012) |
| "The L5 spinal nerve ligation induced tactile allodynia, an increase of CD11b expression, and an increase in the protein expression level of the voltage-dependent Ca(2+) channel α(2)/δ-1 subunit in the spinal dorsal horn on the injured side." | 1.38 | Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model. ( Adachi-Akahane, S; Ito, M; Kuroda, M; Morimoto, S; Oda, S; Sugiyama, A, 2012) |
| "It has been suggested that peripheral neuropathic pain (PNP) may affect up to 3% of the general population." | 1.38 | Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. ( Masramón, X; Navarro, A; Pérez, C; Rejas, J; Saldaña, MT, 2012) |
| " After confirming hyperalgesia, pregabalin or saline (for control mice) in a volume of 10 mL/kg was administered orally at a dosage of 30 mg/kg, twice daily from day 2 after surgery." | 1.38 | The immunomodulatory effect of pregabalin on spleen cells in neuropathic mice. ( Jang, Y; Jeong, DC; Song, HK; Yeom, MY, 2012) |
| "The development of neuropathic pain after peripheral nerve damage occurs with inflammation at the injury site." | 1.38 | The immunomodulatory effect of pregabalin on spleen cells in neuropathic mice. ( Jang, Y; Jeong, DC; Song, HK; Yeom, MY, 2012) |
| "The percentage allodynia relief was only 60% for carbamazepine and 80% for pregabalin by single administration, whereas their co-administration relieved allodynia by 100%." | 1.38 | Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain. ( Ahn, HJ; Choi, SJ; Gwak, MS; Hahm, TS; Kim, JK; Ryu, S; Yu, JM, 2012) |
| "Allodynia was determined using the von Frey hair test and dose-effect curves and isobolograms were used to investigate drug interactions." | 1.38 | Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain. ( Ahn, HJ; Choi, SJ; Gwak, MS; Hahm, TS; Kim, JK; Ryu, S; Yu, JM, 2012) |
| "Carbamazepine and pregabalin ameliorate neuropathic pain synergistically at higher doses." | 1.38 | Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain. ( Ahn, HJ; Choi, SJ; Gwak, MS; Hahm, TS; Kim, JK; Ryu, S; Yu, JM, 2012) |
| "Neuropathic pain was induced by L5 nerve ligation in Sprague-Dawley rats." | 1.38 | Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain. ( Ahn, HJ; Choi, SJ; Gwak, MS; Hahm, TS; Kim, JK; Ryu, S; Yu, JM, 2012) |
| "Mice exhibited spontaneous neuropathic pain behaviors, which were most obvious after ischemia for 5 h." | 1.38 | Patterns of nerve injury and neuropathic pain in ischemic neuropathy after ligation-reperfusion of femoral artery in mice. ( Chiang, HY; Hsieh, JH; Hsieh, ST; Lee, JE; Wang, KC, 2012) |
| "Moreover, animals with neuropathic pain showed significantly improved paw withdrawal thresholds (PWTs) following miR23b infusion." | 1.38 | Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. ( Cho, HT; Choi, JI; Im, YB; Jee, MK; Kang, SK; Kwon, OH, 2012) |
| "Neuropathic pain is a well-known type of chronic pain caused by damage to the nervous system." | 1.38 | Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. ( Cho, HT; Choi, JI; Im, YB; Jee, MK; Kang, SK; Kwon, OH, 2012) |
| " It has also been reported that pregabalin used with oxycodine reveals analgesic effect with smaller dosage than pregabalin alone." | 1.38 | [Case of acute exacerbation of neuropathic cancer pain rapidly relieved by simultaneous oral intake of immediate release oxycodone and pregabalin]. ( Baba, M; Gomwo, I, 2012) |
| "Many drugs approved for neuropathic pain engage spinal noradrenergic and cholinergic systems for analgesia." | 1.37 | A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury. ( Eisenach, JC; Hayashida, K, 2011) |
| "Mechanical allodynia was assessed by measuring the forepaw withdrawal threshold to von Frey filaments, and cold allodynia was evaluated by measuring the time spent in lifting or licking the forepaw after applying acetone to it." | 1.37 | A novel rat forelimb model of neuropathic pain produced by partial injury of the median and ulnar nerves. ( Back, SK; Eun, JS; Kim, MA; Na, HS; Yi, H, 2011) |
| "Our rat forelimb model of neuropathic pain may be useful for studying human neuropathic pain and screening for valuable drug candidates." | 1.37 | A novel rat forelimb model of neuropathic pain produced by partial injury of the median and ulnar nerves. ( Back, SK; Eun, JS; Kim, MA; Na, HS; Yi, H, 2011) |
| "In a model of neuropathic pain, sciatic nerve ligation caused a marked decrease in the latency of paw withdrawal in response to a thermal stimulus only on the ipsilateral side." | 1.37 | Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis. ( Furuya, M; Hatakeyama, N; Horiuchi, H; Imai, S; Kinoshita, H; Kuzumaki, N; Matoba, M; Narita, M; Niikura, K; Senba, E; Suzuki, T; Takemura, Y; Tsukiyama, Y; Yamashita, A; Yamazaki, M; Yanase, M, 2011) |
| "Neuropathic pain is the most difficult pain to manage in the pain clinic, and sleep problems are common among patients with chronic pain including neuropathic pain." | 1.37 | Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis. ( Furuya, M; Hatakeyama, N; Horiuchi, H; Imai, S; Kinoshita, H; Kuzumaki, N; Matoba, M; Narita, M; Niikura, K; Senba, E; Suzuki, T; Takemura, Y; Tsukiyama, Y; Yamashita, A; Yamazaki, M; Yanase, M, 2011) |
| "Accordingly, we hypothesized that tactile allodynia post SCI is mediated by an upregulation of Ca(v)α2δ-1 in dorsal spinal cord." | 1.37 | Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. ( Boroujerdi, A; Kim, D; Luo, DZ; Sharp, K; Steward, O; Zeng, J, 2011) |
| "SCI-induced neuropathic pain can be manifested as both tactile allodynia (a painful sensation to a non-noxious stimulus) and hyperalgesia (an enhanced sensation to a painful stimulus)." | 1.37 | Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. ( Boroujerdi, A; Kim, D; Luo, DZ; Sharp, K; Steward, O; Zeng, J, 2011) |
| "The antihyperalgesic effect of PBN on mechanical hyperalgesia was attenuated by intrathecal bicuculline, a GABA(A) receptor blocker." | 1.37 | Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. ( Chung, JM; Chung, K; Kim, HK; Kim, HY; Lee, KY; Wang, J; Yowtak, J, 2011) |
| "Neuropathic pain was induced by a tight ligation of the L5 spinal nerve (SNL)." | 1.37 | Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. ( Chung, JM; Chung, K; Kim, HK; Kim, HY; Lee, KY; Wang, J; Yowtak, J, 2011) |
| "82." | 1.37 | Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. ( Sun, P; Watson, P; Zhao, Y, 2011) |
| "Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life." | 1.37 | Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. ( Anghelescu, DL; Cheng, C; Faughnan, LG; Hankins, G; Hinds, PS; Jeha, S; Pauley, JL; Pei, D; Pui, CH; Relling, MV; Sandlund, JT, 2011) |
| " There were no statistically significant differences found regarding sex, age or daily dosage between this latter group compared with the patients who registered for the study but did not fill in a questionnaire." | 1.37 | Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. ( Härmark, L; Straus, S; van Grootheest, K; van Puijenbroek, E, 2011) |
| "The indication for pregabalin use was neuropathic pain in 85." | 1.37 | Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. ( Härmark, L; Straus, S; van Grootheest, K; van Puijenbroek, E, 2011) |
| "Three patients with cancer experienced severe side-effects after starting anti-neuropathic pain therapy." | 1.37 | [Pitfalls in the treatment of neuropathic pain in patients with cancer]. ( Engels, Y; Hekster, YA; Schalkwijk, A; Verhagen, CA; Vissers, KC, 2011) |
| "To investigate whether neuropathic pain affects the endogenous pain control system, we examined the effect of neuropathic pain induced by sacral nerve transection on presynaptic GABA release, the kinetics of postsynaptic GABA-activated Cl- currents, and the modulatory effect of μ-opioid receptor (MOR) activation in mechanically isolated PAG neurons with functioning synaptic boutons." | 1.37 | GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain. ( Cho, YW; Hahm, ET; Kim, Y; Lee, JJ, 2011) |
| "Neuropathic pain is a chronic and intractable symptom associated with nerve injury." | 1.37 | GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain. ( Cho, YW; Hahm, ET; Kim, Y; Lee, JJ, 2011) |
| "Neuropathic pain is a clinical condition which remains poorly treated and combinations of pregabalin, an antagonist of the α2δ-subunit of Ca(2+) channels, with tapentadol, a μ-opioid receptor agonist/noradrenaline reuptake inhibitor, or with classical opioids such as oxycodone and morphine might offer increased therapeutic potential." | 1.37 | Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. ( Christoph, T; De Vry, J; Schiene, K; Tallarida, RJ; Tzschentke, TM, 2011) |
| "To report a case of acute elevation of hepatic enzyme levels as a probable adverse reaction associated with pregabalin." | 1.37 | Pregabalin-induced hepatotoxicity. ( Junyent, TT; Pellicer, MJ; Sendra, JM, 2011) |
| " The low pregabalin dosage and the short time to elevation of liver enzyme levels suggest an idiosyncratic reaction." | 1.37 | Pregabalin-induced hepatotoxicity. ( Junyent, TT; Pellicer, MJ; Sendra, JM, 2011) |
| "More patients with neuropathic pain reported an improvement with pregabalin (33%) than duloxetine (21%)." | 1.37 | Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. ( Barohn, RJ; Dimachkie, MM; Herbelin, L; Khan, S; McVey, A; Mittal, M; Mummaneni, RB; Pasnoor, M; Ridings, L; Saperstein, D; Wang, Y, 2011) |
| "The gabapentin has beneficial effect in the FBSS associated neuropathic pain." | 1.37 | Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome. ( Chang, ST; Lai, MH; Lu, SC; Wu, YT, 2011) |
| "Gabapentin was identified in 7013 specimens (12." | 1.37 | Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin. ( Black, DL; Caplan, YH; Cone, EJ; Depriest, A; Heltsley, R; Robert, T, 2011) |
| "A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment." | 1.37 | Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health. ( Ciria, JP; Fernández, MC; Gonzálvez, ML; López-Gómez, V; Mańas, A; Masramon, X; Morillo, V; Pérez, M, 2011) |
| "In rats with four ligatures, prominent mechanical allodynia and thermal hyperalgesia developed; these behavioral signs were not prominent in rats with two ligatures." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "Then, behavioral signs of neuropathic pain were observed for 8 weeks." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids." | 1.37 | [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011) |
| "Patients suffering from neuropathic pain are difficult to treat and many methods are used to resolve this issue." | 1.37 | Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats. ( Chung, SC; Liu, YC; Tsai, YC; Tseng, FL; Yeh, CY, 2011) |
| "Gabapentin has been widely and successfully used in the clinic for many neuropathic pain syndromes since last decade, however its analgesic mechanisms are still elusive." | 1.37 | Analgesic effect of gabapentin in a rat model for chronic constrictive injury. ( Huang, YG; Liu, W; Ma, LL; Yang, N; Zuo, PP, 2011) |
| "Neuropathic pain is a serious chronic disorder caused by lesion or dysfunction in the nervous systems." | 1.36 | Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de ( Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K, 2010) |
| "Reversal of post-SCI neuropathic pain by tiagabine suggests that reduced GABAergic tone may contribute to hyperalgesia symptoms." | 1.36 | Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury. ( Marsh, AD; Marsh, DR; Meisner, JG, 2010) |
| "Current clinical treatments for neuropathic pain include amitriptyline, a tricyclic antidepressant with mixed pharmacology that is also clinically reported to impair cognitive performance; and gabapentin, a compound that selectively interacts with alpha2delta-1 calcium channel subunits." | 1.36 | Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin. ( Arneric, SP; Buccafusco, JJ; Snutch, TP; Terry, AV; Vazdarjanova, A, 2010) |
| " Time to achieve effective dosing is relatively quick and there is a range of dosing available." | 1.36 | Treatment of post-burn neuropathic pain: evaluation of pregablin. ( Turner, L; Wong, L, 2010) |
| "Gabapentin and clonidine were concomitantly administered in a fixed-dose ratio proportional to the predetermined ED(50) of these drugs, thereby obtaining a dose-response curve for the drug combination and its ED(50)." | 1.36 | Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. ( Asada, A; Funao, T; Mori, T; Nishikawa, K; Yamama, Y, 2010) |
| " After confirmation of the established allodynia, gabapentin at 10, 30, 60 and 100μg or clonidine at 5, 15, 30 and 50μg was injected as a monotherapy in conscious rats through the intrathecal catheter to obtain the dose-response curve of %MPE (maximum possible effect) of the antiallodynic effect and its ED(50)." | 1.36 | Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats. ( Asada, A; Funao, T; Mori, T; Nishikawa, K; Yamama, Y, 2010) |
| " Single, parenteral dosing of donepezil (1, 1." | 1.36 | Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies. ( Andersen, LM; Bjerrum, OJ; Folkesson, A; Honoré, PH; Kristensen, P, 2010) |
| "The elusiveness of neuropathic pain mechanisms is a major impediment in developing effective clinical treatments." | 1.36 | Agrin downregulation induced by nerve injury contributes to neuropathic pain. ( Bazan, NG; Cui, JG, 2010) |
| " The PWT in PSL mice was dose-dependently increased by intraperitoneal injection of gabapentin, but the anti-allodynic effects varied according to its dosing time." | 1.36 | Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. ( Hamamura, K; Inoue, K; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Tsuda, M; Uchida, T; Yoshida, M, 2010) |
| "These findings suggest that the dosing time-dependent difference in the anti-allodynic effects of gabapentin is attributable to the circadian oscillation of α2δ-1 subunit expression in the DRG and indicate that the optimizing its dosing schedule helps to achieve rational pharmacotherapy for neuropathic pain." | 1.36 | Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. ( Hamamura, K; Inoue, K; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Tsuda, M; Uchida, T; Yoshida, M, 2010) |
| "Neuropathic pain is characterized by hypersensitivity to innocuous stimuli (tactile allodynia) that is nearly always resistant to NSAIDs or even opioids." | 1.36 | Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. ( Hamamura, K; Inoue, K; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Tsuda, M; Uchida, T; Yoshida, M, 2010) |
| "In both neuropathic pain models, rats exhibited mechanical hypersensitivity, whereas a significant increase in anxiety-like behaviour was observed only in CCI rats (time spent in open arms decreased significantly from 99+/-15." | 1.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "Neuropathic pain was induced in rats by partial sciatic nerve ligation (PNL) and chronic constriction injury (CCI)." | 1.35 | Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin. ( Arndt, K; Ceci, A; Doods, H; Roeska, K; Treede, RD, 2008) |
| "The ability of bicuculline to alleviate allodynia and formalin-evoked hyperalgesia in diabetic rats is consistent with a reversal of the properties of GABA predicted by reduced spinal KCC2 and suggests that reduced KCC2 expression and increased GABA release contribute to spinally mediated hyperalgesia in diabetes." | 1.35 | Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. ( Calcutt, NA; Jolivalt, CG; Lee, CA; Ramos, KM, 2008) |
| "Neuropathic pain is commonly associated with affective disorders such as anxiety and depression." | 1.35 | Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain. ( Blackbeard, J; Pheby, T; Rice, AS; Segerdahl, AR; Wallace, VC, 2008) |
| "Gabapentin was effective and well tolerated in the treatment of neuropathic pain in children." | 1.35 | [Gabapentin for neurophatic pain in children: a case report]. ( Dayioğlu, M; Reisli, R; Tuncer, S, 2008) |
| "Gabapentin is used as an analgesic in neuropathic pain." | 1.35 | [Gabapentin for neurophatic pain in children: a case report]. ( Dayioğlu, M; Reisli, R; Tuncer, S, 2008) |
| "Neuropathic pain was induced in male Sprague-Dawley rats by a surgical ligation of left L5 nerve." | 1.35 | Protective effects of gabapentin on allodynia and alpha 2 delta 1-subunit of voltage-dependent calcium channel in spinal nerve-ligated rats. ( Ahn, HJ; Bae, CD; Cho, HS; Choi, SJ; Gwak, MS; Hahm, TS; Kim, HS; Kim, JA; Lee, SM; Lim, SW; Sim, WS, 2009) |
| "Gabapentin did not produce an anti-allodynic effect, whereas the morphine and gabapentin combination completely decreased allodynia behavior at 30 min post-injection, an effect that persisted until 120 min." | 1.35 | Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. ( Cortés-Arroyo, AR; De la O-Arciniega, M; Díaz-Reval, MI; Domínguez-Ramírez, AM; López-Muñoz, FJ, 2009) |
| "Pregabalin is prescribed for neuropathic pain." | 1.35 | Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure. ( Goldfarb, DS; Hoffman, RS; Matalon, D; Yoo, L, 2009) |
| "Management of neuropathic pain remains problematic; however, cell therapy to treat the effects of pain on the sensory system after spinal cord injury (SCI) could be a useful approach." | 1.35 | Clinical feasibility for cell therapy using human neuronal cell line to treat neuropathic behavioral hypersensitivity following spinal cord injury in rats. ( Eaton, MJ; Wolfe, SQ, 2009) |
| "Gabapentin is a central nervous system inhibitory agent with likely gamma-aminobutyric acid (GABA)-ergic and non-GABAergic mechanisms of action." | 1.35 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
| "gabapentin was studied by isobolographic analysis." | 1.35 | Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. ( Curros-Criado, MM; Herrero, JF, 2009) |
| "Neuropathic pain is characterized by a poor response to classic analgesics." | 1.35 | Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. ( Curros-Criado, MM; Herrero, JF, 2009) |
| "Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Gabapentin and duloxetine reversed mechanical hyperalgesia but did not normalize gait in any nerve injury model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Neuropathic pain is a long-lasting clinical problem that is often refractory to medical management." | 1.35 | A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury. ( Cao, X; Cao, Z; He, X; Li, W; Liu, L; Liu, W; Liu, Z; Miao, L; Xiao, Z; Xue, L, 2008) |
| "Gabapentin has been used effectively for neuropathic pain with mild side effects." | 1.35 | Gabapentin and sexual dysfunction: report of two cases. ( Dalal, A; Zhou, L, 2008) |
| "Our patient is the first patient with neuropathic pain, treated with gabapentin who developed hemichorea, in the absence of brain lesions." | 1.35 | Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain. ( Chang, CC; Chang, ST; Lai, MH; Tsai, KC; Wang, TY, 2008) |
| " We used a repeated dosing paradigm because there are precedents showing that repeated drug exposure may be necessary to demonstrate analgesia in neuropathic pain models." | 1.34 | Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. ( Bennett, GJ; Boroujerdi, A; Luo, ZD; Xiao, W, 2007) |
| " Pregabalin was administered either intraperitoneally (IP) or intrathecally (IT) and dosed up incrementally until an antiallodynic effect without sedation or motor impairment was apparent." | 1.34 | Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. ( Han, DW; Kweon, TD; Lee, JS; Lee, YW, 2007) |
| "Neuropathic pain has both sympathetically maintained pain (SMP) and sympathetic independent pain (SIP) components." | 1.34 | Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. ( Han, DW; Kweon, TD; Lee, JS; Lee, YW, 2007) |
| "Animal models of neuropathic pain have enabled the identification of key pathophysiological changes occurring within nociceptive pathways as a result of injury, and serve an invaluable role for preclinical screening of novel analgesic candidates." | 1.34 | The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Jensen, DG; Rode, F; Thomsen, M, 2007) |
| "In the vincristine-induced neuropathic pain model, lacosamide attenuated thermal allodynia, on the cold plate (4 degrees C), at 10 and 30 mg/kg, and in the warm (38 degrees C) and hot plate (52 degrees C) even at 3 mg/kg." | 1.34 | Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. ( Bain, SC; Beyreuther, BK; Brot, MD; Callizot, N; Feldman, R; Stöhr, T, 2007) |
| "Peripheral neuropathic pain is a common clinical problem with few existing treatments." | 1.34 | Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain. ( Chang, JW; Kim, J; Kim, SJ; Lee, B; Lee, H, 2007) |
| "Gabapentin, which has been suggested as an adjuvant analgesic for neuropathic pain introduced orally, rapidly and significantly alleviated his pain and we could subsequently dispense with ketamine and mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| "His neuropathic pain was not sufficiently responsive to the combination therapy of opioids, non-steroidal antiinflammatory drugs (NSAIDs), continuous infusion of subcutaneous ketamine and oral mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| "Gabapentin appeared to be a safe, effective, and economical treatment for neuropathic pain in this horse." | 1.34 | Gabapentin for the treatment of neuropathic pain in a pregnant horse. ( Davis, JL; Elce, Y; Posner, LP, 2007) |
| " Treatment was continued for 6 days, during which the dosage was progressively decreased, and the mare was discharged." | 1.34 | Gabapentin for the treatment of neuropathic pain in a pregnant horse. ( Davis, JL; Elce, Y; Posner, LP, 2007) |
| "Following recovery from colic surgery to treat compression of the small and large intestines because of a large fetus, the mare was noticed to have signs of femoral neuropathy involving the left hind limb." | 1.34 | Gabapentin for the treatment of neuropathic pain in a pregnant horse. ( Davis, JL; Elce, Y; Posner, LP, 2007) |
| "At baseline of the clinical trial, the neuropathic pain patients reported significantly more sleep disturbance and daytime somnolence, as well as less quantity and adequacy of sleep than patients in the general US population." | 1.33 | Psychometric properties of the Medical Outcomes Study Sleep measure. ( Hays, RD; Martin, SA; Sesti, AM; Spritzer, KL, 2005) |
| "Signs of allodynia also extended to the sciatic nerve territory." | 1.33 | Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. ( Beaulieu, P; Desbiens, K; Leblond, F; Pichette, V; Walczak, JS, 2005) |
| "Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive." | 1.33 | Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2005) |
| "Carbamazepine (300 mg/d) was required for pain control." | 1.33 | Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005) |
| "Occipital neuralgia is an extracranial pain that may be confused with other headaches." | 1.33 | Occipital neuralgia secondary to respiratory tract infection. ( Anagnostopoulou, S; Mourouzis, C; Rallis, G; Saranteas, T; Tesseromatis, C, 2005) |
| "Mechanical allodynia was maximal by 1 week and persisted at blunted levels for at least 18 weeks after injury." | 1.33 | Spinal nerve ligation does not alter the expression or function of GABA(B) receptors in spinal cord and dorsal root ganglia of the rat. ( Bettler, B; Engle, MP; Gassman, M; Hammond, DL; Sykes, KT, 2006) |
| "Amitriptyline was the cheapest strategy, followed by carbamazepine, and both were equally beneficial." | 1.33 | Economic evaluation of oral treatments for neuropathic pain. ( Cepeda, MS; Farrar, JT, 2006) |
| "Gabapentin was the most expensive as well as the least beneficial." | 1.33 | Economic evaluation of oral treatments for neuropathic pain. ( Cepeda, MS; Farrar, JT, 2006) |
| "Four were cancer patients and one suffered from neuropathic pain in the neck (C3)." | 1.33 | Experience with gabapentin for neuropathic pain in adolescents: report of five cases. ( Butkovic, D; Mihovilovic-Novak, B; Toljan, S, 2006) |
| "Gabapentin was the most widely used AED (92% of all AED patients); amitriptyline was the most widely used TCA (79% of all TCA patients)." | 1.33 | Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. ( Berger, A; Dukes, E; Mercadante, S; Oster, G, 2006) |
| "Neuropathic pain is associated with a number of disease states of diverse aetiology that can share common pathophysiological mechanisms." | 1.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "Hindpaw mechanical allodynia was dose-dependently reversed by gabapentin (50 and 100 mg/kg, s." | 1.33 | Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. ( Bjerrum, OJ; Blackburn-Munro, G; Broløs, T; Rode, F, 2006) |
| "The basis of the treatment of painful diabetic neuropathy is the use of drugs that block the transmission of pain (antineuritics) and a good metabolic control of underlying disease." | 1.33 | [Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy]. ( Bastías A, MJ; Olmos C, P; Toro C, L, 2006) |
| "SUNCT, a still relatively unknown headache syndrome, is characterized by attacks of periorbital pain with accompanying ipsilateral autonomic symptoms." | 1.32 | [Case report on a patient with SUNCT-syndrome]. ( Brinkschmidt, T; Jensen, U; Neumeier, S, 2003) |
| "Gabapentin did however produce significant dose-related reversal of tactile allodynia in the rat following a single administration." | 1.32 | Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. ( Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003) |
| "Gabapentin was poorly active against mechanical hyperalgesia in both the rat and guinea-pig following a single oral administration (100 mg x kg(-1)), although upon repeated administration it produced up to 70 and 90% reversal in rat and guinea-pig, respectively." | 1.32 | Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. ( Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003) |
| "Oxcarbazepine is a recently introduced AED that is effective in treating epilepsy and has an improved side-effect profile compared to existing therapies." | 1.32 | Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. ( Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003) |
| "Allodynia and hyperalgesia appeared on day 5 post-inoculation." | 1.31 | Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000) |
| "Gabapentin (Neurontin) was then started with improvement at 1800 mg per day." | 1.31 | SUNCT syndrome responsive to gabapentin (Neurontin). ( Graff-Radford, SB, 2000) |
| "Many patients with neuropathic pain have coexistent sensory deficits." | 1.31 | Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin. ( Chong, MS; Hanna, M; Smith, TE, 2002) |
| "Based on the observations of other authors, we used this drug in dosage varying between 900 and 1,200 mg/day, in three patients with neuropathic pain, of both central and peripheral origin, and in whom the usual treatments had been unsatisfactory or could not be tolerated because of side-effects." | 1.30 | [Treatment of neuropathic pain with gabapentin ++]. ( Sánchez-Valiente, S, 1998) |
| "The management of patients with neuropathic pain is challenging." | 1.30 | The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. ( Abdi, S; Chung, JM; Lee, DH, 1998) |
| "Gabapentin was concluded to be an effective therapeutic option for neuralgia of the IXth cranial nerve before surgery." | 1.30 | [Use of gabapentin in glossopharyngeal neuralgia]. ( Esparcia Navarro, M; García Callejo, FJ; Marco Algarra, J; Martínez Beneyto, MP; Morant Ventura, A; Talamantes Escribá, F, 1999) |
| "To investigate whether neuropathic pain is sensitive to spinal GABA levels, GABA was injected intrathecally after nerve injury and sensory behaviors were evaluated." | 1.30 | A single intrathecal injection of GABA permanently reverses neuropathic pain after nerve injury. ( Eaton, MJ; Karmally, S; Martinez, MA, 1999) |
| "Gabapentin is an anticonvulsant medication used recently as an effective adjuvant agent for treating neuropathic pain." | 1.30 | Using gabapentin to treat neuropathic pain. ( Hays, H; Woodroffe, MA, 1999) |
| "Gabapentin has desirable pharmacokinetic properties and acceptable side effects, which simplify its use." | 1.30 | Using gabapentin to treat neuropathic pain. ( Hays, H; Woodroffe, MA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (3.44) | 18.2507 |
| 2000's | 183 (31.44) | 29.6817 |
| 2010's | 349 (59.97) | 24.3611 |
| 2020's | 30 (5.15) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, S | 1 |
| Nakata, E | 1 |
| Morita, A | 1 |
| Mizuno, K | 1 |
| Yamamura, K | 1 |
| Kato, A | 2 |
| Ohashi, K | 1 |
| Zaręba, P | 2 |
| Gryzło, B | 2 |
| Malawska, K | 2 |
| Sałat, K | 4 |
| Höfner, GC | 2 |
| Nowaczyk, A | 1 |
| Fijałkowski, Ł | 1 |
| Rapacz, A | 2 |
| Podkowa, A | 1 |
| Furgała, A | 1 |
| Żmudzki, P | 1 |
| Wanner, KT | 2 |
| Malawska, B | 3 |
| Kulig, K | 2 |
| Hiroki, T | 1 |
| Suto, T | 3 |
| Ohta, J | 1 |
| Saito, S | 3 |
| Obata, H | 5 |
| Yeo, M | 1 |
| Chen, Y | 1 |
| Jiang, C | 1 |
| Chen, G | 2 |
| Wang, K | 1 |
| Chandra, S | 1 |
| Bortsov, A | 1 |
| Lioudyno, M | 1 |
| Zeng, Q | 1 |
| Wang, P | 2 |
| Wang, Z | 1 |
| Busciglio, J | 1 |
| Ji, RR | 2 |
| Liedtke, W | 1 |
| Migeon, M | 1 |
| Polat, CS | 1 |
| Konak, HE | 1 |
| Akıncı, MG | 1 |
| Onat, SS | 1 |
| Altas, EU | 1 |
| Sukmawan, YP | 1 |
| Anggadiredja, K | 1 |
| Adnyana, IK | 1 |
| Park, SE | 1 |
| Neupane, C | 1 |
| Noh, C | 1 |
| Sharma, R | 1 |
| Shin, HJ | 1 |
| Pham, TL | 1 |
| Lee, GS | 1 |
| Park, KD | 1 |
| Lee, CJ | 1 |
| Kang, DW | 1 |
| Lee, SY | 1 |
| Kim, HW | 3 |
| Park, JB | 2 |
| Cai, X | 1 |
| Qiu, L | 1 |
| Wang, C | 2 |
| Yang, H | 1 |
| Zhou, Z | 1 |
| Mao, M | 1 |
| Zhu, Y | 1 |
| Wen, Y | 1 |
| Cai, W | 1 |
| Zhu, W | 1 |
| Sun, J | 1 |
| Tesfaye, S | 2 |
| Sloan, G | 1 |
| Petrie, J | 1 |
| White, D | 1 |
| Bradburn, M | 1 |
| Julious, S | 1 |
| Rajbhandari, S | 1 |
| Sharma, S | 1 |
| Rayman, G | 1 |
| Gouni, R | 1 |
| Alam, U | 1 |
| Cooper, C | 1 |
| Loban, A | 1 |
| Sutherland, K | 1 |
| Glover, R | 1 |
| Waterhouse, S | 1 |
| Turton, E | 1 |
| Horspool, M | 1 |
| Gandhi, R | 1 |
| Maguire, D | 1 |
| Jude, EB | 1 |
| Ahmed, SH | 1 |
| Vas, P | 1 |
| Hariman, C | 1 |
| McDougall, C | 1 |
| Devers, M | 1 |
| Tsatlidis, V | 1 |
| Johnson, M | 1 |
| Rice, ASC | 3 |
| Bouhassira, D | 3 |
| Bennett, DL | 2 |
| Selvarajah, D | 2 |
| Masri, S | 1 |
| Kenney, AE | 1 |
| Scigliano, D | 1 |
| Juba, KM | 1 |
| Chen, P | 1 |
| Huang, NY | 1 |
| Pang, B | 1 |
| Ye, ZJ | 1 |
| Luo, RX | 1 |
| Liu, C | 2 |
| Gong, Q | 1 |
| Wang, L | 2 |
| Meaadi, J | 1 |
| Obara, I | 1 |
| Eldabe, S | 1 |
| Nazar, H | 1 |
| Kiliç, Z | 1 |
| Aydin Özaslan, E | 1 |
| Hassanzadeh, S | 1 |
| Bagheri, S | 1 |
| Majid Ahmadi, S | 1 |
| Ahmadi, SA | 1 |
| Moradishibany, I | 1 |
| Dolatkhah, H | 1 |
| Reisi, S | 1 |
| Medeiros, P | 1 |
| de Freitas, RL | 1 |
| Boccella, S | 2 |
| Iannotta, M | 2 |
| Belardo, C | 2 |
| Mazzitelli, M | 1 |
| Romano, R | 1 |
| De Gregorio, D | 1 |
| Coimbra, NC | 1 |
| Palazzo, E | 2 |
| Maione, S | 2 |
| Ta, PCP | 1 |
| Dinh, HQ | 1 |
| Nguyen, K | 1 |
| Lin, S | 1 |
| Ong, YL | 1 |
| Ariyawardana, A | 1 |
| Meuwissen, KPV | 1 |
| de Vries, LE | 1 |
| Gu, JW | 1 |
| Zhang, TC | 1 |
| Joosten, EAJ | 1 |
| Luo, H | 1 |
| Liu, HZ | 1 |
| Zhang, WW | 1 |
| Matsuda, M | 1 |
| Lv, N | 1 |
| Xu, ZZ | 1 |
| Zhang, YQ | 1 |
| Maegawa, H | 1 |
| Usami, N | 1 |
| Kudo, C | 1 |
| Hanamoto, H | 1 |
| Niwa, H | 1 |
| Heijmans, L | 1 |
| Joosten, EA | 3 |
| Wan, L | 1 |
| Li, Z | 2 |
| Liu, T | 1 |
| Chen, X | 2 |
| Xu, Q | 1 |
| Yao, W | 1 |
| Zhang, C | 1 |
| Zhang, Y | 3 |
| Senba, E | 3 |
| Kami, K | 2 |
| Shaw, S | 1 |
| Uniyal, A | 1 |
| Gadepalli, A | 1 |
| Tiwari, V | 2 |
| Belinskaia, DA | 1 |
| Shestakova, NN | 1 |
| Venugopala, KN | 1 |
| Deb, PK | 1 |
| Lepski, G | 1 |
| Alexander, RC | 1 |
| Raudibaugh, K | 1 |
| Spierings, ELH | 1 |
| Katz, N | 1 |
| Sun, L | 1 |
| Liu, R | 1 |
| Guo, F | 1 |
| Wen, MQ | 1 |
| Ma, XL | 1 |
| Li, KY | 1 |
| Sun, H | 1 |
| Xu, CL | 1 |
| Li, YY | 1 |
| Wu, MY | 1 |
| Zhu, ZG | 1 |
| Li, XJ | 1 |
| Yu, YQ | 2 |
| Chen, Z | 1 |
| Li, XY | 1 |
| Duan, S | 1 |
| Tashima, R | 1 |
| Koga, K | 1 |
| Yoshikawa, Y | 1 |
| Sekine, M | 1 |
| Watanabe, M | 2 |
| Tozaki-Saitoh, H | 1 |
| Furue, H | 2 |
| Yasaka, T | 1 |
| Tsuda, M | 2 |
| Guida, F | 1 |
| Iannotti, FA | 1 |
| Infantino, R | 1 |
| Ricciardi, F | 1 |
| Cristiano, C | 1 |
| Vitale, RM | 1 |
| Amodeo, P | 1 |
| Marabese, I | 1 |
| de Novellis, V | 1 |
| Paino, S | 1 |
| Calignano, A | 1 |
| Di Marzo, V | 1 |
| Luongo, L | 1 |
| Saxena, AK | 1 |
| Bhardwaj, N | 1 |
| Chilkoti, GT | 1 |
| Malik, A | 1 |
| Thakur, GK | 1 |
| Bajaj, M | 1 |
| Banerjee, A | 1 |
| Banerjee, BD | 1 |
| Singal, A | 1 |
| Mayo-Wilson, E | 5 |
| Qureshi, R | 1 |
| Dickinson, S | 1 |
| Golzarri-Arroyo, L | 1 |
| Hong, H | 4 |
| Görg, C | 1 |
| Li, T | 5 |
| Liu, H | 1 |
| Li, W | 2 |
| Xu, B | 1 |
| Jiang, J | 1 |
| Yang, F | 5 |
| Mazur, G | 1 |
| Ła Tka, K | 1 |
| Latacz, G | 1 |
| Bajda, M | 1 |
| Louis, JV | 1 |
| Lu, Y | 2 |
| Pieschl, R | 1 |
| Tian, Y | 2 |
| Hong, Y | 1 |
| Dandapani, K | 1 |
| Naidu, S | 1 |
| Vikramadithyan, RK | 1 |
| Dzierba, C | 1 |
| Sarvasiddhi, SK | 1 |
| Nara, SJ | 1 |
| Bronson, J | 1 |
| Macor, JE | 1 |
| Albright, C | 1 |
| Kostich, W | 1 |
| Li, YW | 1 |
| Samineni, VK | 1 |
| Premkumar, LS | 1 |
| Faingold, CL | 1 |
| Emiroglu, N | 1 |
| Cengiz, FP | 1 |
| Su, O | 1 |
| Onsun, N | 1 |
| Saffarpour, S | 1 |
| Shaabani, M | 1 |
| Naghdi, N | 1 |
| Farahmandfar, M | 1 |
| Janzadeh, A | 1 |
| Nasirinezhad, F | 1 |
| Merante, D | 2 |
| Rosenstock, J | 2 |
| Sharma, U | 5 |
| Feins, K | 2 |
| Hsu, C | 2 |
| Vinik, A | 2 |
| Nicodemus, JM | 1 |
| Enriquez, C | 1 |
| Marquez, A | 1 |
| Anaya, CJ | 1 |
| Jolivalt, CG | 2 |
| Lee, KH | 1 |
| Rhee, KH | 1 |
| Fusco, N | 4 |
| Canner, JK | 2 |
| Dickersin, K | 5 |
| Katz, P | 1 |
| Pegoraro, V | 1 |
| Liedgens, H | 1 |
| Coupal, TM | 1 |
| Chang, DR | 1 |
| Pennycooke, K | 1 |
| Ouellette, HA | 1 |
| Munk, PL | 1 |
| Wiffen, PJ | 10 |
| Derry, S | 6 |
| Bell, RF | 1 |
| Rice, AS | 5 |
| Tölle, TR | 2 |
| Phillips, T | 1 |
| Moore, RA | 9 |
| Madden, K | 1 |
| Bruera, E | 1 |
| Sahn, JJ | 1 |
| Mejia, GL | 1 |
| Ray, PR | 1 |
| Martin, SF | 1 |
| Price, TJ | 2 |
| Espinosa-Juárez, JV | 3 |
| Jaramillo-Morales, OA | 3 |
| López-Muñoz, FJ | 4 |
| Luo, WJ | 1 |
| Sun, W | 2 |
| Zheng, W | 1 |
| Wang, XL | 1 |
| Wu, FF | 1 |
| Wang, JL | 1 |
| Wang, JS | 1 |
| Guan, SM | 1 |
| Chen, J | 2 |
| Baraldi, C | 1 |
| Pellesi, L | 1 |
| Guerzoni, S | 1 |
| Cainazzo, MM | 1 |
| Pini, LA | 1 |
| Dosenovic, S | 1 |
| Jelicic Kadic, A | 1 |
| Miljanovic, M | 1 |
| Biocic, M | 1 |
| Boric, K | 1 |
| Cavar, M | 1 |
| Markovina, N | 1 |
| Vucic, K | 1 |
| Puljak, L | 1 |
| Jeong, KY | 1 |
| Kang, JH | 1 |
| Goodman, CW | 1 |
| Brett, AS | 1 |
| Cooper, TE | 2 |
| Heathcote, LC | 2 |
| Clinch, J | 2 |
| Gold, JI | 1 |
| Howard, R | 2 |
| Lord, SM | 2 |
| Schechter, N | 2 |
| Wood, C | 2 |
| Krane, E | 1 |
| Sethna, N | 1 |
| Bannister, K | 1 |
| Qu, C | 3 |
| Navratilova, E | 2 |
| Oyarzo, J | 1 |
| Xie, JY | 2 |
| King, T | 1 |
| Dickenson, AH | 7 |
| Porreca, F | 2 |
| Bertizzolo, L | 1 |
| Cowley, T | 2 |
| Doshi, P | 2 |
| Ehmsen, J | 2 |
| Gresham, G | 2 |
| Guo, N | 1 |
| Haythornthwaite, JA | 2 |
| Heyward, J | 2 |
| Pham, D | 1 |
| Payne, JL | 2 |
| Rosman, L | 2 |
| Stuart, EA | 2 |
| Suarez-Cuervo, C | 2 |
| Tolbert, E | 2 |
| Twose, C | 2 |
| Vedula, S | 2 |
| Brown, S | 1 |
| Johnston, B | 1 |
| Amaria, K | 1 |
| Watkins, J | 1 |
| Campbell, F | 1 |
| Pehora, C | 1 |
| McGrath, P | 1 |
| Matsuoka, H | 2 |
| Ishiki, H | 1 |
| Iwase, S | 1 |
| Koyama, A | 2 |
| Kawaguchi, T | 1 |
| Kizawa, Y | 1 |
| Morita, T | 1 |
| Matsuda, Y | 1 |
| Miyaji, T | 1 |
| Ariyoshi, K | 1 |
| Yamaguchi, T | 1 |
| Ahmad, N | 4 |
| Subhan, F | 5 |
| Islam, NU | 1 |
| Shahid, M | 5 |
| Rahman, FU | 1 |
| Sewell, RDE | 2 |
| Chaumette, T | 1 |
| Chapuy, E | 3 |
| Berrocoso, E | 1 |
| Llorca-Torralba, M | 1 |
| Bravo, L | 1 |
| Mico, JA | 1 |
| Chalus, M | 1 |
| Eschalier, A | 4 |
| Ardid, D | 2 |
| Marchand, F | 2 |
| Sors, A | 1 |
| Anderson, D | 1 |
| Beecher, G | 1 |
| Power, C | 1 |
| Bridgland, L | 1 |
| Zochodne, DW | 1 |
| Crowe, MS | 1 |
| Wilson, CD | 1 |
| Leishman, E | 1 |
| Prather, PL | 1 |
| Bradshaw, HB | 1 |
| Banks, ML | 1 |
| Kinsey, SG | 1 |
| Masuda, R | 1 |
| Ajimi, J | 1 |
| Murata, T | 1 |
| Di Pietro, F | 1 |
| Macey, PM | 1 |
| Rae, CD | 1 |
| Alshelh, Z | 1 |
| Macefield, VG | 1 |
| Vickers, ER | 1 |
| Henderson, LA | 1 |
| Lee-Kubli, C | 1 |
| Marshall, AG | 1 |
| Malik, RA | 1 |
| Calcutt, NA | 2 |
| Liang, X | 1 |
| Yu, G | 1 |
| Su, R | 1 |
| Ibrahim, MA | 1 |
| Abdelzaher, WY | 1 |
| Rofaeil, RR | 1 |
| Abdelwahab, S | 1 |
| Ko, MY | 1 |
| Jang, EY | 1 |
| Lee, JY | 1 |
| Kim, SP | 1 |
| Whang, SH | 1 |
| Lee, BH | 2 |
| Kim, HY | 4 |
| Yang, CH | 2 |
| Cho, HJ | 1 |
| Gwak, YS | 3 |
| Barragán-Iglesias, P | 2 |
| Oidor-Chan, VH | 1 |
| Loeza-Alcocer, E | 1 |
| Pineda-Farias, JB | 2 |
| Velazquez-Lagunas, I | 1 |
| Salinas-Abarca, AB | 2 |
| Hong, E | 1 |
| Sánchez-Mendoza, A | 1 |
| Delgado-Lezama, R | 1 |
| Granados-Soto, V | 2 |
| Fleet, JL | 1 |
| Dixon, SN | 1 |
| Kuwornu, PJ | 1 |
| Dev, VK | 1 |
| Montero-Odasso, M | 1 |
| Burneo, J | 1 |
| Garg, AX | 1 |
| Hayashida, KI | 2 |
| Kimuram, M | 1 |
| Eisenach, JC | 6 |
| Chincholkar, M | 1 |
| Inquimbert, P | 2 |
| Moll, M | 1 |
| Latremoliere, A | 2 |
| Tong, CK | 1 |
| Whang, J | 1 |
| Sheehan, GF | 1 |
| Smith, BM | 1 |
| Korb, E | 1 |
| Athié, MCP | 1 |
| Babaniyi, O | 1 |
| Ghasemlou, N | 1 |
| Yanagawa, Y | 1 |
| Allis, CD | 1 |
| Hof, PR | 1 |
| Scholz, J | 2 |
| Huang, T | 1 |
| Fu, B | 1 |
| Wang, J | 3 |
| Wang, B | 1 |
| Liu, SJ | 1 |
| Weng, XC | 1 |
| Alexander, J | 1 |
| Edwards, RA | 1 |
| Brodsky, M | 1 |
| Manca, L | 1 |
| Grugni, R | 1 |
| Savoldelli, A | 1 |
| Bonfanti, G | 1 |
| Emir, B | 6 |
| Whalen, E | 4 |
| Watt, S | 1 |
| Parsons, B | 7 |
| Kato, D | 1 |
| de Andrade, EM | 1 |
| Martinez, RCR | 1 |
| Pagano, RL | 1 |
| Lopes, PSS | 1 |
| Auada, AVV | 1 |
| Gouveia, FV | 1 |
| Antunes, GF | 1 |
| Assis, DV | 1 |
| Lebrun, I | 1 |
| Fonoff, ET | 1 |
| Tillman, L | 1 |
| Zhang, J | 2 |
| Kawatani, M | 1 |
| Martin, TJ | 1 |
| Khuong, TM | 1 |
| Wang, QP | 1 |
| Manion, J | 1 |
| Oyston, LJ | 1 |
| Lau, MT | 1 |
| Towler, H | 1 |
| Lin, YQ | 1 |
| Neely, GG | 1 |
| Chevalier, P | 1 |
| Lamotte, M | 1 |
| Van Campenhout, H | 1 |
| Eyckerman, R | 1 |
| Annemans, L | 1 |
| Villarinho, JG | 1 |
| Pinheiro, Kde V | 1 |
| Pinheiro, Fde V | 1 |
| Oliveira, SM | 1 |
| Machado, P | 1 |
| Martins, MA | 1 |
| Bonacorso, HG | 1 |
| Zanatta, N | 1 |
| Fachinetto, R | 1 |
| Ferreira, J | 2 |
| Kukkar, A | 1 |
| Bali, A | 1 |
| Singh, N | 4 |
| Jaggi, AS | 1 |
| Kumar, N | 2 |
| Cherkas, PS | 1 |
| Varathan, V | 1 |
| Miyamoto, M | 1 |
| Chiang, CY | 1 |
| Dostrovsky, JO | 1 |
| Sessle, BJ | 1 |
| Coderre, TJ | 2 |
| Raptis, E | 1 |
| Vadalouca, A | 2 |
| Stavropoulou, E | 1 |
| Argyra, E | 2 |
| Melemeni, A | 1 |
| Siafaka, I | 2 |
| Hopkins, SC | 1 |
| Zhao, FY | 1 |
| Bowen, CA | 1 |
| Fang, X | 1 |
| Wei, H | 1 |
| Heffernan, ML | 1 |
| Spear, KL | 1 |
| Spanswick, DC | 1 |
| Varney, MA | 1 |
| Large, TH | 1 |
| Garassino, MC | 1 |
| Piva, S | 1 |
| La Verde, N | 1 |
| Spagnoletti, I | 1 |
| Iorno, V | 1 |
| Carbone, C | 1 |
| Febbraro, A | 1 |
| Bianchi, A | 1 |
| Bramati, A | 1 |
| Moretti, A | 1 |
| Ganzinelli, M | 1 |
| Marabese, M | 1 |
| Gentili, M | 1 |
| Torri, V | 1 |
| Farina, G | 1 |
| Trivedi, JR | 1 |
| Silvestri, NJ | 1 |
| Wolfe, GI | 1 |
| Moens, M | 1 |
| Mariën, P | 1 |
| Brouns, R | 1 |
| Poelaert, J | 1 |
| De Smedt, A | 1 |
| Buyl, R | 1 |
| Droogmans, S | 1 |
| Van Schuerbeek, P | 1 |
| Sunaert, S | 1 |
| Nuttin, B | 1 |
| Haribabu, PK | 1 |
| Eliav, E | 3 |
| Heir, GM | 1 |
| Athanasakis, K | 1 |
| Petrakis, I | 1 |
| Karampli, E | 1 |
| Vitsou, E | 1 |
| Lyras, L | 1 |
| Kyriopoulos, J | 1 |
| Lin, TC | 1 |
| Lai, SL | 1 |
| Hsu, SP | 1 |
| Ro, LS | 1 |
| Lau, W | 1 |
| Dykstra, C | 1 |
| Thevarkunnel, S | 1 |
| Silenieks, LB | 1 |
| de Lannoy, IA | 1 |
| Lee, DK | 1 |
| Higgins, GA | 1 |
| Holtedahl, R | 1 |
| Wettermark, B | 1 |
| Brandt, L | 1 |
| Kieler, H | 1 |
| Bodén, R | 1 |
| Librowski, T | 1 |
| Nawiesniak, B | 1 |
| Gluch-Lutwin, M | 1 |
| Hooker, BA | 1 |
| Tobon, G | 1 |
| Baker, SJ | 1 |
| Zhu, C | 1 |
| Hesterman, J | 1 |
| Schmidt, K | 1 |
| Rajagovindan, R | 1 |
| Chandran, P | 1 |
| Joshi, SK | 1 |
| Bannon, AW | 1 |
| Hoppin, J | 1 |
| Beaver, J | 1 |
| Fox, GB | 1 |
| Day, M | 1 |
| Upadhyay, J | 1 |
| Yowtak, J | 2 |
| Chung, K | 2 |
| Chung, JM | 3 |
| Chen, L | 2 |
| Mao, J | 2 |
| Ide, Y | 1 |
| Blanco Tarrio, E | 1 |
| Gálvez Mateos, R | 1 |
| Zamorano Bayarri, E | 1 |
| López Gómez, V | 1 |
| Pérez Páramo, M | 1 |
| Bennett, MI | 1 |
| Laird, B | 1 |
| van Litsenburg, C | 1 |
| Nimour, M | 3 |
| Yezierski, RP | 1 |
| Green, M | 1 |
| Murphy, K | 2 |
| Vierck, CJ | 1 |
| Pedraza, MI | 1 |
| Ruiz, M | 4 |
| Rodríguez, C | 1 |
| Muñoz, I | 1 |
| Barón, J | 1 |
| Mulero, P | 1 |
| Herrero-Velázquez, S | 1 |
| Guerrero-Peral, ÁL | 1 |
| Marchiori, ÉC | 1 |
| Barber, JS | 1 |
| Williams, WB | 1 |
| Bui, PQ | 1 |
| O'Ryan, FS | 1 |
| Sanin, L | 2 |
| Yang, R | 2 |
| Juhn, M | 1 |
| Monge-Márquez, ME | 1 |
| Márquez-Rivas, J | 1 |
| Mayorga-Buiza, MJ | 1 |
| Rivero-Garvía, M | 1 |
| Matsutani, N | 1 |
| Kawamura, M | 2 |
| Roth, T | 1 |
| Arnold, LM | 1 |
| Garcia-Borreguero, D | 1 |
| Resnick, M | 1 |
| Clair, AG | 1 |
| Yu, J | 1 |
| Fu, P | 1 |
| Liu, S | 1 |
| Cui, D | 1 |
| Câmara, CC | 2 |
| Ramos, HF | 1 |
| da Silva, AP | 1 |
| Araújo, CV | 2 |
| Gomes, AS | 1 |
| Vale, ML | 2 |
| Barbosa, AL | 1 |
| Ribeiro, RA | 1 |
| Brito, GA | 1 |
| Costa, CM | 1 |
| Oriá, RB | 2 |
| Manjavachi, MN | 1 |
| Costa, R | 1 |
| Quintão, NL | 2 |
| Calixto, JB | 2 |
| Aldington, D | 2 |
| Cole, P | 1 |
| Lunn, MP | 1 |
| Hamunen, K | 1 |
| Haanpaa, M | 2 |
| Kalso, EA | 1 |
| Basnet, A | 1 |
| Butler, S | 1 |
| Honoré, PH | 2 |
| Butler, M | 1 |
| Gordh, TE | 3 |
| Kristensen, K | 1 |
| Bjerrum, OJ | 5 |
| Guy, S | 1 |
| Mehta, S | 2 |
| Leff, L | 1 |
| Teasell, R | 1 |
| Loh, E | 2 |
| Pérez, C | 10 |
| Navarro, A | 8 |
| Saldaña, MT | 8 |
| Masramón, X | 5 |
| Pérez, M | 3 |
| Rejas, J | 10 |
| Jiang, YQ | 1 |
| Andrade, A | 1 |
| Lipscombe, D | 1 |
| Thangamani, D | 1 |
| Edafiogho, IO | 1 |
| Masocha, W | 2 |
| Darbà, J | 1 |
| Kaskens, L | 1 |
| Álvarez, E | 1 |
| Navarro-Artieda, R | 3 |
| Sicras-Mainar, A | 3 |
| Mercadante, S | 2 |
| Nakai, K | 1 |
| Nakae, A | 1 |
| Hashimoto, R | 1 |
| Mashimo, T | 2 |
| Hosokawa, K | 1 |
| Yamashita, A | 2 |
| Hamada, A | 1 |
| Suhara, Y | 1 |
| Kawabe, R | 1 |
| Yanase, M | 2 |
| Kuzumaki, N | 2 |
| Narita, M | 3 |
| Matsui, R | 1 |
| Okano, H | 1 |
| Aoki, M | 1 |
| Kurauchi, Y | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Sakamoto, K | 1 |
| Ishii, K | 1 |
| Severino, AL | 1 |
| Hayashida, K | 5 |
| Dwyer, JP | 1 |
| Jayasekera, C | 1 |
| Nicoll, A | 1 |
| Dauri, M | 1 |
| Lazzari, M | 1 |
| Casali, M | 1 |
| Tufaro, G | 1 |
| Sabato, E | 1 |
| Sabato, AF | 2 |
| Bao, YH | 1 |
| Zhou, QH | 1 |
| Chen, R | 1 |
| Xu, H | 1 |
| Zeng, LL | 1 |
| Zhang, X | 1 |
| Jiang, W | 1 |
| Du, DP | 1 |
| Bozkurt, M | 1 |
| Gocmez, C | 1 |
| Soylemez, H | 1 |
| Daggulli, M | 1 |
| Em, S | 1 |
| Yildiz, M | 1 |
| Atar, M | 1 |
| Bozkurt, Y | 1 |
| Ozbey, I | 1 |
| Cios, A | 1 |
| Wyska, E | 1 |
| Sałat, R | 1 |
| Mogilski, S | 1 |
| Filipek, B | 1 |
| Więckowski, K | 1 |
| Le Cudennec, C | 1 |
| Castagné, V | 1 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 8 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 2 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 1 |
| Fukasawa, H | 2 |
| Muratake, H | 2 |
| Ito, A | 1 |
| Suzuki, H | 1 |
| Amano, Y | 1 |
| Nagae, M | 2 |
| Sugiyama, K | 2 |
| Shudo, K | 2 |
| Toelle, T | 1 |
| Ye, GL | 1 |
| Savelieva, KV | 1 |
| Vogel, P | 1 |
| Baker, KB | 1 |
| Mason, S | 1 |
| Lanthorn, TH | 1 |
| Rajan, I | 1 |
| Ling, Q | 1 |
| Liu, M | 1 |
| Wu, MX | 1 |
| Xu, Y | 1 |
| Yang, J | 4 |
| Huang, HH | 1 |
| Yu, CX | 1 |
| Parker, L | 1 |
| Huelin, R | 1 |
| Khankhel, Z | 1 |
| Wasiak, R | 1 |
| Mould, J | 1 |
| Iwanowski, P | 1 |
| Kozubski, W | 1 |
| Losy, J | 1 |
| Farrar, JT | 3 |
| Troxel, AB | 1 |
| Haynes, K | 1 |
| Gilron, I | 7 |
| Kerns, RD | 1 |
| Katz, NP | 1 |
| Rappaport, BA | 1 |
| Rowbotham, MC | 1 |
| Tierney, AM | 1 |
| Turk, DC | 2 |
| Irving, G | 1 |
| Tanenberg, RJ | 2 |
| Raskin, J | 1 |
| Risser, RC | 2 |
| Malcolm, S | 1 |
| Patwardhan, A | 1 |
| Ossipov, MH | 1 |
| Becerra, L | 1 |
| Borsook, D | 1 |
| Jinzenji, A | 1 |
| Sogawa, C | 1 |
| Miyawaki, T | 1 |
| Wen, XF | 1 |
| Yi, D | 1 |
| Ohyama, K | 1 |
| Kitayama, S | 1 |
| Sogawa, N | 1 |
| Morita, K | 1 |
| Shen, X | 1 |
| Liu, Y | 2 |
| Xu, S | 1 |
| Zhao, Q | 1 |
| Wu, H | 1 |
| Guo, X | 1 |
| Shen, R | 1 |
| Wang, F | 1 |
| Buys, MJ | 1 |
| Alphonso, C | 1 |
| Wagner, K | 1 |
| Inceoglu, B | 1 |
| Hammock, BD | 2 |
| Dolgun, H | 1 |
| Turkoglu, E | 1 |
| Kertmen, H | 1 |
| Gurer, B | 1 |
| Yilmaz, ER | 1 |
| Comoglu, SS | 1 |
| Sekerci, Z | 1 |
| Ghinea, N | 1 |
| Lipworth, W | 1 |
| Kerridge, I | 1 |
| McIntyre, A | 1 |
| Dijkers, M | 1 |
| Teasell, RW | 1 |
| Takahashi, N | 2 |
| Arai, I | 2 |
| Kayama, S | 2 |
| Ichiji, K | 2 |
| Fukuda, H | 2 |
| Kaga, T | 1 |
| Konno, S | 2 |
| Lee, KS | 1 |
| Liu, JY | 1 |
| Wagner, KM | 1 |
| Pakhomova, S | 1 |
| Dong, H | 1 |
| Morisseau, C | 1 |
| Fu, SH | 1 |
| Ulu, A | 1 |
| Mate, CA | 1 |
| Nguyen, LV | 1 |
| Hwang, SH | 1 |
| Edin, ML | 1 |
| Mara, AA | 1 |
| Wulff, H | 1 |
| Newcomer, ME | 1 |
| Zeldin, DC | 1 |
| Capasso, KE | 1 |
| Manners, MT | 1 |
| Quershi, RA | 1 |
| Gao, R | 1 |
| Hu, H | 1 |
| Barrett, JE | 1 |
| Sacan, A | 1 |
| Ajit, SK | 1 |
| Karmakar, S | 1 |
| Rashidian, H | 1 |
| Chan, C | 1 |
| Toth, C | 1 |
| Erasso, D | 1 |
| Tender, G | 1 |
| Levitt, RC | 1 |
| Cui, JG | 3 |
| Magnaghi, V | 1 |
| Castelnovo, LF | 1 |
| Faroni, A | 1 |
| Cavalli, E | 1 |
| Caffino, L | 1 |
| Colciago, A | 1 |
| Procacci, P | 1 |
| Pajardi, G | 1 |
| Khan, N | 1 |
| Woodruff, TM | 1 |
| Smith, MT | 2 |
| Lin, HC | 1 |
| Huang, YH | 1 |
| Chao, TH | 1 |
| Lin, WY | 1 |
| Sun, WZ | 2 |
| Yen, CT | 1 |
| Xiao, P | 1 |
| Zhu, X | 1 |
| Wu, X | 1 |
| Turcotte, D | 2 |
| Doupe, M | 1 |
| Torabi, M | 1 |
| Gomori, A | 2 |
| Ethans, K | 1 |
| Esfahani, F | 2 |
| Galloway, K | 1 |
| Namaka, M | 2 |
| Xie, Y | 1 |
| Qin, F | 1 |
| Liu, W | 3 |
| Sanderson, C | 2 |
| Quinn, SJ | 2 |
| Agar, M | 1 |
| Chye, R | 1 |
| Clark, K | 2 |
| Doogue, M | 2 |
| Fazekas, B | 1 |
| Lee, J | 1 |
| Lovell, MR | 1 |
| Rowett, D | 1 |
| Spruyt, O | 1 |
| Currow, DC | 2 |
| Meinhold, S | 1 |
| de la Calle, JL | 1 |
| De Andres, J | 1 |
| López, V | 1 |
| Baron, R | 8 |
| Hiom, S | 1 |
| Patel, GK | 1 |
| Newcombe, RG | 1 |
| Khot, S | 1 |
| Martin, C | 1 |
| Ran, R | 1 |
| Gu, J | 1 |
| Fu, J | 1 |
| Zhong, H | 1 |
| Zhao, Y | 2 |
| Gu, Y | 1 |
| Zhang, A | 1 |
| Li, G | 1 |
| Wang, Q | 1 |
| Miranda, HF | 2 |
| Noriega, V | 2 |
| Zepeda, R | 1 |
| Zanetta, P | 2 |
| Prieto-Rayo, J | 1 |
| Prieto, JC | 2 |
| Sierralta, F | 2 |
| Crosby, ND | 1 |
| Weisshaar, CL | 1 |
| Smith, JR | 1 |
| Zeeman, ME | 1 |
| Goodman-Keiser, MD | 1 |
| Winkelstein, BA | 1 |
| Woller, SA | 1 |
| Corr, M | 1 |
| Yaksh, TL | 1 |
| Johannessen Landmark, C | 1 |
| Beiske, G | 1 |
| Baftiu, A | 1 |
| Burns, ML | 1 |
| Johannessen, SI | 1 |
| Sommer, C | 1 |
| Al Otaibi, M | 1 |
| Sathish, J | 1 |
| Djouhri, L | 1 |
| Yadav, R | 1 |
| Yan, X | 1 |
| Maixner, DW | 1 |
| Gao, M | 1 |
| Weng, HR | 1 |
| Lin, H | 1 |
| Heo, BH | 1 |
| Kim, WM | 1 |
| Kim, YC | 1 |
| Yoon, MH | 1 |
| Wang, TX | 1 |
| Yin, D | 1 |
| Guo, W | 1 |
| Liu, YY | 1 |
| Li, YD | 1 |
| Qu, WM | 1 |
| Han, WJ | 1 |
| Hong, ZY | 1 |
| Huang, ZL | 1 |
| Griggs, RB | 1 |
| Bardo, MT | 1 |
| Taylor, BK | 1 |
| Brett, J | 1 |
| Murnion, B | 1 |
| Evrensel, A | 1 |
| Ünsalver, BÖ | 1 |
| Yang, M | 1 |
| Qian, C | 1 |
| Gwynn, J | 1 |
| Ali, G | 3 |
| Abbas, M | 1 |
| Zeb, J | 1 |
| Sewell, RD | 2 |
| Lu, XQ | 1 |
| Yang, L | 1 |
| Deng, YO | 1 |
| Wu, SX | 1 |
| Liu, YG | 1 |
| Lovell, M | 1 |
| Henry, MA | 1 |
| Fairchild, DD | 1 |
| Patil, MJ | 1 |
| Hanania, T | 1 |
| Hain, HS | 1 |
| Davis, SF | 1 |
| Malekiani, SA | 1 |
| Hu, A | 1 |
| Sucholeiki, R | 1 |
| Nix, D | 1 |
| Sucholeiki, I | 1 |
| Plessas, IN | 2 |
| Volk, HA | 2 |
| Rusbridge, C | 2 |
| Vanhaesebrouck, AE | 1 |
| Jeffery, ND | 1 |
| Bugan, I | 1 |
| Karagoz, Z | 1 |
| Altun, S | 1 |
| Djamgoz, MB | 1 |
| Stalin, C | 1 |
| de Sousa, KKO | 1 |
| Brito, GAC | 1 |
| Raposo, RDS | 1 |
| Mendonça, FE | 1 |
| Mietto, BS | 1 |
| Martinez, AMB | 1 |
| Jayarajan, P | 1 |
| Nirogi, R | 1 |
| Shinde, A | 1 |
| Goura, V | 1 |
| Babu, VA | 1 |
| Yathavakilla, S | 1 |
| Bhyrapuneni, G | 1 |
| Batlle, L | 1 |
| Mattie, R | 1 |
| Irwin, R | 1 |
| Kiss, G | 1 |
| Castel, D | 1 |
| Sabbag, I | 1 |
| Brenner, O | 1 |
| Meilin, S | 1 |
| Gill, I | 1 |
| Parrent, AG | 1 |
| Steven, DA | 1 |
| Hutfless, S | 1 |
| Lock, D | 1 |
| Haythornthwaite, J | 1 |
| Singh, S | 1 |
| Kern, KU | 1 |
| Weiser, T | 1 |
| Robertson, K | 1 |
| Marshman, LA | 1 |
| Plummer, D | 1 |
| Garcia, D | 1 |
| Basbaum, AI | 1 |
| Bráz, JM | 1 |
| Yang, Y | 1 |
| Li, CL | 1 |
| Wang, Y | 2 |
| Lu, YF | 1 |
| Fu, H | 1 |
| He, T | 1 |
| Wang, RR | 1 |
| Li, C | 2 |
| Castillo, R | 1 |
| Aranda, N | 1 |
| Schuller, Y | 1 |
| Linthorst, GE | 1 |
| Hollak, CE | 1 |
| Van Schaik, IN | 1 |
| Biegstraaten, M | 1 |
| Yousuf, MS | 1 |
| Kerr, BJ | 1 |
| Porta-Etessam, J | 2 |
| Garcia-Ptacek, S | 1 |
| de la Cruz, C | 1 |
| Cuadrado, ML | 1 |
| Guerrero, AL | 1 |
| de Miguel-Jimeno, JM | 1 |
| Forner-Cordero, I | 1 |
| Zabalza-Azparren, M | 1 |
| Matute-Tobias, B | 1 |
| Kahle, KT | 1 |
| Schmouth, JF | 1 |
| Lavastre, V | 1 |
| Andrews, N | 1 |
| Omura, T | 1 |
| Laganière, J | 1 |
| Rochefort, D | 1 |
| Hince, P | 1 |
| Castonguay, G | 1 |
| Gaudet, R | 1 |
| Mapplebeck, JC | 1 |
| Sotocinal, SG | 1 |
| Duan, J | 1 |
| Ward, C | 1 |
| Khanna, AR | 1 |
| Mogil, JS | 1 |
| Dion, PA | 1 |
| Woolf, CJ | 3 |
| Rouleau, GA | 1 |
| Taguchi Ms, S | 1 |
| Tajima, F | 1 |
| Corona-Ramos, JN | 2 |
| Medina-López, JR | 2 |
| Kim, JY | 1 |
| Kim, DG | 1 |
| Kim, SH | 3 |
| Kwon, OW | 1 |
| You, YS | 1 |
| Matsuura, W | 1 |
| Harada, S | 1 |
| Tokuyama, S | 1 |
| Li, L | 1 |
| Chen, SR | 2 |
| Chen, H | 1 |
| Wen, L | 1 |
| Hittelman, WN | 1 |
| Xie, JD | 1 |
| Pan, HL | 2 |
| Iura, A | 1 |
| Takahashi, A | 1 |
| Hakata, S | 1 |
| Fujino, Y | 1 |
| Sant'Anna, MB | 1 |
| Kusuda, R | 1 |
| Bozzo, TA | 1 |
| Bassi, GS | 1 |
| Alves-Filho, JC | 1 |
| Cunha, FQ | 1 |
| Ferreira, SH | 1 |
| Souza, GR | 1 |
| Cunha, TM | 1 |
| Li, R | 1 |
| Shen, L | 1 |
| Yu, X | 1 |
| Ma, C | 2 |
| Huang, Y | 1 |
| Huang, ZZ | 1 |
| Wei, JY | 1 |
| Ou-Yang, HD | 1 |
| Li, D | 1 |
| Xu, T | 1 |
| Wu, SL | 1 |
| Zhang, XL | 1 |
| Liu, CC | 1 |
| Xin, WJ | 1 |
| De la O-Arciniega, M | 2 |
| Déciga-Campos, M | 1 |
| Domínguez-Ramírez, AM | 2 |
| Rejas-Gutiérrez, J | 2 |
| Pérez-Paramo, M | 2 |
| Hewitt, E | 1 |
| Pitcher, T | 1 |
| Rizoska, B | 1 |
| Tunblad, K | 1 |
| Henderson, I | 1 |
| Sahlberg, BL | 1 |
| Grabowska, U | 1 |
| Classon, B | 1 |
| Edenius, C | 1 |
| Malcangio, M | 1 |
| Lindström, E | 1 |
| Kremer, M | 1 |
| Salvat, E | 1 |
| Muller, A | 1 |
| Yalcin, I | 1 |
| Barrot, M | 1 |
| Lempel, AA | 1 |
| Coll, L | 1 |
| Schinder, AF | 1 |
| Uchitel, OD | 1 |
| Piriz, J | 1 |
| Kalladka, M | 1 |
| Nasri-Heir, C | 1 |
| Ananthan, S | 1 |
| Viswanath, A | 1 |
| Heir, G | 2 |
| Goel, R | 1 |
| Tyagi, N | 1 |
| Moon, HC | 1 |
| Lee, YJ | 1 |
| Cho, CB | 1 |
| Park, YS | 1 |
| Latymer, M | 1 |
| Almas, M | 1 |
| Ortiz, M | 1 |
| Clair, A | 1 |
| Varvara, R | 1 |
| Markman, JD | 1 |
| Jensen, TS | 6 |
| Semel, D | 2 |
| Behar, R | 1 |
| Sadosky, AB | 1 |
| Huang, W | 1 |
| Calvo, M | 1 |
| Pheby, T | 2 |
| Bennett, DLH | 1 |
| Ozbek, Z | 1 |
| Aydin, HE | 1 |
| Kocman, AE | 1 |
| Ozkara, E | 1 |
| Sahin, E | 1 |
| Bektur, E | 1 |
| Vural, M | 1 |
| Kose, A | 1 |
| Arslantas, A | 1 |
| Baycu, C | 1 |
| Akbar, S | 2 |
| Karim, N | 1 |
| Mahmood, W | 1 |
| Fawad, K | 2 |
| Kristensen, PJ | 1 |
| Heegaard, AM | 1 |
| Hestehave, S | 1 |
| Jeggo, RD | 1 |
| Munro, G | 2 |
| Kaufmann, D | 1 |
| West, PJ | 1 |
| Smith, MD | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Devor, M | 1 |
| White, HS | 1 |
| Brennan, KC | 1 |
| Kato, E | 1 |
| Matsuzawa, R | 1 |
| Kobayashi, S | 1 |
| Fukushima, T | 1 |
| Maekawa, M | 1 |
| Hori, Y | 1 |
| Chenaf, C | 1 |
| Libert, F | 1 |
| Courteix, C | 1 |
| Bertrand, M | 1 |
| Gabriel, C | 1 |
| Mocaër, E | 1 |
| Authier, N | 2 |
| Avila-Rojas, SH | 1 |
| Wright, ME | 1 |
| Rizzolo, D | 1 |
| Poucher, M | 1 |
| Cherrier, C | 1 |
| Poucher, AC | 1 |
| Di Patrizio, P | 1 |
| Shanthanna, H | 1 |
| Thabane, L | 1 |
| Devereaux, PJ | 1 |
| Bhandari, M | 1 |
| AlAmri, R | 1 |
| Rajarathinam, M | 1 |
| Kamath, S | 1 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 3 |
| Truini, A | 1 |
| Attal, N | 3 |
| Finnerup, NB | 2 |
| Eccleston, C | 1 |
| Kalso, E | 3 |
| Raja, SN | 3 |
| Ding, W | 1 |
| You, Z | 1 |
| Shen, S | 1 |
| Lim, G | 1 |
| Doheny, JT | 1 |
| Zhu, S | 1 |
| Kogure, T | 1 |
| Sumitani, M | 1 |
| Ikegami, K | 1 |
| Abe, H | 1 |
| Hozumi, J | 1 |
| Inoue, R | 1 |
| Kawahara, K | 1 |
| Yamada, Y | 1 |
| Newton, VL | 1 |
| Guck, JD | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Gardiner, NJ | 1 |
| Jacob, S | 1 |
| Saha, A | 1 |
| Rajabally, Y | 1 |
| Taira, T | 1 |
| Roeska, K | 1 |
| Doods, H | 1 |
| Arndt, K | 1 |
| Treede, RD | 2 |
| Ceci, A | 1 |
| Ling, B | 1 |
| Coudoré, F | 1 |
| Decalonne, L | 1 |
| Tzellos, TG | 1 |
| Papazisis, G | 1 |
| Amaniti, E | 1 |
| Kouvelas, D | 1 |
| Roh, DH | 1 |
| Yoon, SY | 1 |
| Seo, HS | 1 |
| Kwon, YB | 1 |
| Han, HJ | 1 |
| Beitz, AJ | 1 |
| Lee, JH | 2 |
| Tanabe, M | 1 |
| Takasu, K | 2 |
| Takeuchi, Y | 1 |
| Ono, H | 1 |
| Page, RL | 1 |
| Cantu, M | 1 |
| Lindenfeld, J | 1 |
| Hergott, LJ | 1 |
| Lowes, BD | 1 |
| Lee, CA | 1 |
| Ramos, KM | 1 |
| Vondracek, P | 1 |
| Oslejskova, H | 1 |
| Kepak, T | 1 |
| Mazanek, P | 1 |
| Sterba, J | 1 |
| Rysava, M | 1 |
| Gal, P | 1 |
| Stacey, BR | 4 |
| Swift, JN | 1 |
| Yamamoto, T | 2 |
| Bee, LA | 1 |
| Lokshina, I | 1 |
| Feinstein, I | 1 |
| Agin, C | 1 |
| Katz, R | 1 |
| Wallace, VC | 1 |
| Segerdahl, AR | 1 |
| Blackbeard, J | 1 |
| Masa-Vázquez, LA | 1 |
| Villamil-Cajoto, I | 1 |
| Villar Del Castillo, A | 1 |
| Boyd, ST | 1 |
| Mihm, L | 1 |
| Causey, NW | 1 |
| Smith, TL | 1 |
| Baldwin, A | 1 |
| Cunningham, LL | 1 |
| Cook, AM | 1 |
| Ho, TW | 2 |
| Backonja, M | 3 |
| Ma, J | 1 |
| Leibensperger, H | 1 |
| Froman, S | 1 |
| Polydefkis, M | 1 |
| Dayioğlu, M | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Nakajima, K | 1 |
| Tsavaris, N | 1 |
| Kopterides, P | 1 |
| Kosmas, C | 1 |
| Efthymiou, A | 1 |
| Skopelitis, H | 1 |
| Dimitrakopoulos, A | 1 |
| Pagouni, E | 1 |
| Pikazis, D | 1 |
| Zis, PV | 1 |
| Koufos, C | 1 |
| Gatti, A | 1 |
| Occhioni, R | 1 |
| Colini Baldeschi, G | 1 |
| Reale, C | 1 |
| Evans, RW | 1 |
| Pareja, JA | 1 |
| Hahm, TS | 2 |
| Ahn, HJ | 2 |
| Bae, CD | 1 |
| Kim, HS | 1 |
| Lim, SW | 1 |
| Cho, HS | 1 |
| Lee, SM | 1 |
| Sim, WS | 1 |
| Kim, JA | 1 |
| Gwak, MS | 2 |
| Choi, SJ | 2 |
| Bauer, CS | 2 |
| Nieto-Rostro, M | 1 |
| Rahman, W | 2 |
| Tran-Van-Minh, A | 2 |
| Ferron, L | 1 |
| Douglas, L | 2 |
| Kadurin, I | 1 |
| Sri Ranjan, Y | 1 |
| Fernandez-Alacid, L | 1 |
| Millar, NS | 1 |
| Lujan, R | 2 |
| Dolphin, AC | 3 |
| O'Connor, AB | 3 |
| Díaz-Reval, MI | 1 |
| Cortés-Arroyo, AR | 1 |
| Yoo, L | 1 |
| Matalon, D | 1 |
| Hoffman, RS | 1 |
| Goldfarb, DS | 1 |
| Eaton, MJ | 3 |
| Wolfe, SQ | 1 |
| Solaro, C | 1 |
| Boehmker, M | 1 |
| Tanganelli, P | 1 |
| Kruszewski, SP | 1 |
| Paczynski, RP | 1 |
| Kahn, DA | 1 |
| Curros-Criado, MM | 1 |
| Herrero, JF | 1 |
| Piesla, MJ | 1 |
| Leventhal, L | 1 |
| Strassle, BW | 1 |
| Harrison, JE | 1 |
| Cummons, TA | 1 |
| Lu, P | 1 |
| Whiteside, GT | 1 |
| Cabrera Schulmeyer, MC | 1 |
| de la Maza, J | 1 |
| Ovalle, C | 1 |
| Farias, C | 1 |
| Vives, I | 1 |
| Bailey, JM | 2 |
| Tu, D | 3 |
| Holden, RR | 3 |
| Jackson, AC | 1 |
| Houlden, RL | 2 |
| Margolis, JM | 1 |
| Johnston, SS | 1 |
| Chu, BC | 1 |
| Onukwugha, E | 1 |
| Hvidsten, K | 1 |
| Alvir, J | 1 |
| Rossi, JG | 1 |
| Mullins, CD | 1 |
| Zin, CS | 1 |
| Nissen, LM | 1 |
| O'Callaghan, JP | 1 |
| Duffull, SB | 1 |
| Moore, BJ | 1 |
| Blakemore, DC | 1 |
| Bryans, JS | 1 |
| Carnell, P | 1 |
| Carr, CL | 1 |
| Chessum, NE | 1 |
| Field, MJ | 3 |
| Kinsella, N | 1 |
| Osborne, SA | 1 |
| Warren, AN | 1 |
| Williams, SC | 1 |
| Inoue, K | 3 |
| Meisner, JG | 1 |
| Marsh, AD | 1 |
| Marsh, DR | 1 |
| Stump, P | 1 |
| Buccafusco, JJ | 1 |
| Terry, AV | 1 |
| Vazdarjanova, A | 1 |
| Snutch, TP | 1 |
| Arneric, SP | 1 |
| Simpson, DM | 1 |
| Schifitto, G | 1 |
| Clifford, DB | 1 |
| Murphy, TK | 4 |
| Durso-De Cruz, E | 1 |
| Glue, P | 1 |
| Scott, GN | 1 |
| Leong, C | 1 |
| Grossberndt, A | 1 |
| Klowak, M | 1 |
| Intrater, H | 1 |
| da Silva, GF | 1 |
| Antonialli, CS | 1 |
| Rocha, LW | 1 |
| Cechinel Filho, V | 1 |
| Cicció, JF | 1 |
| Audette, J | 1 |
| Gourlay, GK | 1 |
| Haanpää, ML | 1 |
| Kent, JL | 1 |
| Krane, EJ | 1 |
| Lebel, AA | 1 |
| Levy, RM | 1 |
| Mackey, SC | 1 |
| Mayer, J | 1 |
| Miaskowski, C | 1 |
| Schmader, KE | 2 |
| Stacey, B | 2 |
| Stanos, S | 1 |
| Walco, GA | 1 |
| Wells, CD | 1 |
| Lampl, C | 1 |
| Schweiger, C | 1 |
| Haider, B | 1 |
| Lechner, A | 1 |
| van Seventer, R | 2 |
| Bach, FW | 3 |
| Toth, CC | 2 |
| Serpell, M | 2 |
| Temple, J | 1 |
| Torrades, S | 2 |
| Wong, L | 1 |
| Turner, L | 1 |
| Cruccu, G | 2 |
| Hansson, P | 1 |
| Nurmikko, T | 1 |
| Xochilcal-Morales, M | 1 |
| Castro, EM | 1 |
| Guajardo-Rosas, J | 1 |
| Obregón, TN | 1 |
| Acevedo, JC | 1 |
| Chucan, JM | 1 |
| Plancarte-Sanchez, R | 1 |
| Davila, G | 1 |
| Wajsbrot, D | 1 |
| Guerrero, M | 1 |
| Vinueza, R | 1 |
| Freynhagen, R | 3 |
| Cloutier, C | 1 |
| Leon, T | 1 |
| Murphy, KT | 1 |
| Phillips, K | 1 |
| Fournier-Charrière, E | 1 |
| de Tommaso, M | 1 |
| Lavolpe, V | 1 |
| Di Venere, D | 1 |
| Corsalini, M | 1 |
| Vecchio, E | 1 |
| Favia, G | 1 |
| Sardaro, M | 1 |
| Livrea, P | 1 |
| Nolano, M | 1 |
| Ochi, Y | 1 |
| Harada, T | 1 |
| Kikuchi, C | 1 |
| Arakawa, A | 2 |
| Yamama, Y | 1 |
| Nishikawa, K | 1 |
| Funao, T | 1 |
| Mori, T | 1 |
| Asada, A | 1 |
| Folkesson, A | 1 |
| Andersen, LM | 1 |
| Kristensen, P | 1 |
| Yi, H | 1 |
| Kim, MA | 1 |
| Back, SK | 1 |
| Eun, JS | 1 |
| Na, HS | 1 |
| Vaysse, L | 1 |
| Sol, JC | 1 |
| Lazorthes, Y | 1 |
| Courtade-Saidi, M | 1 |
| Jozan, S | 1 |
| Wei-Chong, C | 1 |
| Yam, A | 1 |
| Durkin, B | 1 |
| Page, C | 1 |
| Glass, P | 1 |
| Zlateva, G | 2 |
| Cheung, R | 1 |
| Bazan, NG | 1 |
| Plested, M | 1 |
| Budhia, S | 1 |
| Gabriel, Z | 2 |
| Kusunose, N | 1 |
| Koyanagi, S | 1 |
| Hamamura, K | 1 |
| Matsunaga, N | 1 |
| Yoshida, M | 1 |
| Uchida, T | 1 |
| Ohdo, S | 1 |
| Takemura, Y | 1 |
| Horiuchi, H | 1 |
| Furuya, M | 1 |
| Niikura, K | 1 |
| Imai, S | 1 |
| Hatakeyama, N | 1 |
| Kinoshita, H | 1 |
| Tsukiyama, Y | 1 |
| Matoba, M | 1 |
| Yamazaki, M | 1 |
| Suzuki, T | 1 |
| Hewitt, DJ | 3 |
| Galer, B | 1 |
| Markovitz, P | 1 |
| Gammaitoni, A | 1 |
| Michelson, D | 1 |
| Bolognese, J | 1 |
| Alon, A | 3 |
| Rosenberg, E | 1 |
| Herman, G | 1 |
| Wang, H | 1 |
| Hulsebosch, CE | 1 |
| Boroujerdi, A | 2 |
| Zeng, J | 1 |
| Sharp, K | 1 |
| Kim, D | 1 |
| Steward, O | 1 |
| Luo, DZ | 1 |
| Lee, KY | 1 |
| Kim, HK | 1 |
| Sun, P | 1 |
| Watson, P | 1 |
| Anghelescu, DL | 1 |
| Faughnan, LG | 1 |
| Jeha, S | 1 |
| Relling, MV | 1 |
| Hinds, PS | 1 |
| Sandlund, JT | 1 |
| Cheng, C | 1 |
| Pei, D | 1 |
| Hankins, G | 1 |
| Pauley, JL | 1 |
| Pui, CH | 1 |
| Zaccara, G | 2 |
| Gangemi, P | 1 |
| Perucca, P | 2 |
| Specchio, L | 1 |
| Härmark, L | 1 |
| van Puijenbroek, E | 1 |
| Straus, S | 1 |
| van Grootheest, K | 1 |
| Schalkwijk, A | 1 |
| Verhagen, CA | 1 |
| Engels, Y | 1 |
| Hekster, YA | 1 |
| Vissers, KC | 1 |
| Muthuraman, A | 3 |
| McQuay, HJ | 4 |
| Edwards, J | 1 |
| Morlion, B | 1 |
| Bushmakin, AG | 1 |
| Cappelleri, JC | 1 |
| Janssen, SP | 2 |
| Truin, M | 2 |
| Van Kleef, M | 2 |
| Hahm, ET | 1 |
| Kim, Y | 1 |
| Lee, JJ | 1 |
| Cho, YW | 1 |
| Tassinari, D | 1 |
| Drudi, F | 1 |
| Carloni, F | 1 |
| Possenti, C | 1 |
| Santelmo, C | 1 |
| Castellani, C | 1 |
| Christoph, T | 1 |
| De Vry, J | 1 |
| Schiene, K | 1 |
| Tallarida, RJ | 1 |
| Tzschentke, TM | 1 |
| Erdoğan, G | 1 |
| Ceyhan, D | 1 |
| Güleç, S | 1 |
| Sendra, JM | 1 |
| Junyent, TT | 1 |
| Pellicer, MJ | 1 |
| Mittal, M | 1 |
| Pasnoor, M | 1 |
| Mummaneni, RB | 1 |
| Khan, S | 1 |
| McVey, A | 1 |
| Saperstein, D | 1 |
| Herbelin, L | 1 |
| Ridings, L | 1 |
| Dimachkie, MM | 1 |
| Barohn, RJ | 1 |
| Hanu-Cernat, DE | 1 |
| Phipps, AN | 1 |
| Raphael, JH | 1 |
| Irving, GA | 1 |
| Ahl, J | 1 |
| Robinson, MJ | 1 |
| Skljarevski, V | 1 |
| Malcolm, SK | 1 |
| Wu, YT | 1 |
| Lai, MH | 2 |
| Lu, SC | 1 |
| Chang, ST | 2 |
| Heltsley, R | 1 |
| Depriest, A | 1 |
| Black, DL | 1 |
| Robert, T | 1 |
| Caplan, YH | 1 |
| Cone, EJ | 1 |
| Rehman, SU | 1 |
| Khan, MZ | 1 |
| Hussain, R | 1 |
| Jamshed, A | 1 |
| Mishra, S | 1 |
| Bhatnagar, S | 1 |
| Goyal, GN | 1 |
| Rana, SP | 1 |
| Upadhya, SP | 1 |
| Guzelkucuk, U | 1 |
| Duman, I | 1 |
| Yılmaz, B | 1 |
| Tan, AK | 1 |
| Sikandar, S | 1 |
| Cidral-Filho, FJ | 1 |
| da Silva, MD | 1 |
| Moré, AO | 1 |
| Córdova, MM | 1 |
| Werner, MF | 1 |
| Santos, AR | 2 |
| Mańas, A | 1 |
| Ciria, JP | 1 |
| Fernández, MC | 1 |
| Gonzálvez, ML | 1 |
| Morillo, V | 1 |
| López-Gómez, V | 1 |
| Gunduz, O | 1 |
| Oltulu, C | 1 |
| Guven, R | 1 |
| Buldum, D | 1 |
| Ulugol, A | 1 |
| Shibahara, H | 2 |
| Ando, A | 1 |
| Suzuki, S | 1 |
| Uematsu, N | 1 |
| Nishimura, D | 2 |
| Gordon, J | 1 |
| Lister, S | 2 |
| Prettyjohns, M | 2 |
| McEwan, P | 1 |
| Tetlow, A | 1 |
| Gerard, S | 1 |
| Raijmakers, ME | 1 |
| Jensen, MP | 2 |
| Gammaitoni, AR | 2 |
| Bolognese, JA | 2 |
| Smugar, SS | 2 |
| Galer, BS | 2 |
| Yeh, CY | 1 |
| Chung, SC | 1 |
| Tseng, FL | 1 |
| Tsai, YC | 1 |
| Liu, YC | 1 |
| Martinez, JA | 1 |
| Kasamatsu, M | 1 |
| Rosales-Hernandez, A | 1 |
| Hanson, LR | 1 |
| Frey, WH | 1 |
| Gangemi, PF | 1 |
| Thiagarajan, VR | 1 |
| Shanmugam, P | 1 |
| Krishnan, UM | 1 |
| Okubo, K | 1 |
| Takeshita, N | 1 |
| Ogawa, K | 1 |
| Shinohara, S | 1 |
| Yoneda, Y | 1 |
| Ma, LL | 1 |
| Huang, YG | 1 |
| Yang, N | 1 |
| Zuo, PP | 1 |
| Storm, A | 1 |
| Hansen, MK | 1 |
| Dyhr, H | 1 |
| Marcher, L | 1 |
| Erichsen, HK | 1 |
| Sheykhzade, M | 1 |
| Guan, Y | 1 |
| Baba, M | 2 |
| Gomyo, I | 1 |
| Miyazaki, R | 1 |
| Morimoto, S | 1 |
| Ito, M | 1 |
| Oda, S | 1 |
| Sugiyama, A | 1 |
| Kuroda, M | 1 |
| Adachi-Akahane, S | 1 |
| Schroll, J | 1 |
| Amin, B | 1 |
| Hosseinzadeh, H | 1 |
| Makimura, C | 1 |
| Otsuka, M | 1 |
| Okamoto, W | 1 |
| Fujisaka, Y | 1 |
| Kaneda, H | 1 |
| Tsurutani, J | 1 |
| Nakagawa, K | 1 |
| de Salas-Cansado, M | 1 |
| Grégoire, S | 1 |
| Michaud, V | 1 |
| Sandelin, R | 1 |
| Norrefalk, JR | 1 |
| Brunton, LM | 1 |
| Laporte, DM | 1 |
| Komoly, S | 1 |
| Jang, Y | 1 |
| Song, HK | 1 |
| Yeom, MY | 1 |
| Jeong, DC | 1 |
| Chaparro, LE | 1 |
| de Biase, S | 1 |
| Merlino, G | 1 |
| Lorenzut, S | 1 |
| Valente, M | 1 |
| Gigli, GL | 1 |
| Viguier, F | 1 |
| Michot, B | 1 |
| Kayser, V | 1 |
| Bernard, JF | 1 |
| Vela, JM | 1 |
| Hamon, M | 1 |
| Bourgoin, S | 1 |
| Ibitoye, RT | 1 |
| Rajbhandari, SM | 1 |
| Gonçalves, L | 1 |
| Smith, BH | 1 |
| Higgins, C | 1 |
| Baldacchino, A | 1 |
| Kidd, B | 1 |
| Bannister, J | 1 |
| Vedula, SS | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Solak, Y | 1 |
| Biyik, Z | 1 |
| Atalay, H | 1 |
| Gaipov, A | 1 |
| Guney, F | 1 |
| Turk, S | 1 |
| Covic, A | 1 |
| Goldsmith, D | 1 |
| Kanbay, M | 1 |
| Ryu, S | 1 |
| Kim, JK | 1 |
| Yu, JM | 1 |
| Ogawa, S | 1 |
| Satoh, J | 1 |
| Yoshiyama, T | 1 |
| Suzuki, M | 1 |
| Lee, JE | 1 |
| Wang, KC | 1 |
| Chiang, HY | 1 |
| Hsieh, JH | 1 |
| Hsieh, ST | 1 |
| Chen, WH | 1 |
| Li, TH | 1 |
| Lee, LH | 1 |
| Huang, CC | 1 |
| Dias, QM | 1 |
| Silveira, JW | 1 |
| Reis, GM | 1 |
| Costa, KA | 1 |
| Rossaneis, AC | 1 |
| Fais, RS | 1 |
| Prado, WA | 1 |
| Plaza-Villegas, F | 1 |
| Markman, S | 1 |
| Khan, J | 1 |
| Noma, N | 1 |
| Benoliel, R | 1 |
| Patel, J | 1 |
| Driver, CJ | 1 |
| Chandler, KE | 1 |
| Craig, A | 1 |
| McGonnell, IM | 1 |
| Brodbelt, DC | 1 |
| Wei, B | 1 |
| Kumada, T | 1 |
| Furukawa, T | 1 |
| Sato, K | 1 |
| Fukuda, A | 1 |
| Gallagher, R | 1 |
| Apostle, N | 1 |
| Im, YB | 1 |
| Jee, MK | 1 |
| Choi, JI | 1 |
| Cho, HT | 1 |
| Kwon, OH | 1 |
| Kang, SK | 1 |
| Gomwo, I | 1 |
| Liu, HY | 1 |
| Li, YX | 1 |
| Hao, YJ | 1 |
| Wang, HY | 1 |
| Dai, XY | 1 |
| Sun, T | 1 |
| Yu, JQ | 1 |
| Rauck, R | 1 |
| Makumi, CW | 1 |
| Schwartz, S | 1 |
| Graff, O | 1 |
| Meno-Tetang, G | 1 |
| Bell, CF | 1 |
| Kavanagh, ST | 1 |
| McClung, CL | 1 |
| Taneja, A | 2 |
| Nyberg, J | 2 |
| Danhof, M | 2 |
| Della Pasqua, O | 2 |
| de Lange, EC | 1 |
| Kimura, M | 1 |
| Arcos, M | 1 |
| Palanca, JM | 1 |
| Montes, F | 1 |
| Barrios, C | 1 |
| Lim, HS | 1 |
| Kim, JM | 1 |
| Choi, JG | 1 |
| Ko, YK | 1 |
| Shin, YS | 1 |
| Jeon, BH | 1 |
| Fuzier, R | 1 |
| Serres, I | 1 |
| Guitton, E | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Figueras-Balsells, M | 1 |
| Muñoz-Tudurí, M | 1 |
| Okazaki, R | 1 |
| Namba, H | 1 |
| Yoshida, H | 1 |
| Okai, H | 1 |
| Taguchi, K | 1 |
| Cardenas, DD | 1 |
| Nieshoff, EC | 1 |
| Suda, K | 1 |
| Goto, S | 1 |
| Kaneko, T | 1 |
| Sporn, J | 1 |
| Soulsby, M | 1 |
| Scavone, JM | 1 |
| Suzuki, MM | 1 |
| Knapp, LE | 1 |
| Nizeica, V | 1 |
| Collet, P | 1 |
| Marotte, H | 1 |
| Murashko, NK | 1 |
| Lee, BS | 2 |
| Jun, IG | 1 |
| Park, JY | 1 |
| Tai, Q | 1 |
| Kirshblum, S | 1 |
| Chen, B | 1 |
| Millis, S | 1 |
| Johnston, M | 1 |
| DeLisa, JA | 1 |
| Moore, KA | 2 |
| Kohno, T | 3 |
| Karchewski, LA | 1 |
| Baba, H | 2 |
| Benito-Leon, J | 2 |
| Martinez-Salio, A | 1 |
| Berbel, A | 1 |
| Hunt, CH | 1 |
| Dodick, DW | 1 |
| Bosch, EP | 1 |
| Ahn, SH | 1 |
| Park, HW | 1 |
| Moon, HW | 1 |
| Jang, SH | 1 |
| Sakong, J | 1 |
| Bae, JH | 1 |
| Glanzman, RL | 2 |
| Neumeier, S | 1 |
| Brinkschmidt, T | 1 |
| Jensen, U | 1 |
| Corbin, AE | 1 |
| Young, JP | 3 |
| LaMoreaux, L | 3 |
| Bockbrader, H | 1 |
| Garofalo, EA | 1 |
| Poole, RM | 2 |
| Lovitt, S | 1 |
| McCleane, GJ | 1 |
| Scheinfeld, N | 1 |
| Singh, D | 1 |
| Kennedy, DH | 1 |
| Ries, M | 1 |
| Mengel, E | 1 |
| Kutschke, G | 1 |
| Kim, KS | 1 |
| Birklein, F | 1 |
| Krummenauer, F | 1 |
| Beck, M | 1 |
| Fox, A | 2 |
| Gentry, C | 1 |
| Patel, S | 2 |
| Kesingland, A | 2 |
| Bevan, S | 1 |
| Maimone-Baronello, M | 1 |
| Piccoli, F | 1 |
| La Bella, V | 1 |
| Curran, MP | 1 |
| Wagstaff, AJ | 1 |
| Junker, U | 1 |
| Brunnmüller, U | 2 |
| Ataka, T | 1 |
| Wakai, A | 1 |
| Okamoto, M | 1 |
| Berger, A | 2 |
| Dukes, E | 3 |
| McCarberg, B | 1 |
| Liss, M | 1 |
| Oster, G | 3 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Nicholson, BD | 1 |
| Sabatowski, R | 1 |
| Gálvez, R | 3 |
| Cherry, DA | 1 |
| Jacquot, F | 1 |
| Vincent, E | 1 |
| Maisonobe, P | 1 |
| Versavel, M | 2 |
| Levendoglu, F | 1 |
| Ogün, CO | 1 |
| Ozerbil, O | 1 |
| Ogün, TC | 1 |
| Ugurlu, H | 1 |
| Simpson, MA | 1 |
| Rodrigues-Filho, R | 1 |
| Campos, MM | 1 |
| Bertelli, JA | 1 |
| Dubinsky, RM | 1 |
| Kabbani, H | 1 |
| El-Chami, Z | 1 |
| Boutwell, C | 1 |
| Ali, H | 1 |
| Hahn, K | 1 |
| Arendt, G | 1 |
| Braun, JS | 1 |
| von Giesen, HJ | 1 |
| Husstedt, IW | 1 |
| Maschke, M | 1 |
| Straube, ME | 1 |
| Schielke, E | 1 |
| Sra, KK | 1 |
| Tyring, SK | 1 |
| Wareham, D | 2 |
| Tive, L | 1 |
| Huang, S | 2 |
| Douglas, MW | 1 |
| Johnson, RW | 1 |
| Cunningham, AL | 1 |
| Criscuolo, S | 1 |
| Auletta, C | 1 |
| Lippi, S | 1 |
| Brogi, F | 1 |
| Brogi, A | 1 |
| Lesser, H | 1 |
| Frampton, JE | 1 |
| Foster, RH | 1 |
| Hays, RD | 1 |
| Martin, SA | 1 |
| Sesti, AM | 1 |
| Spritzer, KL | 1 |
| Jääskeläinen, SK | 1 |
| Jensen, NH | 1 |
| Hansen, RW | 1 |
| Hedal, BS | 1 |
| Korsgaard, AG | 1 |
| Jonsson, T | 1 |
| Jeppesen, S | 1 |
| Weaver, DF | 1 |
| Walczak, JS | 1 |
| Pichette, V | 1 |
| Leblond, F | 1 |
| Desbiens, K | 1 |
| Beaulieu, P | 1 |
| Strojek, K | 1 |
| Griesing, T | 3 |
| Balkenohl, M | 1 |
| Hao, S | 1 |
| Mata, M | 1 |
| Wolfe, D | 1 |
| Glorioso, JC | 1 |
| Fink, DJ | 1 |
| Baillie, JK | 1 |
| Power, I | 1 |
| Vera-Llonch, M | 1 |
| Delea, TE | 1 |
| Wang, ST | 1 |
| Edwards, JE | 1 |
| Jean, WH | 1 |
| Wu, CC | 1 |
| Mok, MS | 1 |
| Misery, L | 1 |
| Weissenbacher, S | 1 |
| Ring, J | 1 |
| Hofmann, H | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Mourouzis, C | 1 |
| Saranteas, T | 1 |
| Rallis, G | 1 |
| Anagnostopoulou, S | 1 |
| Tesseromatis, C | 1 |
| Heckmann, JG | 1 |
| Ulrich, K | 1 |
| Dütsch, M | 1 |
| Neundörfer, B | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Martin, WJ | 1 |
| Kinchington, PR | 1 |
| Krah, DL | 1 |
| Abbadie, C | 1 |
| Fleetwood-Walker, SM | 1 |
| Zareba, G | 1 |
| Miller, R | 1 |
| Ewy, W | 1 |
| Corrigan, BW | 1 |
| Ouellet, D | 1 |
| Hermann, D | 1 |
| Kowalski, KG | 1 |
| Lockwood, P | 1 |
| Koup, JR | 1 |
| Donevan, S | 1 |
| El-Kattan, A | 1 |
| Li, CS | 1 |
| Werth, JL | 2 |
| Feltner, DE | 1 |
| Lalonde, RL | 1 |
| Shneker, BF | 1 |
| McAuley, JW | 1 |
| Engle, MP | 1 |
| Gassman, M | 1 |
| Sykes, KT | 1 |
| Bettler, B | 1 |
| Hammond, DL | 1 |
| Cepeda, MS | 1 |
| Butkovic, D | 1 |
| Toljan, S | 1 |
| Mihovilovic-Novak, B | 1 |
| Marsal, C | 1 |
| Vidal, J | 1 |
| Cohen, AS | 1 |
| Gantenbein, AR | 1 |
| Goadsby, PJ | 1 |
| Rode, F | 2 |
| Broløs, T | 2 |
| Blackburn-Munro, G | 2 |
| Moulin, D | 1 |
| Xiao, W | 1 |
| Bennett, GJ | 1 |
| Luo, ZD | 1 |
| Keskinbora, K | 2 |
| Pekel, AF | 2 |
| Aydinli, I | 2 |
| Lefaucheur, JP | 1 |
| Drouot, X | 1 |
| Ménard-Lefaucheur, I | 1 |
| Keravel, Y | 1 |
| Nguyen, JP | 1 |
| Siddall, PJ | 1 |
| Cousins, MJ | 1 |
| Otte, A | 1 |
| Chambers, R | 1 |
| Sonnett, TE | 1 |
| Setter, SM | 1 |
| Campbell, RK | 1 |
| Vrachnou, E | 1 |
| Moka, E | 1 |
| Povedano, M | 1 |
| Gascón, J | 1 |
| Barsukov, IN | 1 |
| Kashin, AV | 1 |
| Kostiuk, GP | 1 |
| Bastías A, MJ | 1 |
| Toro C, L | 1 |
| Olmos C, P | 1 |
| Han, DW | 1 |
| Kweon, TD | 1 |
| Lee, JS | 1 |
| Lee, YW | 1 |
| Melrose, HL | 1 |
| Kinloch, RA | 1 |
| Cox, PJ | 1 |
| Collins, D | 1 |
| Williams, D | 1 |
| Tassone, DM | 1 |
| Boyce, E | 1 |
| Guyer, J | 1 |
| Nuzum, D | 1 |
| Thomsen, M | 1 |
| Jensen, DG | 1 |
| Beyreuther, BK | 1 |
| Callizot, N | 1 |
| Brot, MD | 1 |
| Feldman, R | 1 |
| Bain, SC | 1 |
| Stöhr, T | 1 |
| Davies, A | 1 |
| Hendrich, J | 1 |
| Van Minh, AT | 1 |
| Wratten, J | 1 |
| Terneus, W | 1 |
| Murphy, N | 1 |
| Mockler, M | 1 |
| Ryder, M | 1 |
| Ledwidge, M | 1 |
| McDonald, K | 1 |
| Lee, B | 1 |
| Kim, J | 1 |
| Kim, SJ | 1 |
| Lee, H | 1 |
| Chang, JW | 1 |
| Sommer, M | 1 |
| Bachmann, CG | 1 |
| Liebetanz, KM | 1 |
| Schindehütte, J | 1 |
| Tings, T | 1 |
| Paulus, W | 1 |
| Eisenberg, E | 1 |
| River, Y | 1 |
| Shifrin, A | 1 |
| Krivoy, N | 1 |
| Savica, R | 1 |
| Laganà, A | 1 |
| Calabrò, RS | 1 |
| Casella, C | 1 |
| Musolino, R | 1 |
| Tölle, T | 1 |
| Trostmann, U | 1 |
| Mallison, R | 1 |
| Tilke, C | 1 |
| Brasser, M | 2 |
| Pittrow, D | 1 |
| Okada, M | 1 |
| Shinjo, T | 1 |
| Davis, JL | 1 |
| Posner, LP | 1 |
| Elce, Y | 1 |
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Kavya, R | 1 |
| Vanitha, K | 1 |
| Neelakantan, H | 1 |
| Vecht, CJ | 1 |
| Gray, P | 1 |
| Yoshimura, M | 1 |
| Takazawa, T | 1 |
| Takeshima, K | 1 |
| Liu, Z | 1 |
| Liu, L | 1 |
| Xiao, Z | 1 |
| Cao, X | 1 |
| Cao, Z | 1 |
| Xue, L | 1 |
| Miao, L | 1 |
| He, X | 1 |
| Dalal, A | 1 |
| Zhou, L | 1 |
| Wang, TY | 1 |
| Chang, CC | 1 |
| Tsai, KC | 1 |
| May, M | 1 |
| Binder, A | 1 |
| Stubhaug, A | 1 |
| Arnèr, S | 1 |
| Biber, B | 1 |
| Boivie, J | 1 |
| Mannheimer, C | 1 |
| Kalliomäki, J | 1 |
| Durso-Decruz, E | 1 |
| Giannopoulos, S | 1 |
| Kosmidou, M | 1 |
| Kyritsis, AP | 1 |
| Straube, S | 1 |
| Quintero Wolfe, SC | 1 |
| Cumberbatch, N | 1 |
| Menendez, I | 1 |
| Martinez, M | 1 |
| Eaton, M | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Segal, AZ | 1 |
| Rordorf, G | 1 |
| Stiller, CO | 1 |
| O'Connor, WT | 1 |
| Brodin, E | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 1 |
| Childers, MK | 1 |
| Holland, D | 1 |
| Sorkin, LS | 1 |
| Puig, S | 1 |
| Jones, DL | 1 |
| Sánchez-Valiente, S | 1 |
| Brasseur, L | 1 |
| Parker, F | 1 |
| Chauvin, M | 1 |
| Abdi, S | 1 |
| Lee, DH | 1 |
| Rowbotham, M | 1 |
| Harden, N | 1 |
| Bernstein, P | 1 |
| Magnus-Miller, L | 1 |
| Low, PA | 1 |
| Dotson, RM | 1 |
| García Callejo, FJ | 1 |
| Marco Algarra, J | 1 |
| Talamantes Escribá, F | 1 |
| Martínez Beneyto, MP | 1 |
| Esparcia Navarro, M | 1 |
| Morant Ventura, A | 1 |
| Colman, E | 1 |
| Stadel, BV | 1 |
| Martinez, MA | 1 |
| Karmally, S | 1 |
| Marples, IL | 1 |
| Murray, P | 1 |
| Hays, H | 1 |
| Woodroffe, MA | 1 |
| Beydoun, A | 1 |
| Magnus, L | 1 |
| Clark, JD | 1 |
| Elliott, J | 1 |
| Fudin, J | 1 |
| Audette, CM | 1 |
| Harden, RN | 1 |
| Mertens, P | 1 |
| Ghaemmaghami, C | 1 |
| Bert, L | 1 |
| Perret-Liaudet, A | 1 |
| Sindou, M | 1 |
| Renaud, B | 1 |
| Laird, MA | 1 |
| Gidal, BE | 1 |
| Carver, A | 1 |
| Payne, R | 1 |
| Foley, K | 1 |
| Hughes, J | 1 |
| Singh, L | 1 |
| Takasaki, I | 1 |
| Andoh, T | 1 |
| Nitta, M | 1 |
| Takahata, H | 1 |
| Nemoto, H | 1 |
| Shiraki, K | 1 |
| Nojima, H | 1 |
| Kuraishi, Y | 1 |
| Graff-Radford, SB | 1 |
| Eckhardt, K | 1 |
| Hufschmidt, A | 1 |
| Feuerstein, TJ | 1 |
| Naeem, S | 1 |
| Froestl, W | 1 |
| Capogna, M | 1 |
| Urban, L | 1 |
| Kamp-Jensen, M | 1 |
| Werner, MU | 1 |
| Rovetta, G | 1 |
| Baratto, L | 1 |
| Farinelli, G | 1 |
| Monteforte, P | 1 |
| Corradini, L | 1 |
| Briscini, L | 1 |
| Ongini, E | 1 |
| Bertorelli, R | 1 |
| Frijns, PD | 1 |
| Poole, MR | 1 |
| Maton, S | 1 |
| Picardo, A | 1 |
| Garrido, A | 1 |
| Cuberes, R | 1 |
| Dougherty, JA | 1 |
| Rhoney, DH | 1 |
| Mellegers, MA | 1 |
| Furlan, AD | 1 |
| Mailis, A | 1 |
| Block, F | 1 |
| Chong, MS | 1 |
| Smith, TE | 1 |
| Hanna, M | 1 |
| Bowsher, D | 1 |
| Gehling, M | 1 |
| Tryba, M | 1 |
| Covington, EC | 1 |
| Ross, JR | 1 |
| Waight, C | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Pain Reduction and Changes in Upper Limb Function Produced by Physiotherapy, Ibuprofen Arginine, Gabapentin and the Absence of Treatment, in Carpal Tunnel Syndrome[NCT04025203] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen Versus the Lack of Treatment, in Carpal Tunnel Syndrome.[NCT04328805] | Phase 4 | 45 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Oral Gabapentin Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04285281] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04329247] | 40 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | |||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011] | 3 participants (Actual) | Observational | 2020-01-10 | Terminated (stopped due to PI request - low enrollment) | |||
| A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679] | Phase 4 | 167 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156] | Phase 3 | 450 participants | Interventional | 2005-03-31 | Completed | ||
| A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078] | Phase 4 | 450 participants | Interventional | 2005-01-31 | Completed | ||
| Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475] | Phase 3 | 314 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| EEG Mapping During High Frequency/High Density Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome[NCT02751216] | 20 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study[NCT02650362] | 10 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study[NCT02650349] | 11 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain[NCT00385671] | Phase 4 | 407 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial[NCT03422861] | 80 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo[NCT00159666] | Phase 4 | 255 participants | Interventional | 2004-10-31 | Completed | ||
| An 8-Week Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150mg-600mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain[NCT00301223] | Phase 3 | 309 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury[NCT00407745] | Phase 3 | 220 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy[NCT01466101] | 0 participants (Actual) | Interventional | 2011-01-31 | Withdrawn (stopped due to PI left the institution. No subjects screened or enrolled.) | |||
| Preoperative Use of Pregabalin and Analgesia Levels After Laparoscopic Cholecystectomy[NCT01321801] | 50 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain[NCT03210766] | 20 participants (Actual) | Observational | 2014-09-01 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)[NCT05142228] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion[NCT03035656] | Phase 4 | 228 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)[NCT04246619] | Phase 4 | 254 participants (Actual) | Interventional | 2019-11-12 | Terminated (stopped due to The statistical analysis will still provide relevant results with the same statistical power as initially planned.COVID-19 pandemic prolonged the recruiting period and consequently affected the costs of the clinical trial.) | ||
| A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropath[NCT00407511] | Phase 4 | 121 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug[NCT00570310] | Phase 1 | 104 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia[NCT02024568] | Phase 2 | 38 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain[NCT00292188] | Phase 4 | 255 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Topical Compounded Pain Creams And Pain Perception (TOPCAPP)[NCT01862848] | 285 participants (Actual) | Observational [Patient Registry] | 2012-11-30 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294] | 52 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Randomized Controlled Trial Comparing Two Different Bladder Instillation Treatments for Interstitial Cystitis/Bladder Pain Syndrome[NCT03463915] | Phase 3 | 90 participants (Actual) | Interventional | 2019-01-25 | Completed | ||
| Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)[NCT00643760] | Phase 2 | 421 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury[NCT02736890] | Phase 2 | 8 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to funding not available to continue) | ||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Improving the Quality of Life of People With Multiple Sclerosis and Their Caregivers With a Telemedicine Mindfulness-Based Intervention[NCT02364505] | 156 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Internet-based Cognitive Behavioural Therapy (MoodUP) in Improving Psychological Outcomes Among Perinatal Women: A Prospective Randomised Double-blind Parallel-group Trial[NCT03970057] | 364 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Pregabalin vs. Placebo as an Add on for Complex Regional Pain Syndrome of the Upper Limb Managed by Stellate Ganglion Block[NCT00891397] | 14 participants (Actual) | Interventional | 2007-11-30 | Terminated (stopped due to Unable to recruit patients) | |||
| Pharmacokinetic Non-interaction Study Between Pregabalin 150 mg and Tramadol 50 mg, Administered Individually or in Combination, Single Dose in Healthy Subjects of Both Genders Under Fasting Conditions[NCT05389150] | Phase 1 | 30 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair[NCT02292095] | Phase 4 | 260 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Comparison of the Analgesic Effect Between the Motor Cortex Stimulation (tDCS and rTMS) and the Trans-spinal Stimulation (tsDCS ) in the Algoneurodystrophy of Members. A Randomised Clinical Trial. tDCS : Transcranial Direct-current Stimulation rTMS : Repe[NCT02817880] | 36 participants (Actual) | Interventional | 2016-07-25 | Completed | |||
| Primary Motor Cortex Plasticity and the Bottom up Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST)in Osteoarthritis Chronic Pain[NCT01855958] | 26 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Effect of Transcranial Direct Current Stimulation and Electro Acupuncture in Pain, Functional Capability and Cortical Excitability in Patients With Osteoarthritis.[NCT01747070] | 60 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| A Phase II, Placebo-controlled, Double-blind, Randomized Crossover Trial of Pregabalin for the Prophylaxis of Pegfilgrastim-induced Bone Pain[NCT03407430] | Phase 2 | 11 participants (Actual) | Interventional | 2016-01-27 | Terminated (stopped due to Low patient accrual) | ||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331] | Phase 4 | 80 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Identification of Differentially Expressed Genes in RNAseq Data of Patients With Failed Back Surgery Syndrome Treated With Different Modalities of Spinal Cord Stimulation: Looking for Biomarkers of Response and Effectiveness[NCT05712980] | 40 participants (Anticipated) | Observational | 2023-02-28 | Not yet recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled, Three-Arm Trial Examining Sublingual Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee.[NCT04992962] | Phase 2 | 66 participants (Anticipated) | Interventional | 2021-07-29 | Recruiting | ||
| An Open-label, Single-centre, Parallel-group Clinical Investigation, to Evaluate the Effectiveness and In-use Tolerability of a Range of Four Orthotic Insoles on Target Areas of Pain in the Lower Body, Associated With Musculoskeletal Stress, Experienced b[NCT04746755] | 145 participants (Actual) | Interventional | 2019-06-21 | Terminated (stopped due to Participants experienced data collection issues when using the eDiary, these issues increased the burden and lowered compliance. Updates to the eDiary were unsuccessful at resolving the issues so the decision was taken to terminate the Investigation.) | |||
| Effects of a Self-management Program for Temporomandibular Myalgia in Subjects With Fibromyalgia: a Single Arm Study[NCT05426655] | 40 participants (Anticipated) | Interventional | 2022-06-16 | Recruiting | |||
| Side Effects of Two Different Mandibular Advancement Devices (MAD) in the Treatment of Snoring and Obstructive Sleep Apnea Syndrome (OSAS)[NCT04050514] | 65 participants (Actual) | Interventional | 2019-12-01 | Completed | |||
| The Effect of Repetitive Transcranial Magnetic Stimulation on Diabetic Peripheral Neuropathic Pain: A Randomized Controlled Trial[NCT04833660] | 22 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | |||
| The Effectiveness of Radial Shockwave Therapy on Myofascial Pain Syndrome: A Mixed Method Study That Combines a Randomised Control Trial and Semi-Structured Interview.[NCT05381987] | 120 participants (Anticipated) | Interventional | 2022-04-21 | Recruiting | |||
| Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study[NCT04051203] | Phase 1 | 35 participants (Anticipated) | Interventional | 2019-02-01 | Active, not recruiting | ||
| Assessment and Treatment Responses to Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial[NCT02884531] | 101 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Effect of Muscle Energy Technique on Craniovertebral and Shoulder Angles in Forward Head Posture[NCT05642130] | 60 participants (Anticipated) | Interventional | 2022-09-22 | Active, not recruiting | |||
| Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA®[NCT03720119] | 78 participants (Actual) | Observational | 2015-01-27 | Completed | |||
| The Use of Virtual Reality for Lumbar Pain Management in an Outpatient Spine Clinic: An Exploratory Comparative Randomized Trial[NCT03819907] | 45 participants (Actual) | Interventional | 2019-04-08 | Completed | |||
| A Double Blind, Randomized Crossover Study of Efficacy and Safety of Topical Menthol, With and Without Mannitol, in the Treatment of Painful Diabetic Peripheral Neuropathy[NCT02728687] | Phase 1/Phase 2 | 72 participants (Actual) | Interventional | 2017-03-15 | Completed | ||
| Randomized Controlled Trial of Fractional CO2 Laser vs Sham Laser for Women With Provoked Vestibulodynia Who Have Failed Conservative Management[NCT03390049] | 0 participants (Actual) | Interventional | 2018-08-31 | Withdrawn (stopped due to No funding) | |||
| Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome: a Multicentric Randomized Controlled Trial[NCT04043780] | 60 participants (Actual) | Interventional | 2019-09-24 | Completed | |||
| Addressing Opioid Use Disorder With an External Multimodal Neuromodulation Device: Clinical Evaluation of DuoTherm for Opioid-Sparing in Chronic Low Back Pain[NCT04494698] | 100 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Addressing Opioid Use Disorder With an External Multimodal Neuromodulation Device: Clinical Evaluation of DuoTherm for Opioid-Sparing in Acute Low Back Pain[NCT04491175] | 60 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Effects of Tele-prehabilitation on Clinical and Muscular Recover in Patients Waiting for Knee Replacement: a Randomized Controlled Trial[NCT05668312] | 58 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation for the Treatment of Sub-acute and Chronic Low Back Pain in a Military Population: A Randomized Crossover Design[NCT03539588] | 30 participants (Actual) | Interventional | 2017-04-12 | Completed | |||
| A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multiple-Dose, Active and Placebo-Controlled Efficacy Study of Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars[NCT03785756] | Phase 3 | 280 participants (Anticipated) | Interventional | 2019-04-29 | Recruiting | ||
| Perioperative Visual Therapy May Help Prevent Phantom Limb Pain[NCT02383979] | Phase 4 | 115 participants (Anticipated) | Interventional | 2010-08-31 | Recruiting | ||
| Acupuncture for Female Interstitial Cystitis/Painful Bladder Syndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial[NCT02232282] | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?[NCT02313480] | 39 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Retrospective Longitudinal Cohort Study to Determine the Effectiveness of Integrated a Clinical Pathway Approach for Chronic Pain Treatment With Acupuncture in a Pain Clinic[NCT04490798] | 3,245 participants (Actual) | Observational | 2020-06-12 | Completed | |||
| A Randomised, Double-blind, Double-dummy, Parallel-group, Single Dose, Active and Placebo-controlled Efficacy and Pharmacokinetics/Pharmacodynamics Study of 2 x 200 mg Ibuprofen Liquid Capsules for the Treatment of Pain After Surgical Removal of Impacted [NCT05484401] | Phase 3 | 294 participants (Actual) | Interventional | 2022-08-09 | Completed | ||
| Evaluation of Pain Before and After Removal of Non-obstructive Kidney Stones[NCT03657667] | 43 participants (Actual) | Interventional | 2018-08-28 | Completed | |||
| Efficacy of an Internet-based Intervention for Dental Anxiety[NCT03680755] | Phase 2 | 450 participants (Anticipated) | Interventional | 2019-07-24 | Active, not recruiting | ||
| Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain - a Single-blinded Randomized Controlled Trial[NCT04786145] | 120 participants (Anticipated) | Interventional | 2020-02-15 | Active, not recruiting | |||
| Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial[NCT02356406] | Phase 2 | 52 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Effect of Scapula-focused Treatment With Additional Motor Control Exercises on Pain and Disability in Patients With Subacromial Pain Syndrome: A Randomized Controlled Trial[NCT02695524] | 60 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Randomized, Double-blind, Placebo Controlled, Superiority Phase II Study to Evaluate the Safety, Pharmacokinetic, Efficacy of Gabapentin as add-on to Morphine in Children From 3 Months to Less Than 18 Years[NCT03275012] | Phase 2 | 0 participants (Actual) | Interventional | 2017-04-04 | Withdrawn (stopped due to Study not started) | ||
| Randomized, Double-blind, Double-dummy, Active Controlled, Multicentre, Non-inferiority Phase-III Study to Compare Gabapentin Liquid Formulation to Tramadol in Children Experiencing Moderate to Severe Chronic Neuropathic or Mixed Pain[NCT02722603] | Phase 3 | 2 participants (Actual) | Interventional | 2018-09-12 | Terminated (stopped due to The study was early terminated due to insufficient recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.39 |
| Pregabalin 300 mg/Day | -0.82 |
| Pregabalin 600 mg/Day | -1.14 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.23 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.10 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.32 |
| Pregabalin 300 mg/Day | -1.95 |
| Pregabalin 600 mg/Day | -2.09 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.36 |
| Pregabalin 300 mg/Day | -2.01 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.38 |
| Pregabalin 300 mg/Day | -2.04 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.57 |
| Pregabalin 300 mg/Day | -1.17 |
| Pregabalin 600 mg/Day | -1.80 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.80 |
| Pregabalin 300 mg/Day | -1.40 |
| Pregabalin 600 mg/Day | -1.93 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.89 |
| Pregabalin 300 mg/Day | -1.53 |
| Pregabalin 600 mg/Day | -2.00 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.91 |
| Pregabalin 300 mg/Day | -1.57 |
| Pregabalin 600 mg/Day | -2.07 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg/Day | -1.72 |
| Pregabalin 600 mg/Day | -2.06 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.04 |
| Pregabalin 300 mg/Day | -1.76 |
| Pregabalin 600 mg/Day | -2.13 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.18 |
| Pregabalin 300 mg/Day | -1.85 |
| Pregabalin 600 mg/Day | -2.12 |
"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.93 |
| Pregabalin 600 mg/Day | -2.06 |
The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.74 |
| Pregabalin 300 mg/Day | -1.59 |
| Pregabalin 600 mg/Day | -1.36 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -7.91 |
| Pregabalin 300 mg/Day | -11.45 |
| Pregabalin 600 mg/Day | -9.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 0.37 |
| Pregabalin 300 mg/Day | 0.69 |
| Pregabalin 600 mg/Day | 0.54 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 12.08 |
| Pregabalin 300 mg/Day | 17.69 |
| Pregabalin 600 mg/Day | 21.73 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -9.03 |
| Pregabalin 300 mg/Day | -15.40 |
| Pregabalin 600 mg/Day | -12.81 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.63 |
| Pregabalin 300 mg/Day | -3.02 |
| Pregabalin 600 mg/Day | -4.47 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -6.00 |
| Pregabalin 300 mg/Day | -5.96 |
| Pregabalin 600 mg/Day | -1.56 |
The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.96 |
| Pregabalin 300 mg/Day | 0.83 |
| Pregabalin 600 mg/Day | 4.83 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 10.34 |
| Pregabalin 300 mg/Day | 11.84 |
| Pregabalin 600 mg/Day | 12.89 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| Pregabalin 300 mg/Day | 3.29 |
| Pregabalin 600 mg/Day | 4.40 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.84 |
| Pregabalin 300 mg/Day | 5.33 |
| Pregabalin 600 mg/Day | 7.81 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 2.70 |
| Pregabalin 300 mg/Day | 2.43 |
| Pregabalin 600 mg/Day | 3.86 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.13 |
| Pregabalin 300 mg/Day | 5.05 |
| Pregabalin 600 mg/Day | 6.35 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 4.38 |
| Pregabalin 300 mg/Day | 2.28 |
| Pregabalin 600 mg/Day | 3.97 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 3.00 |
| Pregabalin 300 mg/Day | 8.06 |
| Pregabalin 600 mg/Day | 11.16 |
The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | 5.28 |
| Pregabalin 300 mg/Day | 4.20 |
| Pregabalin 600 mg/Day | 12.87 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.83 |
| Pregabalin 300 mg/Day | -1.43 |
| Pregabalin 600 mg/Day | -1.39 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -0.59 |
| Pregabalin 300 mg/Day | -0.80 |
| Pregabalin 600 mg/Day | -0.96 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -2.82 |
| Pregabalin 300 mg/Day | -4.60 |
| Pregabalin 600 mg/Day | -4.95 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -3.68 |
| Pregabalin 300 mg/Day | -6.03 |
| Pregabalin 600 mg/Day | -6.36 |
The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -16.92 |
| Pregabalin 300 mg/Day | -24.19 |
| Pregabalin 600 mg/Day | -24.41 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.20 |
| Pregabalin 300 mg/Day | -1.82 |
| Pregabalin 600 mg/Day | -1.94 |
Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Placebo | -1.27 |
| Expected Exposure Pregabalin 300 mg/Day | -1.93 |
| Expected Exposure Pregabalin 600 mg/Day | -1.90 |
Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.3 |
| Pregabalin 300 mg/Day | 2.9 |
| Pregabalin 600 mg/Day | 2.7 |
A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)
| Intervention | participants (Number) |
|---|---|
| Placebo | 29 |
| Pregabalin 300 mg/Day | 39 |
| Pregabalin 600 mg/Day | 16 |
The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation
| Intervention | score on scale (Mean) |
|---|---|
| Placebo | 3.4 |
| Pregabalin 300 mg/Day | 3.2 |
| Pregabalin 600 mg/Day | 2.8 |
A 21-item, patient-completed questionnaire to assess characteristics of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score. There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.57 |
| Duloxetine | -3.13 |
| Gabapentin + Duloxetine | -2.54 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | kilogram (Least Squares Mean) |
|---|---|
| Pregabalin | 1.00 |
| Duloxetine | -2.39 |
| Gabapentin + Duloxetine | -1.06 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Pregabalin | -1.30 |
| Duloxetine | 0.80 |
| Gabapentin + Duloxetine | 1.05 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Gabapentin + Duloxetine | -2.39 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.12 |
| Duloxetine | -2.62 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily nighttime pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.30 |
| Duloxetine | -2.71 |
| Gabapentin + Duloxetine | -2.49 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the daily worst pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | -2.59 |
| Duloxetine | -3.08 |
| Gabapentin + Duloxetine | -2.86 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 65 |
| Duloxetine | 68 |
| Gabapentin + Duloxetine | 72 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 59 |
| Duloxetine | 64 |
| Gabapentin + Duloxetine | 68 |
Elevated heart rate: >=100 beats per minute (bpm) + an increase of >=10 bpm if baseline <100 bpm. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 2 |
| Duloxetine | 9 |
| Gabapentin + Duloxetine | 6 |
This is a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved at endpoint. It is based on a comparison between baseline and endpoint scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Duloxetine | 50 |
| Gabapentin + Duloxetine | 47 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). (NCT00385671)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pregabalin | 3.03 |
| Duloxetine | 3.01 |
| Gabapentin + Duloxetine | 2.83 |
Number of participants who discontinued. The reasons for discontinuation are presented in the participant flow. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 38 |
| Duloxetine | 51 |
| Gabapentin + Duloxetine | 36 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 56.0 |
| Duloxetine | 35.0 |
| Gabapentin + Duloxetine | 28.0 |
This is the number of days required to first achieve a nominal outcome reflecting whether or not a clinically-important efficacy outcome was achieved. It is based on a comparison between baseline and post-baseline scores on an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Used were the weekly mean of the scores of the average pain severity over the last 24 hours. The weekly averages were based on daily assessments recorded by patients in their diaries. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | days (Median) |
|---|---|
| Pregabalin | 35.0 |
| Duloxetine | 28.0 |
| Gabapentin + Duloxetine | 28.0 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. Categories: better=negative change in score; same=no change in score; worse=positive change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| better, total; n=122, n=126, n=128 | same, total; n=122, n=126, n=128 | worse, total; n=122, n=126, n=128 | better, cognitive toxicity; n=126, n=129, n=128 | same, cognitive toxicity; n=126, n=129, n=128 | worse, cognitive toxicity; n=126, n=129, n=128 | better, somatomotor toxicity; n=122, n=126, n=129 | same, somatomotor toxicity; n=122, n=126, n=129 | worse, somatomotor toxicity; n=122, n=126, n=129 | |
| Duloxetine | 84 | 5 | 37 | 80 | 6 | 43 | 74 | 19 | 33 |
| Gabapentin + Duloxetine | 86 | 4 | 38 | 82 | 5 | 41 | 74 | 19 | 36 |
| Pregabalin | 68 | 8 | 46 | 75 | 9 | 42 | 60 | 15 | 47 |
The Resource Utilization Scale measures direct and indirect costs (collected only for US sites). Direct costs include inpatient and outpatient costs, while indirect costs include lost days of work and caregiver time spent with patients. Inpatient costs include costs associated with hospitalizations and time spent in emergency rooms and psychiatric rooms. Outpatient costs include costs associated with visits to various health care providers, home health care by health care providers, and partial care. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hours worked, greater, n=86, n=90, n=83 | hours worked, same, n=86, n=90, n=83 | hours worked, lower, n=86, n=90, n=83 | hours volunteered, greater, n=86, n=91, n=82 | hours volunteered, same, n=86, n=91, n=82 | hours volunteered, lower, n=86, n=91, n=82 | psychiatric visits, greater, n=92, n=93, n=90 | psychiatric visits, same, n=92, n=93, n=90 | psychiatric visits, lower, n=92, n=93, n=90 | outpatient group visits, greater, n=91, n=92, n=91 | outpatient group visits, same, n=91, n=92, n=91 | outpatient group visits, lower, n=91, n=92, n=91 | outpatient ind. visits, greater, n=91, n=88, n=90 | outpatient ind. visits, same, n=91, n=88, n=90 | outpatient ind. visits, lower, n=91, n=88, n=90 | days of partial care, greater, n=93, n=95, n=90 | days of partial care, same, n=93, n=95, n=90 | days of partial care, lower, n=93, n=95, n=90 | nights of partial care, greater, n=92, n=95, n=91 | nights of partial care, same, n=92, n=95, n=91 | nights of partial care, lower, n=92, n=95, n=91 | ER visits-psychiatric, greater, n=93, n=94, n=91 | ER visits-psychiatric, same, n=93, n=94, n=91 | ER visits-psychiatric, lower, n=93, n=94, n=91 | ER visits-nonpsychiatric, greater,n=91, n=95, n=88 | ER visits-nonpsychiatric, same,n=91, n=95, n=88 | ER visits-nonpsychiatric, lower,n=91, n=95, n=88 | phone mental health, greater,n=94, n=95, n=90 | phone mental health, same,n=94, n=95, n=90 | phone mental health, lower,n=94, n=95, n=90 | nonpsychiatric visits, greater, n=89, n=94, n=83 | nonpsychiatric visits, same, n=89, n=94, n=83 | nonpsychiatric visits, lower, n=89, n=94, n=83 | unpaid care, greater, n=84, n=87, n=86 | unpaid care, same, n=84, n=87, n=86 | unpaid care, lower, n=84, n=87, n=86 | missed work caregiver, greater, n=6, n=9, n=5 | missed work caregiver, same, n=6, n=9, n=5 | missed work caregiver, lower, n=6, n=9, n=5 | paid care, greater, n=60, n=58, n=58 | paid care, same, n=60, n=58, n=58 | paid care, less, n=60, n=58, n=58 | |
| Duloxetine | 12 | 66 | 12 | 8 | 77 | 6 | 0 | 91 | 2 | 0 | 92 | 0 | 1 | 84 | 3 | 1 | 94 | 0 | 1 | 94 | 0 | 0 | 94 | 0 | 4 | 85 | 6 | 1 | 93 | 1 | 20 | 46 | 28 | 0 | 87 | 0 | 0 | 8 | 1 | 0 | 58 | 0 |
| Gabapentin + Duloxetine | 13 | 59 | 11 | 10 | 66 | 6 | 2 | 84 | 4 | 1 | 89 | 1 | 4 | 81 | 5 | 2 | 87 | 1 | 2 | 89 | 0 | 0 | 91 | 0 | 4 | 78 | 6 | 2 | 87 | 1 | 18 | 45 | 20 | 0 | 85 | 1 | 0 | 5 | 0 | 0 | 58 | 0 |
| Pregabalin | 10 | 65 | 11 | 7 | 66 | 13 | 2 | 88 | 2 | 0 | 90 | 1 | 3 | 84 | 4 | 2 | 91 | 0 | 1 | 91 | 0 | 0 | 91 | 2 | 3 | 83 | 5 | 1 | 92 | 1 | 24 | 44 | 21 | 2 | 82 | 0 | 0 | 6 | 0 | 0 | 60 | 0 |
14-item subject-rated scale assessing changes in sexual activity and functioning; structured interview/questionnaire, designed to measure medication related changes in sexual functioning. 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Total score: obtained across all 5 dimensions, ranges from 14 to 70. Subscale scores: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Categories: better=positive change in score; same=no change in score; worse=negative change in score. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total, better; n=62, n=67, n=66 | male, total, same; n=62, n=67, n=66 | male, total, worse; n=62, n=67, n=66 | female, total, better; n=39, n=42, n=43 | female, total, same; n=39, n=42, n=43 | female, total, worse; n=39, n=42, n=43 | male, pleasure, better; n=64, n=67, n=69 | male, pleasure, same; n=64, n=67, n=69 | male, pleasure, worse; n=64, n=67, n=69 | female, pleasure, better; n=40, n=42, n=43 | female, pleasure, same; n=40, n=42, n=43 | female, pleasure, worse; n=40, n=42, n=43 | male, desire/frequency, better; n=65, n=67, n=69 | male, desire/frequency, same; n=65, n=67, n=69 | male, desire/frequency, worse; n=65, n=67, n=69 | female, desire/frequency, better; n=42, n=42, n=43 | female, desire/frequency, same; n=42, n=42, n=43 | female, desire/frequency, worse; n=42, n=42, n=43 | male, desire/interest, better; n=65, n=67, n=70 | male, desire/interest, same; n=65, n=67, n=70 | male, desire/interest, worse; n=65, n=67, n=70 | female, desire/interest, better; n=42, n=42, n=45 | female, desire/interest, same; n=42, n=42, n=45 | female, desire/interest, worse; n=42, n=42, n=45 | male, arousal, better; n=65, n=67, n=70 | male, arousal, same; n=65, n=67, n=70 | male, arousal, worse; n=65, n=67, n=70 | female, arousal, better; n=40, n=42, n=45 | female, arousal, same; n=40, n=42, n=45 | female, arousal, worse; n=40, n=42, n=45 | male, orgasm, better; n=64, n=67, n=69 | male, orgasm, same; n=64, n=67, n=69 | male, orgasm, worse; n=64, n=67, n=69 | female, orgasm, better; n=40, n=42, n=43 | female, orgasm, same; n=40, n=42, n=43 | female, orgasm, worse; n=40, n=42, n=43 | |
| Duloxetine | 26 | 9 | 32 | 23 | 5 | 14 | 11 | 40 | 16 | 16 | 21 | 5 | 20 | 29 | 18 | 12 | 21 | 9 | 18 | 19 | 30 | 18 | 14 | 10 | 24 | 29 | 14 | 18 | 10 | 14 | 18 | 31 | 18 | 17 | 13 | 12 |
| Gabapentin + Duloxetine | 31 | 11 | 24 | 18 | 7 | 18 | 21 | 32 | 16 | 6 | 32 | 5 | 24 | 23 | 22 | 12 | 24 | 7 | 26 | 17 | 27 | 16 | 17 | 12 | 23 | 33 | 14 | 15 | 16 | 14 | 17 | 29 | 23 | 11 | 16 | 16 |
| Pregabalin | 24 | 9 | 29 | 13 | 5 | 21 | 13 | 39 | 12 | 10 | 23 | 7 | 12 | 36 | 17 | 11 | 21 | 10 | 20 | 19 | 26 | 13 | 12 | 17 | 20 | 28 | 17 | 11 | 14 | 15 | 12 | 29 | 23 | 15 | 13 | 12 |
Presented are numbers of participants who discontinued due to a change from baseline in laboratory analytes or vital signs. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Increased blood creatinine | Increased blood glucose | |
| Duloxetine | 0 | 0 |
| Gabapentin + Duloxetine | 1 | 0 |
| Pregabalin | 0 | 1 |
Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | millimeter mercury (Least Squares Mean) | |
|---|---|---|
| Diastolic | Systolic | |
| Duloxetine | 2.24 | -3.08 |
| Gabapentin + Duloxetine | -0.79 | -2.08 |
| Pregabalin | 0.18 | -3.31 |
A self-reported scale that measures the interference of pain in the past 24 hours on enjoyment of life. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.63 | -2.09 |
| Gabapentin + Duloxetine | 5.02 | -2.33 |
| Pregabalin | 4.38 | -1.82 |
A self-reported scale that measures the interference of pain in the past 24 hours on mood. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.08 | -1.85 |
| Gabapentin + Duloxetine | 4.10 | -1.43 |
| Pregabalin | 3.42 | -1.46 |
A self-reported scale that measures the interference of pain in the past 24 hours on normal work. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.98 | -1.86 |
| Gabapentin + Duloxetine | 5.15 | -1.88 |
| Pregabalin | 4.61 | -1.63 |
A self-reported scale that measures the interference of pain in the past 24 hours on relations with other people. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 3.08 | -1.27 |
| Gabapentin + Duloxetine | 3.29 | -1.17 |
| Pregabalin | 2.96 | -0.97 |
A self-reported scale that measures the interference of pain in the past 24 hours on sleep. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.97 | -2.12 |
| Gabapentin + Duloxetine | 5.40 | -2.50 |
| Pregabalin | 4.91 | -2.29 |
A self-reported scale that measures the interference of pain in the past 24 hours on walking ability. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.52 | -2.56 |
| Gabapentin + Duloxetine | 5.79 | -2.09 |
| Pregabalin | 5.25 | -1.88 |
A self-reported scale that measures the interference of pain in the past 24 hours on general activity. The Interference scores range from 0 (does not interfere) to 10 (completely interferes). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.38 |
| Gabapentin + Duloxetine | 5.03 | -1.86 |
| Pregabalin | 4.24 | -1.51 |
The Interference scores range from 0 (does not interfere) to 10 (completely interferes). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.61 | -2.00 |
| Gabapentin + Duloxetine | 4.83 | -1.90 |
| Pregabalin | 4.25 | -1.62 |
A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.65 | -2.44 |
| Gabapentin + Duloxetine | 5.75 | -2.29 |
| Pregabalin | 5.53 | -1.80 |
A self-reported scale that measures the severity of pain based on the least pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.18 | -1.55 |
| Gabapentin + Duloxetine | 4.07 | -1.54 |
| Pregabalin | 4.23 | -1.27 |
A self-reported scale that measures the severity of pain based on the pain right now. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 5.03 | -2.24 |
| Gabapentin + Duloxetine | 5.36 | -2.19 |
| Pregabalin | 4.98 | -1.77 |
A self-reported scale that measures the severity of pain based on the worst pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 Weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.87 | -3.02 |
| Gabapentin + Duloxetine | 7.00 | -2.64 |
| Pregabalin | 6.73 | -2.34 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 4.47 | -1.16 |
| Gabapentin + Duloxetine | 4.40 | -1.13 |
| Pregabalin | 4.27 | -1.06 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | millimole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.45 | 0.19 |
| Gabapentin + Duloxetine | 7.99 | 0.67 |
| Pregabalin | 8.24 | 0.16 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | percent (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 7.51 | -0.01 |
| Gabapentin + Duloxetine | 7.16 | 0.07 |
| Pregabalin | 7.57 | -0.12 |
Aspartate aminotransferase = AST Alanine aminotransferase = ALT Gamma glutamyl transferase = GGT Alkaline phosphatase = AlkPhos (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units/liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| baseline, AST, n=119, n=121, n=118 | change, AST, n=119, n=121, n=118 | baseline, ALT, n=120, n=122, n=120 | change, ALT, n=120, n=122, n=120 | baseline, GGT, n=121, n=123, n=120 | change, GGT, n=121, n=123, n=120 | baseline, AlkPhos, n=121, n=123, n=120 | change, AlkPhos, n=121, n=123, n=120 | |
| Duloxetine | 22.84 | -0.52 | 25.04 | -0.16 | 34.29 | -3.03 | 83.74 | 0.55 |
| Gabapentin + Duloxetine | 23.42 | -0.48 | 24.39 | 0.03 | 43.93 | -2.55 | 82.18 | 1.78 |
| Pregabalin | 22.55 | 1.12 | 23.88 | -0.13 | 40.80 | 1.17 | 84.97 | 2.80 |
The LSEQ assesses the effects of psychoactive compounds on sleep and early morning behavior. Participants mark a series of 100 mm line analogue scales, indicating the direction and magnitude of any changes in behavioral state they experience following administration of the drug. Scores are represented in millimeters, higher scores indicate better sleep and better early morning behavior. Subscale score ranges: GTS=0-300, QOS=0-200, AFS=0-200, BFW=0-300. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| GTS, n=122, n=119, n=118 | QOS, n=121, n=118, n=118 | AFS, n=122, n=118, n=118 | BFW, n=124, n=115, n=118 | |
| Duloxetine | 17.40 | 7.39 | 8.14 | 21.04 |
| Gabapentin + Duloxetine | 14.75 | 9.64 | 11.86 | 14.33 |
| Pregabalin | 10.96 | 9.32 | 10.02 | 19.67 |
The Portland Neurotoxicity Scale is a 15-item, patient-completed questionnaire designed to assess the degree of impact of anti-epileptic drug therapy on a number of cognitive and somatomotor parameters. The total score ranges from 15-135 with higher scores indicating more toxicity. The cognitive toxicity score ranges from 10-90 and the somatomotor toxicity score ranges from 5-45, for both higher scores indicate more toxicity. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| total, n=122, n=126, n=128 | cognitive toxicity, n=126, n=129, n=128 | somatomotor toxicity, n=122, n=126, n=129 | |
| Duloxetine | -8.92 | -6.23 | -2.58 |
| Gabapentin + Duloxetine | -7.29 | -5.29 | -1.91 |
| Pregabalin | -6.27 | -5.12 | -1.36 |
14-item subject-rated scale assessing medication related changes in sexual activity + functioning. Structured interview/questionnaire. It measures five dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; and orgasm. The total score is obtained across all 5 dimensions, ranging from 14 to 70. Subscale score ranges: desire/frequency=2-10; desire/interest=3-15; pleasure=1-5; arousal=3-15; orgasm=3-15. Higher scores = better sexual functioning. Least-squares means: adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| male, total; n=62, n=67, n=66 | female, total; n=39; n=42, n=43 | male, pleasure; n=64, n=67, n=69 | female, pleasure; n=40, n=42, n=43 | male, desire/frequency; n=65, n=67, n=69 | female, desire/frequency; n=42, n=42, n=43 | male, desire/interest; n=65, n=67, n=70 | female, desire/interest; n=42, n=42, n=45 | male, arousal; n=65, n=67, n=70 | female, arousal; n=40, n=42, n=45 | male, orgasm; n=64, n=67, n=69 | female, orgasm; n=40, n=42, n=43 | |
| Duloxetine | 0.48 | 1.12 | -0.06 | 0.47 | 0.06 | 0.26 | -0.19 | 0.34 | 0.52 | 0.07 | 0.18 | -0.05 |
| Gabapentin + Duloxetine | 1.29 | -0.61 | 0.13 | -0.09 | 0.16 | 0.30 | 0.05 | 0.01 | 0.52 | -0.30 | 0.17 | -0.85 |
| Pregabalin | -0.53 | -0.01 | 0.08 | 0.15 | -0.02 | 0.21 | -0.27 | -0.17 | 0.17 | -0.11 | -0.39 | 0.31 |
The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30, higher values indicate greater disruption in the patient's life. Item 1 assesses the effect of the patient's symptoms on their work/school schedule, Item 2 on their social life/leisure activities, and Item 3 on their family life/home responsibilities. Subscales scores range: 0-10, higher values indicate greater disruption in the patient's life. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| Total | Item 1 | Item 2 | Item 3 | |
| Duloxetine | -3.47 | -1.21 | -1.12 | -1.17 |
| Gabapentin + Duloxetine | -4.54 | -1.95 | -1.53 | -1.54 |
| Pregabalin | -4.96 | -1.96 | -1.64 | -1.70 |
(NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | micromole/liter (Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 8.07 | -0.28 |
| Gabapentin + Duloxetine | 8.23 | -0.42 |
| Pregabalin | 8.43 | -0.51 |
"Treatment-emergent high body weight: weight at last visit >=107% of baseline weight.~Treatment-emergent low body weight: weight at last visit <=93% of baseline weight." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| high | low | |
| Duloxetine | 1 | 10 |
| Gabapentin + Duloxetine | 3 | 8 |
| Pregabalin | 6 | 2 |
"Elevated systolic blood pressure: >=130 millimeter mercury (mm Hg) + an increase of >=10 mm Hg if baseline <130 mm Hg.~Elevated diastolic blood pressure: >=85 mm Hg + an increase of >=10 mm Hg if baseline <85 mm Hg." (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| diastolic, n=94, n=98, n=100 | systolic, n=42, n=39, n=56 | |
| Duloxetine | 12 | 15 |
| Gabapentin + Duloxetine | 13 | 16 |
| Pregabalin | 11 | 20 |
Treatment-emergent: within range at baseline, out of range after baseline. Ranges in Units/Liter (U/L). Aspartate Aminotransferase (AST): female (f): >34, male (m): >36. Alanine Aminotransferase (ALT): f:<69 years (yr) >34, ≥69yr >32; m: <69yr >43, ≥69yr >35. Total Bilirubin (TBili): >21. Gamma Glutamyl Transferase (GGT): f: <59yr >49, ≥59yr >50; m: <59yr >61, ≥59yr >50. Fasting Plasma Glucose (FPG): <59yr >6.4, ≥59yr >6.7. Hemoglobin A1C (HbA1C) >6%. Alkaline Phosphatase (AlkPhos): f: 18-50yr >106, 50-70yr >123, 70-80yr >164, ≥80yr >221; m: 18-50yr >129, 50-70yr >131, 70-80yr >156, ≥80yr >187 (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| AST, n=113, n=116, n=109 | ALT, n=111, n=104, n=110 | TBili, n=119, n=121, n=116 | GGT, n=102, n=105, n=96 | FPG, n=33, n=30, n=36 | HbA1C, n=17, n=18, n=29 | AlkPhos, n=112, n=114, n=113 | |
| Duloxetine | 6 | 6 | 0 | 6 | 11 | 2 | 3 |
| Gabapentin + Duloxetine | 4 | 10 | 0 | 6 | 18 | 10 | 4 |
| Pregabalin | 4 | 3 | 2 | 2 | 7 | 6 | 4 |
Contribution to reduction in pain directly by treatment and indirectly by treatment through the reduction of depressive symptoms using path analysis. The direct treatment effect estimates the mean drug difference in pain reduction directly through treatment; the indirect treatment effect estimates the contribution that treatment plays to the mean drug difference in pain reduction indirectly through the reduction in mood symptoms; the total effect estimates the drug difference in reducing pain in sum through the specified path of direct and indirect treatment effects. (NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | coefficient (Number) | ||
|---|---|---|---|
| Direct Treatment Effect | Indirect Treatment Effect | Total Treatment Effect | |
| Ordinary Coefficient | -0.449 | 0.014 | -0.435 |
(NCT00385671)
Timeframe: baseline through 12 weeks
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea | Peripheral Oedema | Insomnia | Somnolence | Anxiety | Dizziness | Dysuria | Headache | Hyperhidrosis | Sedation | Allergic Oedema | Anorgasmia | Increased Blood Creatine | Increased Blood Glucose | Bruxism | Cerebrovascular Accident | Chest Discomfort | Depression | Dermatitis | Diarrhoea | Dry mouth | Enterovirus Infection | Fatigue | Generalized Oedema | Facial Hypoaesthesia | Lacunar Infarction | Loss of Consciousness | Lymphoma | Mental Impairment | Muscular Weakness | Myoclonus | Pollakiuria | Pulomnary Embolism | Rash | Sleep Disorder | Urticaria | Vomiting | |
| Duloxetine | 4 | 0 | 4 | 2 | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Gabapentin + Duloxetine | 4 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Pregabalin | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Ordinal scale: 0=no pain, 10=worst possible pain. Data=weekly mean of scores of average pain severity over last 24 hours (h). Scores: daily assessments recorded by patients in diaries. Only patients adhering to key protocol criteria included: baseline Weekly Mean 24h Average Pain Score ≥4; 80-120% compliant with study Drug, each visit; baseline Michigan Neuropathy Screening Instrument Physical Assessment Total Score ≥3; gabapentin taper ≤14 days, no HbA1c ≥12% post randomization; no contraindicated medications used. Least-squares means=adjustment due to baseline severity + investigative site. (NCT00385671)
Timeframe: baseline, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| baseline | change | |
| Duloxetine | 6.02 | -2.58 |
| Gabapentin + Duloxetine | 5.74 | -2.40 |
| Pregabalin | 5.74 | -2.12 |
This is an ordinal scale with scores from 0 (no pain) to 10 (worst possible pain). Data presented represent the weekly mean of the scores of the average pain severity over the last 24 hours. Scores are based on daily assessments recorded by patients in their diaries. De novo: use of gabapentin for <56 contiguous days prior to randomization. Prior use: use of gabapentin for >=56 contiguous days prior to randomization. Least-squares means represent adjustment due to baseline severity and investigative site. (NCT00385671)
Timeframe: baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| de novo, baseline | de novo, week 1 | de novo, week 2 | de novo, week 3 | de novo, week 4 | de novo, week 5 | de novo, week 6 | de novo, week 7 | de novo, week 8 | de novo, week 9 | de novo, week 10 | de novo, week 11 | de novo, week 12 | prior use, baseline | prior use, week 1 | prior use, week 2 | prior use, week 3 | prior use, week 4 | prior use, week 5 | prior use, week 6 | prior use, week 7 | prior use, week 8 | prior use, week 9 | prior use, week 10 | prior use, week 11 | prior use, week 12 | |
| Duloxetine | 5.39 | -0.71 | -1.22 | -1.83 | -2.35 | -2.65 | -2.64 | -2.73 | -2.78 | -2.89 | -2.86 | -2.98 | -3.08 | 5.99 | -0.48 | -0.99 | -1.32 | -1.61 | -1.95 | -2.03 | -2.14 | -2.16 | -2.38 | -2.45 | -2.46 | -2.46 |
| Gabapentin + Duloxetine | 5.49 | -0.38 | -1.10 | -1.62 | -1.67 | -1.81 | -1.88 | -2.07 | -2.06 | -2.10 | -1.92 | -2.09 | -2.10 | 5.92 | -0.65 | -1.28 | -1.68 | -1.75 | -1.96 | -1.98 | -2.17 | -2.31 | -2.37 | -2.44 | -2.41 | -2.53 |
| Pregabalin | 5.24 | -0.22 | -0.39 | -0.71 | -0.84 | -0.95 | -1.09 | -1.08 | -1.26 | -1.21 | -1.42 | -1.48 | -1.62 | 5.91 | -0.30 | -0.70 | -1.18 | -1.64 | -1.72 | -1.92 | -1.93 | -1.89 | -2.04 | -2.14 | -2.27 | -2.39 |
DAAC was derived from participant's daily pain diary, where pain was measured on an 11-point Numerical Rating Scale (NRS-Pain)ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). The DAAC was calculated as the mean of all daily pain diary rating post baseline minus the baseline score then multiplied by the proportion of the planned study duration completed by the participant. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | -1.66 |
| Placebo | -1.07 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 49 |
| Placebo | 30 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Placebo | 33 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 31 |
| Placebo | 16 |
NPSI - Temporal item which assesses the duration (number of hours during the last 24 hours) of spontaneous ongoing pain. Improved duration would be a decrease in the number of hours of spontaneous ongoing pain during the last 24 hours compared to baseline. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 39 |
| Placebo | 28 |
NPSI - Temporal item which assesses the paroxysmal pain (number of pain attacks during the last 24 hours). Improvement in the number of attacks would be a decrease in the number of paroxysms during the last 24 hours compared to baseline. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 48 |
| Placebo | 38 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 6.9 | -0.8 |
| Pregabalin | 6.7 | -1.4 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 6.3 | -0.5 |
| Pregabalin | 5.2 | -1.0 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 100, 98) | |
| Placebo | 12.8 | -0.2 |
| Pregabalin | 15.0 | -6.2 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 43.8 | 5.7 |
| Pregabalin | 42.3 | 11.6 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 51.2 | -8.0 |
| Pregabalin | 51.9 | -17.3 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104,105) | Change from baseline at endpoint (n = 100, 98) | |
| Placebo | 6.2 | 0.2 |
| Pregabalin | 5.9 | 0.6 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 104) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 35.6 | -4.7 |
| Pregabalin | 31.2 | 2.2 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 100, 97) | |
| Placebo | 39.7 | -4.9 |
| Pregabalin | 36.3 | -0.8 |
Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 103) | Change from baseline at endpoint (n = 100, 95) | |
| Placebo | 45.9 | -5.8 |
| Pregabalin | 45.7 | -10.8 |
"The Modified Brief Pain Inventory (mBPI-10) Interference Scale is a self administered questionnaire that assessed pain interference with functional activities over the past week. The items were measured on an 11 point scale, ranging from does not interfere (0) to completely interferes (10). A composite score, the pain interference index, was calculated by averaging the 10 items that comprised the scale." (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 4.9 | -1.1 |
| Pregabalin | 4.7 | -1.6 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104, 106) | Change from baseline at endpoint (n = 99, 99) | |
| Placebo | 0.4 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.5 | -0.1 |
| Pregabalin | 0.5 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.4 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1- Burning pain (n = 100, 99) | 2- Squeezing pain (n = 100, 99) | 3- Pain like pressure (n = 100, 99) | 5- Electric shocks (n = 100, 99) | 6- Stabbing pain (n = 100, 99) | 8- By light touching (n = 100, 99) | 9- By pressure (n = 100, 99) | 10- By something cold (n = 100, 99) | 11- Pins and needles (n = 99, 99) | 12- Tingling (n = 99, 99) | |
| Placebo | -1.00 | -0.41 | -0.20 | -0.68 | -0.52 | -0.94 | -1.10 | -0.52 | -0.62 | -0.83 |
| Pregabalin | -1.39 | -1.04 | -0.73 | -1.77 | -1.13 | -0.78 | -1.22 | -0.89 | -1.01 | -0.99 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 104, 106) | Change from baseline at endpoint (n = 99, 99) | |
| Placebo | 0.5 | -0.1 |
| Pregabalin | 0.5 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.3 | -0.1 |
| Pregabalin | 0.4 | -0.1 |
Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint (n = 100, 99) | |
| Placebo | 0.4 | -0.0 |
| Pregabalin | 0.4 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (dynamic mechanical allodynia - gentle stroking with foam brush) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 2.3 | -0.3 |
| Pregabalin | 2.7 | -0.6 |
Participant rated pain scale. The pain produced by the applied stimulus (static mechanical allodynia - gentle constant mechanical pressure) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 2.6 | -0.3 |
| Pregabalin | 2.9 | -1.0 |
Participant rated pain scale. The pain produced by the applied stimulus (Cold allodynia - touch with cool metal rod 13-17 degrees celsius was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 72) | |
| Placebo | 2.7 | 0.4 |
| Pregabalin | 2.5 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (Cold hyperalgesia - touch with cold metal rod 4 degrees celsius) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 72) | |
| Placebo | 2.8 | 0.4 |
| Pregabalin | 2.8 | -0.1 |
Participant rated pain scale. The pain produced by the applied stimulus (Punctata hyperalgesia - pinprick) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=83,82) | Change from baseline at endpoint (n=79,75) | |
| Placebo | 3.4 | -0.4 |
| Pregabalin | 3.9 | -1.0 |
Participant rated pain scale. The pain produced by the applied stimulus (Temporal summation to tactile stimuli - repeated touching/tapping) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 83, 82) | Change from baseline at endpoint (n = 79, 75) | |
| Placebo | 3.9 | -0.8 |
| Pregabalin | 4.1 | -0.5 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline | Change from baseline at endpoint | |
| Placebo | 6.5 | -1.2 |
| Pregabalin | 6.5 | -1.9 |
Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). (NCT00407745)
Timeframe: Baseline, Week 1 through16
| Intervention | score on scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n = 111, 108) | Change at Week 1 (n = 111, 107) | Change at Week 2 (n = 110, 105) | Change at Week 3 (n = 107, 105) | Change at Week 4 (n = 107, 103) | Change at Week 5 (n = 105, 101) | Change at Week 6 (n = 105, 99) | Change at Week 7 (n = 103, 98) | Change at Week 8 (n = 101, 97) | Change at Week 9 (n = 98, 97) | Change at Week 10 (n = 97, 91) | Change at Week 11 (n = 96, 90) | Change at Week 12 (n = 96, 91) | Change at Week 13 (n = 93, 91) | Change at Week 14 (n = 93, 92) | Change at Week 15 (n = 93, 92) | Change at Week 16 (n = 89, 90) | |
| Placebo | 6.51 | -0.38 | -0.62 | -0.86 | -1.03 | -1.07 | -1.22 | -1.34 | -1.32 | -1.37 | -1.32 | -1.43 | -1.44 | -1.39 | -1.34 | -1.41 | -1.36 |
| Pregabalin | 6.44 | -0.85 | -1.26 | -1.35 | -1.64 | -1.87 | -1.89 | -2.02 | -1.96 | -1.99 | -2.03 | -2.04 | -1.90 | -2.02 | -2.00 | -2.09 | -2.17 |
Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n = 105, 105) | Change from baseline at endpoint (n = 105, 104) | |
| Placebo | 5.2 | -1.0 |
| Pregabalin | 4.9 | -2.0 |
Pain related sleep interference was assessed on an 11 point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). (NCT00407745)
Timeframe: Baseline, Week 1 through 16
| Intervention | score on scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (n = 111, 107) | Change at Week 1 (n = 111, 106) | Change at Week 2 (n = 110, 104) | Change at Week 3 (n = 107, 104) | Change at Week 4 (n = 107, 102) | Change at Week 5 (n = 105, 100) | Change at Week 6 (n = 105, 98) | Change at Week 7 (n = 103, 97) | Change at Week 8 (n = 101, 96) | Change at Week 9 (n = 98, 96) | Change at Week 10 (n = 97, 90) | Change at Week 11 (n = 96, 89) | Change at Week 12 (n = 96, 90) | Change at Week 13 (n = 93, 90) | Change at Week 14 (n = 93, 91) | Change at Week 15 (n = 93, 91) | Change at Week 16 (n = 89, 89) | |
| Placebo | 5.18 | -0.26 | -0.49 | -0.61 | -0.90 | -0.91 | -0.99 | -1.10 | -1.11 | -1.11 | -1.12 | -1.20 | -1.20 | -1.19 | -1.18 | -1.11 | -1.17 |
| Pregabalin | 4.86 | -0.96 | -1.29 | -1.36 | -1.59 | -1.81 | -1.86 | -1.98 | -1.97 | -2.03 | -2.18 | -2.08 | -2.07 | -2.08 | -2.09 | -2.15 | -2.25 |
The PGIC is a participant-rated instrument measuring change in the participant's overall status on a 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. (NCT00407745)
Timeframe: Baseline, Week 16
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 1-Very much improved | 2-Much improved | 3-Minimally improved | 4-No change | 5-Minimally worse | 6-Much worse | 7-Very much worse | |
| Placebo | 2 | 25 | 24 | 40 | 5 | 3 | 0 |
| Pregabalin | 7 | 33 | 38 | 19 | 2 | 0 | 1 |
11 point Likert scale: range 0 to 10 (no pain to worst possible pain) over past 24 hours. Baseline score = mean score of preceding 7 days (including Visit 2). Final end of treatment (EOT) pain score = mean pain score from last 7 post-Baseline days preceding Visit 8 (Week 12) or last 7 days on study drug for those who did not complete the study. Change = mean at EOT minus mean at Baseline. (NCT00407511)
Timeframe: Baseline, End of Treatment
| Intervention | scores on scale (Mean) |
|---|---|
| Pregabalin | -3.8 |
Self-administered questionnaire: change from Baseline in mean pain severity index over past 24 hours; 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level). Change = mean score at observation minus mean score at Baseline. (NCT00407511)
Timeframe: Baseline, Week 8, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 8 (n=102) | Week 12 (n=98) | EOT/LOCF (n=102) | |
| Pregabalin | -4.2 | -4.7 | -4.6 |
100-mm line (Visual Analog Scale) marked by the subject to measure their degree of anxiety over past 24 hours. Range: 0 = not at all anxious to 100 = extremely anxious. Change = mean score at observation minus mean score at Baseline. (NCT00407511)
Timeframe: Baseline, Week 8, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 8 (n=99) | Week 12 (n=97) | EOT/LOCF (n=101) | |
| Pregabalin | -39.2 | -41.4 | -40.5 |
Daily sleep interference measured on an 11-point Likert scale. Range: 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Change = mean at observation minus mean at Baseline. Evaluations recorded in patient's daily sleep diaries. (NCT00407511)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (n=120) | Week 2 (n=118) | Week 3 (n=114) | Week 4 (n=110) | Week 5 (n=104 | Week 6 (n=103) | Week 7 (n=100) | Week 8 (n=100) | Week 9 (n=97) | Week 10 (n=99) | Week 11 (n=98) | Week 12 (n=96) | EOT/LOCF (n=120) | |
| Pregabalin | -1.0 | -1.8 | -2.5 | -2.8 | -3.0 | -3.1 | -3.3 | -3.4 | -3.5 | -3.5 | -3.5 | -3.4 | -3.1 |
11 point Likert scale; range: 0 to 10 (no pain to worst possible pain) over past 24 hours. Baseline score = mean score of preceding 7 days (including Visit 2). Weekly pain score = mean pain score from last 7 post-Baseline days preceding observation visit or last 7 days on study drug for early termination. Change = mean at observation minus mean at Baseline. (NCT00407511)
Timeframe: Week 4, Week 8, Week 12
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 4 (n=110) | Week 8 (n=100) | Week 12 (n=96) | |
| Pregabalin | -3.2 | -3.9 | -4.2 |
Self-administered questionnaire: change from Baseline in mean pain interference with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. 11-point scale from 0 (does not interfere) to 10 (completely interferes). Change = observation mean minus Baseline mean. (NCT00407511)
Timeframe: Baseline, Week 8, Week 12, End of Treatment/Last Observation Carried Forward (EOT/LOCF)
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 8 (n=102) | Week 12 (n=98) | EOT/LOCF (n=102) | |
| Pregabalin | -3.8 | -4.2 | -4.0 |
100 mm line (Visual Analog Scale) marked by subject; Intensity of pain range (over past week): 0 = no pain to 100 = worst possible pain. Change = observation mean minus Baseline mean. (NCT00407511)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (n = 120) | Week 2 (n = 116) | Week 3 (n = 116) | Week 4 (n = 109) | Week 8 (n = 102) | Week 12 (n = 98) | EOT/LOCF (n = 120) | |
| Pregabalin | -18.8 | -28.5 | -34.9 | -41.0 | -46.6 | -49.0 | -45.9 |
7-point investigator rating scale of change in participant's status since beginning study medication. Range: 1 (very much improved) to 7 (very much worse). (NCT00407511)
Timeframe: End of Treatment/ Last Observation Carried Forward (Week 12 or last post-baseline assessment)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much Worse | Very much worse | |
| Pregabalin | 41 | 55 | 5 | 2 | 0 | 0 | 0 |
Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). Score=[(5-mean of non-missing items)*100]/4. (NCT00407511)
Timeframe: Baseline, Week 8, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=78) | Week 8 (n=100) | Week 12 (n=97) | EOT/LOCF (n=105) | |
| Pregabalin | 62.34 | 90.38 | 91.66 | 91.40 |
Satisfaction with current pain medication response scale: 0 (worst possible response) to 100 (best possible response). Score=[(5-mean of non-missing items)*100]/4. (NCT00407511)
Timeframe: Baseline, Week 8, Week 12, EOT/LOCF
| Intervention | scores on scale (Mean) | |||
|---|---|---|---|---|
| Baseline (n=78) | Week 8 (n=100) | Week 12 (n=97) | EOT/LOCF (n=105) | |
| Pregabalin | 52.56 | 85.92 | 88.56 | 88.08 |
7-point participant rating scale for change observed in their overall status since beginning of study medication. Range: 1 (very much improved) to 7 (very much worse) (NCT00407511)
Timeframe: End of Treatment/ Last Observation Carried Forward (Week 12 or last post-baseline assessment)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Pregabalin | 37 | 53 | 12 | 1 | 0 | 0 | 0 |
Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization) (NCT00570310)
Timeframe: 6 Weeks
| Intervention | Days (Least Squares Mean) |
|---|---|
| Pregabalin | 15.54 |
| Placebo | 7.87 |
Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine) (NCT00570310)
Timeframe: Baseline and 6 Weeks
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Pregabalin | 0.14 |
| Placebo | 1.57 |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 6.52 |
| Placebo | 7.36 |
Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety. (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 9.94 |
| Placebo | 11.63 |
"Hospital Anxiety and Depression Scale Depression Score (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response (lowering of hedonic tone). Score range = 0 to 21; higher scores indicate a greater intensity of depression" (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 5.23 |
| Placebo | 6.20 |
Hospital Anxiety and Depression Scale (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response (lowering of hedonic tone). Score range = 0 to 21; higher scores indicate a greater intensity of depression (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 12.04 |
| Placebo | 11.80 |
Number of subjects responding to have had optimal sleep. Optimal sleep is 1 item in the Medical Outcome Study (MOS)sleep scale, a patient-reported measure consisting of twelve items that assess the key constructs of sleep. Subjects were asked to recall sleep-related activities over the past week. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 58 |
| Placebo | 45 |
Neuropathic Pain Symptom Inventory (NPSI) includes 10 descriptors (scale 0-10) of different pain symptoms & 2 temporal items assessing the duration of spontaneous ongoing and paroxysmal pain. A total intensity score is calculated by sub grouping the questions into five pain dimensions, summing the five sub groups, and converting into a percentage. (NCT00292188)
Timeframe: Week 8
| Intervention | percentage score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 33.29 |
| Placebo | 37.12 |
Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range: 0 (no pain) to 10 (worst possible pain). Endpoint weekly mean pain score: mean of the last 7 available pain scores from a daily pain diary during double blind treatment. (NCT00292188)
Timeframe: each day of Week 8
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | 4.61 |
| Placebo | 5.23 |
11-point numerical scale with which the patient describes pain interference with sleep over past 24 hours; range: 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Endpoint weekly mean score: mean of last 7 available scores from daily sleep interference diary during double-blind treatment. (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 2.93 |
| Placebo | 3.73 |
Clinical Global Impression of Change (CGIC): clinician's judgment of overall change in the patient's condition over a defined period on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| very much improved | much improved | minimally improved | no change | minimally worse | much worse | very much worse | |
| Placebo | 6 | 18 | 26 | 61 | 9 | 3 | 1 |
| Pregabalin | 11 | 33 | 36 | 33 | 5 | 4 | 1 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=124, 124) | Week 8 (n=118, 120) | |
| Placebo | 20.90 | 18.47 |
| Pregabalin | 18.27 | 14.16 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline (n=116, 118) | Week 8 (n=112, 113) | |
| Placebo | 17.83 | 15.43 |
| Pregabalin | 15.55 | 11.71 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=116, 118) | Week 8 (n=112, 113) | |
| Placebo | 38.76 | 33.62 |
| Pregabalin | 34.57 | 26.18 |
Medical Outcome Study (MOS) is a patient-rated questionnaire consisting of 12 items that assess key constructs of sleep (7 subscales as well as a 9-item overall sleep problems index. MOS-Sleep Scale is scored from 0 to 100. A higher score indicates more disturbance. (NCT00292188)
Timeframe: Week 8
| Intervention | score on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sleep Disturbance (n=117, 118) | Snoring (n=111, 118) | Awaken Short of Breath/Headache (n= 118, 117) | Sleep Quantity (n=117, 118) | Sleep Adequacy (n=119, 119) | Somnolence (n=116, 114) | Sleep Problems Index-6 (n=112, 111) | Sleep problems Index-9 (n=111, 107) | |
| Placebo | 46.45 | 37.87 | 20.66 | 6.48 | 44.61 | 32.33 | 51.72 | 42.98 |
| Pregabalin | 35.73 | 38.92 | 14.71 | 6.39 | 55.25 | 34.64 | 42.20 | 35.43 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 3 | 16 | 14 | 23 | 23 | 47 | 5 | 7 | 13 | 26 | 34 | 36 |
| Pregabalin | 5 | 3 | 13 | 24 | 39 | 42 | 4 | 10 | 8 | 22 | 34 | 42 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 4 | 14 | 14 | 29 | 26 | 39 | 7 | 5 | 16 | 27 | 33 | 33 |
| Pregabalin | 4 | 8 | 13 | 27 | 33 | 41 | 3 | 12 | 14 | 26 | 27 | 38 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | particpants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 6 | 12 | 7 | 15 | 35 | 51 | 3 | 11 | 6 | 23 | 27 | 51 |
| Pregabalin | 2 | 8 | 6 | 22 | 23 | 64 | 1 | 9 | 9 | 26 | 22 | 52 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 10 | 14 | 8 | 23 | 33 | 38 | 9 | 7 | 11 | 31 | 35 | 28 |
| Pregabalin | 7 | 7 | 6 | 40 | 30 | 36 | 3 | 11 | 13 | 28 | 36 | 29 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 1 | 15 | 15 | 25 | 27 | 43 | 4 | 5 | 13 | 27 | 30 | 42 |
| Pregabalin | 5 | 6 | 5 | 20 | 42 | 48 | 3 | 10 | 11 | 23 | 32 | 41 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 1 | 9 | 6 | 27 | 36 | 45 | 6 | 9 | 6 | 22 | 31 | 47 |
| Pregabalin | 2 | 6 | 3 | 31 | 33 | 51 | 4 | 6 | 12 | 28 | 31 | 39 |
Modified Brief Pain Inventory Short Form (m-BPI-sf): self-administered questionnaire to assess severity of pain (measured by 4 items)and impact of pain on daily functions (measured by 7 items)in past 24 hours. Items are rated on an 11-point scale ranging from 0 to 10, with higher scores indicating greater pain and/or interference due to pain. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| pain interference index Baseline (n=125, 126) | pain interference index Week 8 (n=120, 121) | pain severity index Baseline (n= 122, 125) | pain severity index Week 8 (n=120, 120) | |
| Placebo | 4.69 | 4.17 | 5.72 | 5.21 |
| Pregabalin | 4.57 | 3.31 | 5.36 | 4.20 |
Based on weekly mean daily pain rating score (DPRS), responders were defined as subjects with a >= 30% and >=50% reduction in weekly mean scores from baseline until endpoint (Week 8). Endpoint was calculated as the mean of the last 7 available pain scores from the daily pain diary while in the double-blind treatment phase. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |
|---|---|---|
| 30% Responder | 50% Responder | |
| Placebo | 32 | 18 |
| Pregabalin | 50 | 30 |
Pain Treatment Satisfaction Scale (PTSS); Efficacy: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 42.73 | 37.88 |
| Pregabalin | 43.23 | 53.21 |
Pain Treatment Satisfaction Scale (PTSS); Impact of Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Screening (n=113, 113) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 53.60 | 42.56 |
| Pregabalin | 54.53 | 52.64 |
Pain Treatment Satisfaction Scale (PTSS); Medication Characteristics: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 59.39 | 70.39 |
| Pregabalin | 57.44 | 71.52 |
Pain Treatment Satisfaction Scale (PTSS); Satisfaction with Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range:1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | Week 8 (n=122, 121) | |
| Placebo | 51.05 | 54.15 |
| Pregabalin | 50.33 | 62.36 |
Patient Global Impression of Change (PGIC): a patient-rated instrument that measures change in patient's overall status on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| very much improved | much improved | minimally improved | no change | minimally worse | much worse | very much worse | |
| Placebo | 6 | 22 | 26 | 52 | 10 | 7 | 2 |
| Pregabalin | 13 | 27 | 41 | 30 | 3 | 3 | 3 |
Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range:0 (no pain) to 10 (worst possible pain). Mean of scores available for each week. (NCT00292188)
Timeframe: Baseline through Week 8
| Intervention | score on scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=125, 125) | Week 2 (n=121, 119) | Week 3 (n=113, 116) | Week 4 (n=108, 108) | Week 5 (n=106, 104) | Week 6 (n=104, 101) | Week 7 (n=99, 99) | Week 8 (n=97, 97) | |
| Placebo | 5.79 | 5.64 | 5.44 | 5.27 | 5.26 | 5.34 | 5.26 | 5.24 |
| Pregabalin | 5.54 | 5.37 | 4.91 | 4.95 | 4.80 | 4.76 | 4.74 | 4.64 |
Total scores range: 0-36 (0= no symptoms to 36= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | scores on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -6.7 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -5.8 |
VAS is measured on marking on a 10-centimeter (cm) ruler (measured in cm, 0= no pain and 10= most severe pain possible) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -1.9 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -1.8 |
Adverse events will only be those determined to be related to the study drug (NCT03463915)
Timeframe: End of study (6 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 1 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 5 |
Total scores range: 0-100 (higher scores on the symptom-severity scale suggestive of greater severity of symptoms and higher scores on the quality-of-life scale suggestive of better quality of life) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -24.2 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -18.8 |
20 question self-administered questionnaire on the presence and absence of pelvic floor symptoms. Score ranges from 0 (least distress) to 300 (most distress). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -6.4 |
Total scores range: 0-35 (0= no symptoms to 35= the most severe symptoms) (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | score on a scale (Mean) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | -5.3 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | -2.7 |
Measures sexual function in women with pelvic floor disorders. Queries about arousal, orgasm, partner-related issues, sexual quality, and desire. The tool also takes into account those who are not sexually active. The questionnaire was used in the study solely to determine if patients had improved dyspareunia (as a categorical variable). (NCT03463915)
Timeframe: Assessed at baseline, 3 and 6 weeks; change from baseline to week 6 reported
| Intervention | participants (Number) |
|---|---|
| Bladder Instillation WITH Triamcinolone Acetonide | 4 |
| Bladder Instillation WITHOUT Triamcinolone Acetonide | 4 |
Baseline and EOMT scores are the pain scores each participant reported after taking a 50-foot walk at the randomization and Week 13/Withdrawal visits, respectively, using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with BMI, baseline pain intensity after 50-foot walk, pain intensity prior to 50-foot walk at the visit being assessed, and grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.38 |
| GEn 1200 mg/Day | -2.32 |
| GEn 2400 mg/Day | -2.36 |
| GEn 3600 mg/Day | -2.52 |
| PGB 300 mg/Day | -2.17 |
Baseline and EOMT values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (Baseline) and the earliest date of Week 13 visit/Withdrawal visit/last dose of study drug (EOMT). Participants used a hand-held diary to rate their API over the preceding 24 hours, using an 11-point Pain Intensity Numerical Rating Scale (PI-NRS) (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as the EOMT score minus the Baseline score. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.08 |
| GEn 1200 mg/Day | -2.43 |
| GEn 2400 mg/Day | -2.10 |
| GEn 3600 mg/Day | -2.63 |
| PGB 300 mg/Day | -1.65 |
"Current pain is defined as the participant's assessment of pain intensity right now. Participants recorded their current evening pain intensity in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used." (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.19 |
| GEn 1200 mg/Day | -2.24 |
| GEn 2400 mg/Day | -2.10 |
| GEn 3600 mg/Day | -2.66 |
| PGB 300 mg/Day | -1.65 |
"Current pain is defined as the participant's assessment of pain intensity right now. Participants recorded their current morning pain intensity in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used." (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.90 |
| GEn 1200 mg/Day | -2.08 |
| GEn 2400 mg/Day | -1.95 |
| GEn 3600 mg/Day | -2.40 |
| PGB 300 mg/Day | -1.50 |
Mean daily use of rescue medication (milligrams of acetaminophen) was calculated by determining the average number of tablets taken per day of rescue medication (Commerical Tylenol) during treatment and multiplying that by 500 mg. Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | milligrams (Least Squares Mean) |
|---|---|
| Placebo | -261.99 |
| GEn 1200 mg/Day | -171.64 |
| GEn 2400 mg/Day | -102.51 |
| GEn 3600 mg/Day | -228.54 |
| PGB 300 mg/Day | -246.07 |
Day-time is defined as the time between rising in the morning and going to bed at night. Participants recorded day-time API on a daily basis in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.07 |
| GEn 1200 mg/Day | -2.35 |
| GEn 2400 mg/Day | -2.06 |
| GEn 3600 mg/Day | -2.54 |
| PGB 300 mg/Day | -1.50 |
Day-time worst pain is defined as the partipant's assessment of their worst pain between rising in the morning and going to bed at night. Participants recorded day-time worst pain in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.33 |
| GEn 1200 mg/Day | -2.35 |
| GEn 2400 mg/Day | -2.25 |
| GEn 3600 mg/Day | -2.88 |
| PGB 300 mg/Day | -1.62 |
Night-time is defined as the time between going to bed at night and rising in the morning. Participants recorded night-time API on a daily basis in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.99 |
| GEn 1200 mg/Day | -2.15 |
| GEn 2400 mg/Day | -2.04 |
| GEn 3600 mg/Day | -2.71 |
| PGB 300 mg/Day | -1.83 |
Night-time worst pain is defined as the partipant's assessment of their worst pain between going to bed at night and rising in the morning. Participants recorded night-time worst pain in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.25 |
| GEn 1200 mg/Day | -2.24 |
| GEn 2400 mg/Day | -2.25 |
| GEn 3600 mg/Day | -3.00 |
| PGB 300 mg/Day | -1.86 |
Participants assessed sleep interference due to pain on a daily basis in the morning upon awakening using an 11-point NRS (0=pain does not interfere with sleep, 10=pain completely interferes with sleep). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.35 |
| GEn 1200 mg/Day | -2.54 |
| GEn 2400 mg/Day | -2.45 |
| GEn 3600 mg/Day | -3.01 |
| PGB 300 mg/Day | -2.24 |
"The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved. EOMT response is defined as the score recorded at the Week 13/Withdrawal visit." (NCT00643760)
Timeframe: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | participants (Number) |
|---|---|
| Placebo | 39 |
| GEn 1200 mg/Day | 20 |
| GEn 2400 mg/Day | 22 |
| GEn 3600 mg/Day | 50 |
| PGB 300 mg/Day | 17 |
"The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of very much improved or much improved. EOMT response is defined as the score recorded at the Week 13/Withdrawal visit." (NCT00643760)
Timeframe: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | participants (Number) |
|---|---|
| Placebo | 46 |
| GEn 1200 mg/Day | 22 |
| GEn 2400 mg/Day | 24 |
| GEn 3600 mg/Day | 53 |
| PGB 300 mg/Day | 62 |
Sustained improvement in the 24-hour average pain intensity score is defined as at least 2 consecutive days on which the 24-hour average pain intensity score is >=2 points less than the mean 24-hour average pain intensity score at baseline. Time to onset is measured from baseline and was calculated as first day of event minus last day of baseline and is expressed in days. Baseline score is the calculated mean of the 24-hour average pain score for each participant during the last 7 days prior to randomization. (NCT00643760)
Timeframe: Any time post-baseline until date of last dose of study medication (up to Week 13)
| Intervention | days (Median) |
|---|---|
| Placebo | 24 |
| GEn 1200 mg/Day | 25 |
| GEn 2400 mg/Day | 22 |
| GEn 3600 mg/Day | 15 |
| PGB 300 mg/Day | 29 |
The POMS-B, an emotional functioning instrument, assesses mood, tension, and other psychological symptoms and consists of 30-items assessed on a 5-point scale (0=not at all to 4=extremely). 6 summary scores are calculated: Tension/Anxiety, Depression/Rejection, Anger/Hostility, Vigor/Activity, Fatigue/Inertia, and Confusion/Bewilderment; and range from 0-20 (higher scores = more negative mood state). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Tension/Anxiety Domain Score | Depression/Rejection Domain Score | Anger/Hostility Domain Score | Vigor/Activity Domain Score | Fatigue/Inertia Domain Score | Confusion/Bewilderment Domain Score | |
| GEn 1200 mg/Day | -0.6 | -0.2 | -0.8 | -0.1 | -0.5 | 0.2 |
| GEn 2400 mg/Day | -0.7 | -0.6 | -0.5 | 0.1 | -1.1 | -0.1 |
| GEn 3600 mg/Day | -0.9 | -0.3 | -0.3 | 0.7 | -1.1 | 0.0 |
| PGB 300 mg/Day | -0.3 | 0.4 | -0.3 | -0.4 | -0.1 | -0.2 |
| Placebo | -1.0 | -0.5 | -0.5 | 0.6 | -0.8 | -0.3 |
The SF-MPQ, a general pain instrument, assesses the characteristics and intensity of pain and consists of 15-items assessed on a 4-point scale (0=none, 1=mild, 2=moderate, and 3=severe). 3 summary scores are calculated: sensory score (sum of items 1-11, range 0-33), affective score (sum of items 12-15, range 0-12), total score (sum of items 1-15, range 0-45), where lower scores = lower pain/impact. Analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| SF-MPQ Total Score | SF-MPQ Sensory Score | SF-MPQ Affective Score | |
| GEn 1200 mg/Day | -6.55 | -4.83 | -1.65 |
| GEn 2400 mg/Day | -6.75 | -5.31 | -1.45 |
| GEn 3600 mg/Day | -7.56 | -5.50 | -2.07 |
| PGB 300 mg/Day | -4.01 | -2.73 | -1.26 |
| Placebo | -5.85 | -4.25 | -1.63 |
The NPS assesses pain qualities and consists of 11-items, 10 assessed on an 11-point NRS (0=no impact to 10=greatest impact); and 1 open-ended question not used in score calculation. 4 summary scores are calculated: NPS 10 (items 1-7, 9-11), NPS 8 (8 pain descriptor items), NPS Non-Allodynic (NA) (8 NA items), and NPS 4 (4 pain quality items); and range from 0 to 100 (0=no impact and 100=greatest impact). The analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) | |||
|---|---|---|---|---|
| NPS 10 Score | NPS 8 Score | NPS Non-Allodynic Score | NPS 4 Score | |
| GEn 1200 mg/Day | -18.43 | -17.83 | -18.89 | -20.90 |
| GEn 2400 mg/Day | -22.24 | -21.84 | -22.86 | -25.15 |
| GEn 3600 mg/Day | -25.49 | -25.14 | -26.35 | -27.84 |
| PGB 300 mg/Day | -16.16 | -16.19 | -15.63 | -16.06 |
| Placebo | -18.92 | -18.73 | -19.37 | -20.54 |
The SF-36 is a general health-related quality of life instrument consisting of 36 items with various response options (Yes/No, 5- to 6-point Likert scale). Summary scores are calculated for 8 domains and 2 components (physical and mental); where scores range from 0 to 100 (higher scores = better quality of life). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | scores on a scale (Least Squares Mean) | |
|---|---|---|
| SF-36 Physical Component Summary Score | SF-36 Mental Component Summary Score | |
| GEn 1200 mg/Day | 3.5 | 0.4 |
| GEn 2400 mg/Day | 3.7 | 1.5 |
| GEn 3600 mg/Day | 4.6 | 1.6 |
| PGB 300 mg/Day | 3.7 | 0.7 |
| Placebo | 3.1 | 2.5 |
The BPI, a general pain instrument, assesses the severity and interference of pain; and consists of 6 items assessed on an 11-point NRS (0=no impact and 10=greatest impact). 2 summary scores are calculated: BPI Severity Score (average of first 4 items) and BPI Interference Score (average of 7 responses to item 6); where each summary score ranges from 0 to 10 (0=no impact and 10=greatest impact). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates. (NCT00643760)
Timeframe: Baseline and EOMT
| Intervention | scores on a scale (Least Squares Mean) | |
|---|---|---|
| Brief Pain Inventory Severity of Pain | Brief Pain Inventory Interference of Pain | |
| GEn 1200 mg/Day | -2.3 | -2.0 |
| GEn 2400 mg/Day | -2.4 | -2.1 |
| GEn 3600 mg/Day | -2.8 | -2.5 |
| PGB 300 mg/Day | -1.7 | -1.9 |
| Placebo | -2.1 | -2.0 |
Baseline and EOMT scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization and EOMT, respectively. Percent reduction from baseline was calculated as the [(EOMT score minus the baseline score)divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity. (NCT00643760)
Timeframe: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| >= 0% reduction from baseline | >= 10% reduction from baseline | >= 20% reduction from baseline | >= 30% reduction from baseline | >= 40% reduction from baseline | >= 50% reduction from baseline | >= 60% reduction from baseline | >= 70% reduction from baseline | >= 80% reduction from baseline | >= 90% reduction from baseline | 100% reduction from baseline | |
| GEn 1200 mg/Day | 55 | 43 | 36 | 31 | 28 | 26 | 21 | 17 | 11 | 5 | 4 |
| GEn 2400 mg/Day | 50 | 42 | 34 | 25 | 19 | 15 | 11 | 6 | 5 | 2 | 1 |
| GEn 3600 mg/Day | 101 | 91 | 78 | 66 | 55 | 46 | 41 | 25 | 17 | 8 | 5 |
| PGB 300 mg/Day | 55 | 42 | 36 | 28 | 20 | 14 | 9 | 5 | 4 | 3 | 3 |
| Placebo | 103 | 86 | 73 | 57 | 46 | 35 | 26 | 15 | 11 | 4 | 3 |
"Mean change from baseline. Participants are asked Taking into account your pain level and how it affects your life, are you feeling better, the same or worse than when you started treatment? and then to quantify the magnitude of the change. with the 7-Point guy Farrar which measures the global treatment effect from with scale from 0 to 6, higher score indicates worse outcomes." (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 2.2 | 2.4 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo Then Botulinum Toxin A | 0.3 | 0.3 | 0 | 0 | 5 | 5 | 3 | 1 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting day-to-day activities subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4.2 | 5.4 | 5 | 5 | 4.8 | 7 | 6.7 | 7 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.3 | 2.7 | 2.7 | 2.7 | 2.7 | 2 | 3 | 4 | 5 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting mood subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.6 | 6.6 | 5.8 | 5.2 | 5.6 | 7 | 7 | 7.3 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.7 | 2.7 | 2.7 | 4.3 | 5.7 | 2 | 3 | 4 | 7 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting sleep subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.8 | 4.6 | 5 | 6 | 6.2 | 8 | 8 | 8 | 7.3 |
| Placebo Then Botulinum Toxin A | 6.7 | 4.7 | 3.3 | 6 | 6.7 | 1 | 3 | 4 | 5 |
Participant rated pain intensity from 0-10, with higher score indicating more pain (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 7.6 | 6.4 | 5.6 | 5.6 | 5.6 | 8 | 8 | 6.7 | 8 |
| Placebo Then Botulinum Toxin A | 8 | 8 | 8 | 8 | 8 | 5 | 5 | 6 | 7 |
PGI measures activity affected by pain. Full score is 0 to 10000, with higher score indicating better function (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4250 | 5240 | 5219 | 3725 | 4330 | 3333.3 | 3333.3 | 3333.3 | 3333.3 |
| Placebo Then Botulinum Toxin A | 1500 | 1550 | 1825 | 2800 | 1800 | 3500 | 3750 | 3000 | 1500 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
"PPT during cold water immersion (PPT+CPM): By measuring PPT during cold water immersion, we evaluated the degree to which pain perception is modulated by conditioned pain modulation (CPM) following the presentation of an initial heterotopic noxious stimulus. Subjects immersed their left hands into cold water (zero to 1°C) for 1 minute. During the last 30 seconds of cold-water immersion, the PPT procedure was administered at the right forearm. The temperature was held constant across during the experiment for each subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST | 12.62 |
| Placebo-sham | 9.15 |
"To determine the cortical silent period (CSP), subjects were instructed to squeeze the dynamometer using their fingers at 20% of maximal force when a single pulse stimulus (130% rMT) was applied. The result was the average of five consecutive measurements. The CSP was determined by the interval between the stimulus and the motor response elicited in the subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated before and within one hour after intervention.
| Intervention | ms (milliseconds). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 50.93 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 48.92 |
"ICF was evaluated using an inter-stimuli intervals (ISIs) of 12 ms with paired-pulse and similar parameters for the conditioning and test stimuli. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEP). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICF was done by the ratio of the mean ICF by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.20 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.78 |
"ICI was evaluated using inter-stimuli intervals (ISIs) of 2 ms with paired-pulse stimulation. The subthreshold stimulus was set at 80% of rMT (conditioning stimulus) , and the suprathreshold test stimulus was set at 130% of rMT. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEPs). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICI was done by the ratio of the mean ICI by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated in one day. The cortical excitability before and within an hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.75 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.57 |
"Cortical excitability was assessed using a MagPro X100 (MagVenture Company, Lucernemarken, Denmark) and a figure-of-8 coil centered over the left motor cortex (M1). Subjects were seated in a comfortable reclining chair with their arms and hands lying relaxed on the armrests. The investigators measured the resting motor threshold (rMT) of the right first dorsal interosseous (FDI) muscle. The MEPs were recorded by surface electromyography (EMG) using Ag-AgCl cup electrodes in a belly tendon montage. Resting motor threshold (rMT) was defined as the stimulus intensity at which peak-to-peak MEP amplitude of 50 µV (microvolts) was obtained in at least 5 of 10 consecutive trials.~MEP was defined as approximately 130% of the rMT or the stimulus intensity at which peak-to-peak MEP amplitude of at least 1 mV was obtained in 10 consecutive trials. The result of the MEP was the average of 10 curves (unconditioned MEP).~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | mV (millivolts). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.14 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 1.12 |
"The intensity of pain was measured by a 10-cm VAS. VAS scores ranged from no pain (zero) to the worst possible pain possible (10 cm). The pain score on VAS during the last 24 hours was used to classify the subjects into two groups: (1) absence of pain or mild pain (scores equal to or lower than 4 cm) and (2) moderate, intense, or worst possible pain (scores higher than 4 cm).~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated within twenty four hours before and within one hour after the intervention.
| Intervention | cm ( mean). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.88 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 3.36 |
"PPT (alone): The patient was instructed to verbally report the perception of pain onset. The investigator assessed PPT using an electronic algometer (J Tech Medical Industries, USA). The device had a 1-cm2 hard-rubber probe, which was applied over structures at L1- L5 dermatome at the knee and at the contralateral forearm. The average values of PPT in kgf/cm2 for three successive readings taken at intervals of 3-5 min were used as the outcomes.~# Below, the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 8.82 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 6.66 |
"Compare the maximum change in pain score from baseline between pregabalin and placebo within cycle 1 and across the 2 cycles.~The ten-point numerical scale is scored from 0 to 10. They will use this scale to rate their pain (and separately bone/joint pain) with 0 signifying no pain and 10 signifying the worst pain you can imagine. Each patient will be assessed regularly, including: before therapeutic intervention (i.e. at consent/screening), first day of chemotherapy administration (during cycles 1 & 2), 4 days after pegfilgrastim administration (during cycles 1 & 2), and 8 days after pegfilgrastim administration (during cycles 1 & 2)." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| First Intervention = Pregabalin | 0.4 |
| Second Intervention = Placebo | 2 |
| First Intervention = Placebo | 0 |
| Second Intervention = Pregabalin | 1.67 |
"Compare the maximum neuropathic pain score between pregabalin and placebo within cycle 1 and across the 2 cycles.~The ID Pain scale (also know as the Identify Pain scale) is a 6-item, participant-completed screening tool designed to help differentiate nociceptive and neuropathic pain. This pain score also helps to evaluate the presence/absence of neuropathic pain at a given point of time.~Did the pain feel like pins and needles?~Did the pain feel hot/burning?~Did the pain feel numb?~Did the pain feel like electrical shocks?~Is the pain made worse with the touch of clothing or bed sheets?~Is the pain limited to your joints?~A yes response to questions 1-5 are scored as 1; for question 6, a yes is scored as -1. As such, higher scores (approaching 5) signify worse outcomes. The scale's total range for a patient is -1 to 5." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| First Intervention = Pregabalin | 0.2 |
| Second Intervention = Placebo | 0.5 |
| First Intervention = Placebo | 0 |
| Second Intervention = Pregabalin | 0.33 |
"Compare the number of days of breakthrough analgesic use between pregabalin and placebo within cycle 1 and across the 2 cycles.~The number of days of breakthrough analgesic use (i.e additional pain medication being required) is evaluated based on participant-provided medication logs kept during study treatment. If additional pain medication outside of their normal pain control regimen was reported, this day counts as 1. The total days for each patient are then reported, with a total range from zero to 14 (for patients with breast cancer) or zero to 21 (for patients with a lymphoma)." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | days (Mean) |
|---|---|
| First Intervention = Pregabalin | 1.4 |
| Second Intervention = Placebo | 3.25 |
| First Intervention = Placebo | 0.67 |
| Second Intervention = Pregabalin | 0 |
"Compare the proportion of patients who have an increase in pain score of ≥ 3 from baseline through the end of study medication in cycle 1 between Arm A and Arm B.~The ten-point numerical scale is scored from 0 to 10. They will use this scale to rate their pain (and separately bone/joint pain) with 0 signifying no pain and 10 signifying the worst pain you can imagine." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| First Intervention = Pregabalin | 0 |
| First Intervention = Placebo | 0 |
CTCAE The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| First Intervention = Pregabalin | 0 |
| Second Intervention = Pregabalin | 0 |
"Compare the proportion of patients who have an increase in bone/joint pain score of ≥ 3 from baseline through the end of study medication in cycle 1 between Arm A and Arm B.~The ten-point numerical scale is scored from 0 to 10. They will use this scale to rate their pain (and separately bone/joint pain) with 0 signifying no pain and 10 signifying the worst pain you can imagine." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | proportion (Number) |
|---|---|
| First Intervention = Pregabalin | 0 |
| First Intervention = Placebo | 0 |
"Compare the proportion of patients who have an increase in pain score of ≥ 3 from baseline between pregabalin and placebo across the 2 cycles.~The ten-point numerical scale is scored from 0 to 10. They will use this scale to rate their pain (and separately bone/joint pain) with 0 signifying no pain and 10 signifying the worst pain you can imagine." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | proportion (Number) |
|---|---|
| First Intervention = Pregabalin | 0 |
| Second Intervention = Placebo | 0.5 |
| First Intervention = Placebo | 0 |
| Second Intervention = Pregabalin | 0.333 |
"Compare the proportion of patients with severe pain between pregabalin and placebo within cycle 1 and across the 2 cycles.~The ten-point numerical scale is scored from 0 to 10. They will use this scale to rate their pain (and separately bone/joint pain) with 0 signifying no pain and 10 signifying the worst pain you can imagine." (NCT03407430)
Timeframe: Up to 12 weeks
| Intervention | proportion (Number) |
|---|---|
| First Intervention = Pregabalin | 0.4 |
| Second Intervention = Placebo | 0.25 |
| First Intervention = Placebo | 0.67 |
| Second Intervention = Pregabalin | 0 |
"The evaluation of the pain intensity was based on a 11-point Numerical Pain Rating Scale (NPRS score from 0= no pain to 10= the most intense pain imaginable). Patients recorded the NPRS score every day of treatment in their diary.~The improvement in the pain intensity is defined as a decrease in NPRS scores from baseline to the end of treatment." (NCT03720119)
Timeframe: Every day for 15 days
| Intervention | Score on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPRS score of Day 1 | NPRS score of Day 2 | NPRS score of Day 3 | NPRS score of Day 4 | NPRS score of Day 5 | NPRS score of Day 6 | NPRS score of Day 7 | NPRS score of Day 8 | NPRS score of Day 9 | NPRS score of Day 10 | NPRS score of Day 11 | NPRS score of Day 12 | NPRS score of Day 13 | NPRS score of Day 14 | NPRS score of Day 15 | |
| Single Cohort | 6.7 | 5.4 | 5.0 | 4.7 | 4.1 | 3.9 | 3.6 | 3.6 | 3.6 | 3.4 | 3.2 | 3.2 | 3.3 | 3.0 | 2.8 |
"The evaluation of wound pain relief was based on a 5-point Visual Rating Scale (0 = none improvement; 4 = total relief).~Patients recorded the VRS score every day of treatment in their diary. The improvement in the pain relief was defined as a VRS scores at end of treatment significantly greater than 0." (NCT03720119)
Timeframe: Every day for 15 days
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 272404424 | Day 372404424 | Day 472404424 | Day 572404424 | Day 672404424 | Day 772404424 | Day 872404424 | Day 972404424 | Day 1072404424 | Day 1172404424 | Day 1272404424 | Day 1372404424 | Day 1472404424 | Day 1572404424 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| None relief | Mild | Complete relief | Moderate | A lot | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in worst pain as measured by the Brief Pain Inventory-Short Form. Scores range from 0 to 10 and higher scores indicate more pain. Change is calculated as the 6 weeks score minus the baseline score. (NCT02232282)
Timeframe: 0 weeks, 6 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Minimal Acupuncture | -2.08 |
| Standard Acupuncture Treatment | -2.91 |
The total number of adverse events experienced by women receiving acupuncture (NCT02232282)
Timeframe: 0 weeks, 12 weeks
| Intervention | total number of adverse events (Number) |
|---|---|
| Minimal Acupuncture | 0 |
| Standard Acupuncture Treatment | 0 |
The total number of acupuncture sessions stopped due to poor tolerability of acupuncture (NCT02232282)
Timeframe: 0 weeks, 6 weeks
| Intervention | total number of sessions (Number) |
|---|---|
| Minimal Acupuncture | 0 |
| Standard Acupuncture Treatment | 0 |
The Brazilian version of Shoulder Pain and Disability Index ranging 0 to 100 points. Lower scores indicate better functionality (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| baseline | 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 65.7 | 43.5 | 39.7 | 34.2 |
| Scapula-focused Exercises | 63.3 | 49.8 | 37.1 | 32.8 |
Pain Numerical Rating Scale from 0 to 10. Lower values indicate improvement in pain (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 3.9 | 1.5 | 1.3 | 1.2 |
| Scapula-focused Exercises | 3.7 | 2.7 | 1.8 | 0.5 |
Tampa Scale of Kinesiophobia ranging 17 to 68 points. High scores indicate high degree kinesiophobia (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Kinesiophobia baseline | Kinesiophobia 4 weeks | Kinesiophobia 8 weeks | Kinesiophobia 16 weeks | |
| Motor Control Exercises | 42.8 | 40.7 | 38.9 | 37.5 |
| Scapula-focused Exercises | 42.1 | 39.8 | 40.2 | 38.7 |
Strength of serratus anterior, trapezius muscles, abduction, adduction, internal and external rotation movements the arm with hand held Dynamometer. (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | Kilogram-force (Mean) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shoulder abduction baseline | Shoulder abduction 4 weeks | Shoulder abduction 8 weeks | Shoulder abduction 16 weeks | Shoulder adduction baseline | Shoulder adduction 4 weeks | Shoulder adduction 8 weeks | Shoulder adduction 16 weeks | Shoulder external rotation baseline | Shoulder external rotation 4 weeks | Shoulder external rotation 8 weeks | Shoulder external rotation 16 weeks | Shoulder Internal rotation baseline | Shoulder Internal rotation 4 weeks | Shoulder Internal rotation 8 weeks | Shoulder Internal rotation 16 weeks | Serratus Anterior Baseline | Serratus Anterior 4 weeks | Serratus Anterior 8 weeks | Serratus Anterior 16 weeks | Upper Trapezius Baseline | Upper Trapezius 4 weeks | Upper Trapezius 8 weeks | Upper Trapezius 16 weeks | Middle Trapezius Baseline | Middle Trapezius 4 weeks | Middle Trapezius 8 weeks | Middle Trapezius 16 weeks | Lower Trapezius baseline | Lower Trapezius 4 weeks | Lower Trapezius 8 weeks | Lower Trapezius 16 weeks | |
| Motor Control Exercises | 5.5 | 6.3 | 7.1 | 7 | 7.9 | 9 | 9.2 | 9 | 5.7 | 6.1 | 6.5 | 6.4 | 9.4 | 10.4 | 11.4 | 10.7 | 6.8 | 10 | 10.8 | 10.6 | 8.8 | 11.1 | 12.1 | 11.4 | 3.3 | 4.1 | 4.4 | 4.6 | 3.1 | 4 | 4 | 4.1 |
| Scapula-focused Exercises | 6.2 | 7.1 | 7.9 | 7.8 | 7.8 | 8.8 | 9.2 | 8.5 | 5.8 | 5.9 | 6.5 | 6.9 | 8.6 | 9.1 | 10.4 | 10.3 | 7.2 | 9.1 | 10.3 | 11.1 | 8.3 | 9.8 | 11.1 | 11 | 4.4 | 4.9 | 5.1 | 5.4 | 4.3 | 4.6 | 5 | 5 |
Global Perceived Effect Scale ranging -5 to +5 points. Positive values indicate improvement and negative values indicate worsening of symptoms (NCT02695524)
Timeframe: four, eight weeks and sixteen weeks of randomization
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 2.8 | 3.3 | 3.1 |
| Scapula-focused Exercises | 2 | 2.9 | 3.3 |
abduction, adduction, internal and external rotation of the shoulder (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | degrees (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shoulder Flexion Baseline | Shoulder Flexion 4 weeks | Shoulder Flexion 8 weeks | Shoulder Flexion 16 weeks | Shoulder Abduction Baseline | Shoulder Abduction 4 weeks | Shoulder Abduction 8 weeks | Shoulder Abduction 16 weeks | Shoulder External Rotation Baseline | Shoulder External Rotation 4 weeks | Shoulder External Rotation 8 weeks | Shoulder External Rotation 16 weeks | Shoulder Internal Rotation Baseline | Shoulder Internal Rotation 4 weeks | Shoulder Internal Rotation 8 weeks | Shoulder Internal Rotation 16 weeks | |
| Motor Control Exercises | 129 | 148.5 | 147.8 | 149.9 | 120.2 | 145.2 | 145.5 | 141.3 | 60.9 | 66.7 | 68.3 | 70 | 48.6 | 53.4 | 54.6 | 54.8 |
| Scapula-focused Exercises | 132.5 | 140.4 | 148 | 146.6 | 125.3 | 139 | 147.8 | 143.2 | 60.1 | 66.4 | 73.7 | 71.4 | 49.2 | 53.9 | 59.2 | 57.1 |
Medrisk Questionnaire ranging 13 to 80 points. High scores indicate satisfaction with treatment (NCT02695524)
Timeframe: four, eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Medrisk 4 weeks | Medrisk 8 weeks | Medrisk 16 weeks | |
| Motor Control Exercises | 63.1 | 63.6 | 63.8 |
| Scapula-focused Exercises | 60.8 | 61.3 | 62 |
upward rotation and tilt of the scapula (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | degrees (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upward Rotation 0º Baseline | Upward Rotation 0º 4 weeks | Upward Rotation 0º 8 weeks | Upward Rotation 0º 16 weeks | Upward Rotation 90º baseline | Upward Rotation 90º 4 weeks | Upward Rotation 90º 8 weeks | Upward Rotation 90º 16 weeks | Upward Rotation 180º baseline | Upward Rotation 180º 4 weeks | Upward Rotation 180º 8 weeks | Upward Rotation 180º 16 weeks | Anterior Tilt 0º baseline | Anterior Tilt 0º 4 weeks | Anterior Tilt 0º 8 weeks | Anterior Tilt 0º 16 weeks | Anterior Tilt 90º baseline | Anterior Tilt 90º 4 weeks | Anterior Tilt 90º 8 weeks | Anterior Tilt 90º 16 weeks | Anterior Tilt 180º baseline | Anterior Tilt 180º 4 weeks | Anterior Tilt 180º 8 weeks | Anterior Tilt 180º 16 weeks | |
| Motor Control Exercises | 7 | 5.7 | 5.7 | 6.5 | 13.6 | 14.5 | 17.6 | 20.6 | 35.5 | 39.3 | 44.3 | 44.5 | 19 | 19 | 19.4 | 19.6 | 14.2 | 13.6 | 12.3 | 11.7 | 4.2 | 3.2 | 0.1 | 0.7 |
| Scapula-focused Exercises | 5.6 | 5.3 | 5 | 5.1 | 12.8 | 13.3 | 15 | 16.8 | 30.7 | 37.3 | 40.9 | 39.7 | 18.4 | 18.4 | 19.7 | 18.7 | 15 | 14.6 | 15.1 | 13.2 | 4.3 | 2 | 3.1 | 0.6 |
115 reviews available for gamma-aminobutyric acid and Neuralgia
| Article | Year |
|---|---|
Is gabapentin a safe and effective treatment for nonneuropathic pain?
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2021 |
Gabapentin-Induced Overflow Urinary Incontinence: A Case Report and Review of the Literature.
Topics: Amines; Analgesics; Carcinoma, Non-Small-Cell Lung; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2023 |
The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2023 |
Efficacy of gabapentin in the treatment of trigeminal neuralgia: A systematic review of randomized controlled trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2019 |
Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain.
Topics: Chronic Disease; gamma-Aminobutyric Acid; Ganglia, Spinal; Humans; Neuralgia; Serotonin; Spinal Cord | 2020 |
Epoxyeicosatrienoic acids: Emerging therapeutic agents for central post-stroke pain.
Topics: Analgesics; Animals; Brain; Chronic Pain; Eicosanoids; gamma-Aminobutyric Acid; Humans; Inflammation | 2020 |
Adenosine receptor signalling: Probing the potential pathways for the ministration of neuropathic pain.
Topics: Adrenergic Agonists; Analgesics; Animals; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid | 2020 |
Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; | 2017 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Fructose; Gabapentin; gamm | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Antidepressants for chronic non-cancer pain in children and adolescents.
Topics: Abdominal Pain; Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Child; Chronic | 2017 |
Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Amines; Amitriptyline; Anticonvulsants; Child; Chronic Pain; Complex Regional Pain Syndr | 2017 |
Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.
Topics: Amines; Bias; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Pharmacotherapy for Neuropathic Pain in Japan.
Topics: Aged; Algorithms; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Cyclohexanecar | 2017 |
The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy.
Topics: Animals; Biomarkers; Depression; Diabetic Neuropathies; gamma-Aminobutyric Acid; H-Reflex; Humans; N | 2018 |
Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review.
Topics: Analgesics; Animals; Calcium Channels; Disease Models, Animal; Gabapentin; gamma-Aminobutyric Acid; | 2018 |
Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K
Topics: Central Nervous System; Chloride Channels; Chlorides; Epilepsy; gamma-Aminobutyric Acid; Gene Target | 2019 |
Implications and mechanism of action of gabapentin in neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2013 |
Treatment of painful peripheral neuropathy.
Topics: Analgesics; Antidepressive Agents; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Neural | 2013 |
Update on neuropathic pain treatment: ion channel blockers and gabapentinoids.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Human | 2013 |
Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Neoplasms; Neuralgia; Pregabalin | 2013 |
A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions.
Topics: Analgesics; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Epilepsies, Partial; Fibromyalg | 2014 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2014 |
Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
Topics: Anticonvulsants; Anxiety Disorders; Cost-Benefit Analysis; Economics, Pharmaceutical; Epilepsy; gamm | 2014 |
Managing difficult pain conditions in the cancer patient.
Topics: Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Cyclohexanec | 2014 |
Analgesia for the cirrhotic patient: a literature review and recommendations.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia; | 2014 |
A systematic review of pharmacoeconomic studies for pregabalin.
Topics: Amines; Analgesics; Anticonvulsants; Chronic Disease; Cost-Benefit Analysis; Cyclohexanecarboxylic A | 2015 |
Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis.
Topics: Amines; Analgesics; Anxiety; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Depression; Gaba | 2014 |
Nortriptyline for neuropathic pain in adults.
Topics: Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanecarbox | 2015 |
[DRUG THERAPY OF NEUROPATHIC PAIN BASED ON THE LATEST RECOMMENDATIONS].
Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, Opioid; Anticonvulsants; Antidepressive | 2015 |
Pregabalin and gabapentin for the treatment of sciatica.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2016 |
Gabapentin for Chronic Neuropathic Pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2015 |
Cell transplants to treat the "disease" of neuropathic pain and itch.
Topics: Animals; Cell Transplantation; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Neuralgia; Prurit | 2016 |
The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy.
Topics: Adult; Aged; Analgesics; Diabetic Neuropathies; Double-Blind Method; Female; gamma-Aminobutyric Acid | 2016 |
Pain management strategies for neuropathic pain in Fabry disease--a systematic review.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fabry Disease; Gabapentin; gamm | 2016 |
The Role of Regulatory Transporters in Neuropathic Pain.
Topics: Animals; Biogenic Monoamines; Chlorides; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Membrane Tr | 2016 |
Combined approaches for the relief of spinal cord injury-induced neuropathic pain.
Topics: Acupuncture Therapy; Chronic Pain; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain Management; Spin | 2016 |
Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights.
Topics: Analgesics; Animals; Antidepressive Agents; gamma-Aminobutyric Acid; Humans; Neuralgia | 2016 |
Continuous neuropathic pain secondary to endoscopic procedures: report of two cases and review of the literature.
Topics: Adult; Amines; Analgesics; Clonazepam; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; GABA | 2016 |
Does Duration of Neuropathic Pain Impact the Effectiveness of Pregabalin?
Topics: Aged; Analgesics; Diabetic Neuropathies; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2017 |
An update on the pharmacologic management and treatment of neuropathic pain.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cannabinoids; Cyclohexanec | 2017 |
Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials.
Topics: Amines; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Low | 2016 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
[Chronic intrathecal drug administration for the control of intractable pain].
Topics: Amines; Analgesics, Opioid; Anesthetics, Local; Baclofen; Calcium Channel Blockers; Clonidine; Cyclo | 2008 |
Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gamma-Aminobut | 2008 |
Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury.
Topics: Amines; Analgesics; Animals; Brain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid | 2008 |
Possible heart failure exacerbation associated with pregabalin: case discussion and literature review.
Topics: Aged; Analgesics; Female; gamma-Aminobutyric Acid; Heart Failure; Humans; Male; Middle Aged; Neuralg | 2008 |
Pregabalin for neuropathic pain based on recent clinical trials.
Topics: Analgesics; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Neuralgia; Pregabalin; Treatm | 2006 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
Treatment of neuropathic pain: an overview of recent guidelines.
Topics: Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Canada; Cyclohexa | 2009 |
[The mechanism and control of neuropathic pain].
Topics: Brain-Derived Neurotrophic Factor; Chlorine; gamma-Aminobutyric Acid; Humans; Interferon-gamma; Ion | 2009 |
A treatment algorithm for neuropathic pain: an update.
Topics: Algorithms; Analgesics; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain M | 2009 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
Topics: Acetamides; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Antidepressive Agents; Cyclo | 2010 |
The anti-allodynic alpha(2)delta ligand pregabalin inhibits the trafficking of the calcium channel alpha(2)delta-1 subunit to presynaptic terminals in vivo.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2010 |
[Pharmacology profile and clinical findings of pregabalin (Lyrica capsule)].
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Herpes Zoster; Humans; Mice; Neuralgia; Pain, Postoper | 2010 |
Pregabalin for the treatment of postsurgical pain.
Topics: Acute Disease; Analgesics; Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; ga | 2010 |
Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies.
Topics: Adolescent; Adult; Age Factors; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Mid | 2010 |
Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review.
Topics: Analgesics; Anesthetics, Local; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Humans; Lidocaine | 2010 |
GABA and central neuropathic pain following spinal cord injury.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Interneurons; Neuralgia; Neuroglia; Posterior Horn Cells; | 2011 |
The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.
Topics: Analgesics; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Neuralgia; Outcome Assessmen | 2011 |
WITHDRAWN: Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; ga | 2011 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2011 |
[Neuropathic pain in oncology. Novel evidence for clinical practice].
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2011 |
The adverse event profile of pregabalin across different disorders: a meta-analysis.
Topics: Adolescent; Analgesics; Anxiety Disorders; Double-Blind Method; Epilepsies, Partial; Fibromyalgia; g | 2012 |
Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action.
Topics: Animals; Chronic Pain; Electric Stimulation Therapy; gamma-Aminobutyric Acid; Mice; Mice, Transgenic | 2012 |
Use of gabapentin and pregabalin for hand surgery patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hand; Humans; | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Topics: Acetaminophen; Adult; Amines; Analgesics; Antidepressive Agents, Tricyclic; Benzodiazepinones; Cyclo | 2012 |
ADMET considerations for restless leg syndrome drug treatments.
Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; D | 2012 |
Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
Topics: Analgesics; Asian People; Diabetic Neuropathies; Dose-Response Relationship, Drug; gamma-Aminobutyri | 2012 |
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvu | 2003 |
Treatment and prevention of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2003 |
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
The use of gabapentin for the treatment of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Interactio | 2003 |
Gabapentin: in postherpetic neuralgia.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes | 2003 |
Gabapentin: a viewpoint by Brett R. Stacey.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes Zoster; H | 2003 |
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Acupuncture Analgesia; Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Anti-Infla | 2004 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Adrenal Cortex Hormones; Adult; Amines; Amitriptyline; Analgesics, Non-Nar | 2003 |
Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dizziness; Dose-Response Relationship, Drug; | 2004 |
Tolerability of treatments for postherpetic neuralgia.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; | 2004 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Amines; Antidepressive Agents, Tricyclic; Antiviral Agents; Arabinofuranos | 2004 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
Pregabalin: a new agent for the treatment of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Anxiety Agents; Anticonvulsants; Diabetic Neuropathies; Fibr | 2005 |
How modeling and simulation have enhanced decision making in new drug development.
Topics: Alzheimer Disease; Amines; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III a | 2005 |
Pregabalin: a new neuromodulator with broad therapeutic indications.
Topics: Agoraphobia; Anxiety; Diabetic Neuropathies; Epilepsy; gamma-Aminobutyric Acid; Herpesviridae Infect | 2005 |
Pregabalin for the treatment of painful neuropathy.
Topics: Analgesics; Clinical Trials as Topic; gamma-Aminobutyric Acid; Humans; Neuralgia; Peripheral Nervous | 2006 |
Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2006 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Topics: Analgesics; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Drug Interactions; Epileps | 2007 |
Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Cerebellar Ataxia; Cyclo | 2007 |
Antiepileptic drugs in the treatment of neuropathic pain.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gamma-Ami | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Forecasting; Gabapen | 2007 |
Treatment of painful neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gaba | 2007 |
Pregabalin in the management of central neuropathic pain.
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Humans; Multiple Sclerosis; Neuralgia; Pregabalin; Ris | 2007 |
[Function of spinal GABA receptor and its modulation].
Topics: Anesthetics, Intravenous; Animals; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Neuralgia; Patc | 2007 |
[Alpha2-adrenergic receptors in the dorsal horn of the spinal cord--their function and the descending inhibitory systems].
Topics: Acetylcholine; Adrenergic alpha-2 Receptor Agonists; Amines; Analgesics; Animals; Brain-Derived Neur | 2007 |
Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.
Topics: Analgesics; Diabetic Neuropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 2008 |
Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma | 2008 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Nonepileptic uses of gabapentin.
Topics: Acetates; Amines; Analgesics; Antimanic Agents; Antiparkinson Agents; Bipolar Disorder; Clinical Tri | 1999 |
Gabapentin: a new tool in the treatment of neuropathic pain.
Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1999 |
Use of gabapentin in the treatment of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2000 |
[Gabapentin--yet another antiepileptic agent for the treatment of neuropathic pain?].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Clinical Trials as Topic; Controlled Clinical Trials | 2001 |
Gabapentin: a unique anti-epileptic agent.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Complex Part | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dose-Response R | 2001 |
[Gabapentin for therapy of neuropathic pain].
Topics: Acetates; Amines; Animals; Biological Availability; Brain; Clinical Trials as Topic; Cyclohexanecarb | 2001 |
Anticonvulsants for neuropathic pain and detoxification.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Acids; Gabapenti | 1998 |
77 trials available for gamma-aminobutyric acid and Neuralgia
| Article | Year |
|---|---|
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomise
Topics: Amitriptyline; Analgesics; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; Double-Blin | 2022 |
Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial.
Topics: Amines; Analgesics; Clonidine; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neur | 2023 |
A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability.
Topics: Analgesics; Cross-Over Studies; Diabetes Mellitus; Diabetic Neuropathies; gamma-Aminobutyric Acid; H | 2021 |
Modulation of mRNA Expression of IL-6 and mTORC1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study.
Topics: Analgesics; Cognitive Behavioral Therapy; Feasibility Studies; gamma-Aminobutyric Acid; Humans; Infa | 2021 |
Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bridged Bicyclo Compounds; Diabetic Neuropathies; Female | 2017 |
A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2016 |
Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study.
Topics: Aged; Aged, 80 and over; Amines; Confusion; Cyclohexanecarboxylic Acids; Disease-Free Survival; Dizz | 2018 |
Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study.
Topics: Aged; Analgesics, Opioid; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Neu | 2014 |
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study.
Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson | 2013 |
Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis.
Topics: Adult; Analgesics; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Neuralgia; Pa | 2013 |
Donepezil provides positive effects to patients treated with gabapentin for neuropathic pain: an exploratory study.
Topics: Adult; Aged; Algorithms; Amines; Analgesics; Cyclohexanecarboxylic Acids; Cyclohexanols; Donepezil; | 2014 |
Association between neuropathic pain, pregabalin treatment, and erectile dysfunction.
Topics: Adult; Analgesics; Coitus; Depression; Erectile Dysfunction; gamma-Aminobutyric Acid; Humans; Libido | 2014 |
Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combi | 2014 |
Gabapentin versus pregabalin in relieving early post-surgical neuropathic pain in patients after lumbar disc herniation surgery: a prospective clinical trial.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diskectomy; Female; Follow-Up Studies; | 2014 |
Therapeutic efficacy of pregabalin in patients with leg symptoms due to lumbar spinal stenosis.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Female; gamma-A | 2014 |
Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial.
Topics: Aged; Analgesics; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind | 2014 |
Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Topics: Adult; Aged; Analgesics; Bridged Bicyclo Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Dronabinol; Female; Gab | 2015 |
Comparison of gabapentin versus topiramate on clinically affected dogs with Chiari-like malformation and syringomyelia.
Topics: Amines; Analgesics; Animals; Arnold-Chiari Malformation; Cross-Over Studies; Cyclohexanecarboxylic A | 2015 |
Efficacy of pregabalin in neuropathic pain in paediatric oncological patients.
Topics: Adolescent; Analgesics; Antineoplastic Agents; Child; Female; Follow-Up Studies; gamma-Aminobutyric | 2009 |
Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies.
Topics: Adolescent; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Diphenhydram | 2009 |
Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Delayed-Action Preparations; Drug Therapy, Combination; | 2009 |
Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Multiple Sclero | 2009 |
Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy.
Topics: Adult; Aged; Analgesia; Analgesics; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; ga | 2010 |
Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy.
Topics: Adult; Aged; Analgesia; Analgesics; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; ga | 2010 |
Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy.
Topics: Adult; Aged; Analgesia; Analgesics; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; ga | 2010 |
Analgesic effects of a single preoperative dose of pregabalin after laparoscopic sleeve gastrectomy.
Topics: Adult; Aged; Analgesia; Analgesics; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; ga | 2010 |
Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
Topics: Administration, Oral; Aged; Amines; Analgesics; Antidepressive Agents, Tricyclic; Canada; Cross-Over | 2009 |
Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.
Topics: Adult; Aged; Analgesics; Evidence-Based Medicine; Female; Follow-Up Studies; gamma-Aminobutyric Acid | 2010 |
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Topics: Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Diabetic Neuropathies; Double-Blind Method; | 2010 |
Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Analgesics; Analysis of Variance; Double-Blind Method; Female; Follow-Up Studies; gamma-Amino | 2010 |
Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Cohort Studies; Drug Prescriptions; Dru | 2010 |
Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Double-Blind Method; Female; gamma-Aminobuty | 2010 |
A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Colombia; Dose-Response Relationship, Drug; Ecuador; Fem | 2010 |
The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy.
Topics: Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Fem | 2010 |
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.
Topics: Analgesics; Analysis of Variance; Drug Administration Schedule; Female; gamma-Aminobutyric Acid; Hum | 2011 |
Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain.
Topics: Analgesics; Anxiety; Depression; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain Measurement; Prega | 2011 |
Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Therapy, Combinat | 2011 |
A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Double- | 2012 |
Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2012 |
The pain quality response profile of pregabalin in the treatment of neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; Drug Administration Sc | 2012 |
Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
Topics: Adult; Aged; Analgesics; Antidepressive Agents; Duloxetine Hydrochloride; Female; gamma-Aminobutyric | 2012 |
Sensory and affective pain descriptors respond differentially to pharmacological interventions in neuropathic conditions.
Topics: Amines; Analgesics; Case-Control Studies; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2013 |
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Analgesics; Ethnicity; Female; gamma-Aminobutyric Acid; | 2013 |
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.
Topics: Adult; Aged; Amines; Analgesics; Antipruritics; Chi-Square Distribution; Cross-Over Studies; Cyclohe | 2012 |
A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetic Neuropathies; Dose-Response Relationship, Drug; | 2013 |
A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury.
Topics: Analgesics; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neuralg | 2013 |
[Neuropathy pain: tactic of treatment].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug The | 2012 |
Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.
Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response | 2002 |
Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 2003 |
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
Topics: Adult; Affect; Aged; Analgesics, Non-Narcotic; Dizziness; Double-Blind Method; Edema; Female; gamma- | 2003 |
Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fabry Disease; Ga | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, D | 2004 |
Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Disabili | 2004 |
A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2004 |
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Diabetic Neuropathies; Double-Blind Method | 2004 |
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Diabetic Neuropathies; Double-Blind Method | 2004 |
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Diabetic Neuropathies; Double-Blind Method | 2004 |
Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Diabetic Neuropathies; Double-Blind Method | 2004 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cross-Over Studies; Cyclohex | 2005 |
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Diabetic Neuropathies; Double-Blind Method; Female; | 2005 |
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Diabetic Neuropathies; Double-Blind Method; Female; | 2005 |
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Diabetic Neuropathies; Double-Blind Method; Female; | 2005 |
Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Diabetic Neuropathies; Double-Blind Method; Female; | 2005 |
Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2005 |
Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; | 2005 |
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.
Topics: Adult; Age Distribution; Aged; Amines; Analgesics; Cohort Studies; Cross-Sectional Studies; Cyclohex | 2007 |
[Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain].
Topics: Amines; Amitriptyline; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
Topics: Adult; Affect; Aged; Aged, 80 and over; Analgesics; Anxiety; Disability Evaluation; Dose-Response Re | 2006 |
[The tebantin use in the complex therapy of pain syndrome during the mixed forms of alcoholic polyneuropathy].
Topics: Alcoholic Neuropathy; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fe | 2006 |
Pregabalin in restless legs syndrome with and without neuropathic pain.
Topics: Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neuralgia; Patient Sat | 2007 |
Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Comb | 2007 |
Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study.
Topics: Aged; Analgesics; Diabetic Neuropathies; Double-Blind Method; Drug Administration Schedule; Female; | 2008 |
Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
Topics: Adolescent; Adult; Aged; Anxiety; Diabetic Neuropathies; Dizziness; Dose-Response Relationship, Drug | 2008 |
Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blin | 2008 |
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.
Topics: Analgesics; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Neuralgia; | 2008 |
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Central Nervous System Diseases; Cyclohexanecarboxyli | 1998 |
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic | 1998 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Bl | 2001 |
391 other studies available for gamma-aminobutyric acid and Neuralgia
| Article | Year |
|---|---|
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, | 2010 |
Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; GABA Plasma Membrane Transport Proteins; GABA | 2020 |
Spinal γ-Aminobutyric Acid Interneuron Plasticity Is Involved in the Reduced Analgesic Effects of Morphine on Neuropathic Pain.
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Interneurons; Morphine; Neuralgia; Rats; Spinal Cord | 2022 |
Repurposing cancer drugs identifies kenpaullone which ameliorates pathologic pain in preclinical models via normalization of inhibitory neurotransmission.
Topics: Action Potentials; Analgesics; Animals; Benzazepines; Cancer Pain; Catenins; Cells, Cultured; Delta | 2021 |
Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury.
Topics: Amines; Analgesics; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2023 |
Anti-neuropathic Pain Mechanistic Study on
Topics: Animals; gamma-Aminobutyric Acid; Male; Mice; Neuralgia; Oils, Volatile; Pregabalin; Receptors, Opio | 2023 |
Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model.
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Hyperalgesia; Mice; Monoamine Oxidase Inhibitors; Neur | 2022 |
Hippocampal Inhibitory Synapsis Deficits Induced by α5-Containing GABA
Topics: Animals; Chromosome Pairing; Cognitive Dysfunction; gamma-Aminobutyric Acid; Hippocampus; Neuralgia; | 2022 |
Proteomic and metabolomic approaches elucidate the molecular mechanism of emodin against neuropathic pain through modulating the gamma-aminobutyric acid (GABA)-ergic pathway and PI3K/AKT/NF-κB pathway.
Topics: Animals; Emodin; gamma-Aminobutyric Acid; Neuralgia; NF-kappa B; Phosphatidylinositol 3-Kinases; Pro | 2023 |
Abuse and addiction in gabapentinoid drug users for neuropathic pain.
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Drug Users; Female; Gabapentin; gamma-Aminobutyric | 2023 |
Characterization of the sensory, affective, cognitive, biochemical, and neuronal alterations in a modified chronic constriction injury model of neuropathic pain in mice.
Topics: Animals; Aspartic Acid; Behavior, Animal; Brain; Cognition; gamma-Aminobutyric Acid; Male; Mice; Neu | 2020 |
Burst and Tonic Spinal Cord Stimulation Both Activate Spinal GABAergic Mechanisms to Attenuate Pain in a Rat Model of Chronic Neuropathic Pain.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Ligation; Male; Neuralgia; Rats; Rats, Spr | 2020 |
Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy.
Topics: Animals; Astrocytes; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Humans; Interleuki | 2019 |
Dopaminergic Modulation of Orofacial Mechanical Hypersensitivity Induced by Infraorbital Nerve Injury.
Topics: Animals; Cranial Nerves; Dopamine; Extracellular Signal-Regulated MAP Kinases; Facial Nerve Injuries | 2020 |
Potentiation of spinal GABA inhibition as a therapeutic target for chronic neuropathic pain: from transplantation to physical exercise.
Topics: Exercise; gamma-Aminobutyric Acid; Humans; Hyperalgesia; Neural Inhibition; Neuralgia; Spinal Cord | 2020 |
Transplantation of GABAergic precursors into the spinal cord to alleviate neuropathic pain.
Topics: gamma-Aminobutyric Acid; Humans; Neuralgia; Pain; Spinal Cord | 2020 |
Parabrachial nucleus circuit governs neuropathic pain-like behavior.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; | 2020 |
A subset of spinal dorsal horn interneurons crucial for gating touch-evoked pain-like behavior.
Topics: Animals; gamma-Aminobutyric Acid; Hyperalgesia; Interneurons; Male; Mechanoreceptors; Neuralgia; Noc | 2021 |
2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors.
Topics: Amino Acid Sequence; Animals; Anxiety; Behavior, Animal; Chlorocebus aethiops; Cognition; COS Cells; | 2021 |
Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neuralgia | 2021 |
Stereological Study of Changes of GABA-Immunoreactive Neurons in Spinal Dorsal Horn of SNI Rats.
Topics: Animals; Body Weight; GABAergic Neurons; gamma-Aminobutyric Acid; Immune System; Male; Neuralgia; Ne | 2021 |
Novel Functionalized Amino Acids as Inhibitors of GABA Transporters with Analgesic Activity.
Topics: Amino Acids; Analgesics; Animals; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; | 2021 |
[
Topics: Amines; Animals; Autoradiography; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R | 2017 |
Neuropathic pain-induced enhancement of spontaneous and pain-evoked neuronal activity in the periaqueductal gray that is attenuated by gabapentin.
Topics: Action Potentials; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amino | 2017 |
Gabapentin-induced aquagenic wrinkling of the palms.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hand De | 2017 |
In vivo evaluation of the hippocampal glutamate, GABA and the BDNF levels associated with spatial memory performance in a rodent model of neuropathic pain.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Chromatography, High Pressure Liqu | 2017 |
Murine model and mechanisms of treatment-induced painful diabetic neuropathy.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Disease Models, Animal; Enzyme | 2017 |
ANTI-NOCICEPTIVE EFFECT OF AGRIMONIA EUPATORIA EXTRACT ON A CISPLATIN-INDUCED NEUROPATHIC MODEL.
Topics: Agrimonia; Amines; Analgesics; Animals; Cisplatin; Cyclohexanecarboxylic Acids; Foot; Gabapentin; ga | 2016 |
Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster.
Topics: Aged; Aged, 80 and over; Amines; Anesthetics, Local; Cyclohexanecarboxylic Acids; Duloxetine Hydroch | 2017 |
Radiologic Findings in Gabapentin-Induced Myositis.
Topics: Adult; Amines; Analgesics; Biomarkers; Computed Tomography Angiography; Contrast Media; Cyclohexanec | 2017 |
Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer.
Topics: Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Chronic Pain; Cyclohex | 2017 |
Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice.
Topics: Amines; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Follow-Up Studies; | 2017 |
Investigation of spinal nerve ligation-mediated functional activation of the rat brain using manganese-enhanced MRI.
Topics: Amines; Animals; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Amino | 2018 |
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Drug Approval; Drug Utilization; Gaba | 2017 |
Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma-Aminobutyric | 2017 |
Gabapentin and its salicylaldehyde derivative alleviate allodynia and hypoalgesia in a cisplatin-induced neuropathic pain model.
Topics: Aldehydes; Amines; Animals; Cisplatin; Cyclohexanecarboxylic Acids; Drug Interactions; Female; Gabap | 2017 |
Effects of S 38093, an antagonist/inverse agonist of histamine H3 receptors, in models of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin; gamma- | 2018 |
A neuropathic pain syndrome associated with hantavirus infection.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanecarboxylic Acids; Gab | 2017 |
The flavonoid 6-methoxyflavone allays cisplatin-induced neuropathic allodynia and hypoalgesia.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Behavior, Animal; Cisplatin; Cyclohexanecarboxyl | 2017 |
The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.
Topics: Amines; Analgesics; Animals; Benzodioxoles; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 2017 |
Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study).
Topics: Amines; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Data Collection; Ga | 2018 |
The relationship between thalamic GABA content and resting cortical rhythm in neuropathic pain.
Topics: Adult; Aged; Brain Mapping; Brain Waves; Cerebral Cortex; Electroencephalography; Female; gamma-Amin | 2018 |
Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Blood Pressure; Cyclohexanecarboxylic Acids; Dis | 2018 |
Efficacy and safety of combined low doses of either diclofenac or celecoxib with gabapentin versus their single high dose in treatment of neuropathic pain in rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; D | 2018 |
The Role of Ventral Tegmental Area Gamma-Aminobutyric Acid in Chronic Neuropathic Pain after Spinal Cord Injury in Rats.
Topics: Animals; Chronic Pain; gamma-Aminobutyric Acid; Male; Neuralgia; Rats; Rats, Sprague-Dawley; Spinal | 2018 |
Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Animals, Newborn; Astrocytes; Cyclohexanecarboxy | 2018 |
Blockade of α2-adrenergic or metabotropic glutamate receptors induces glutamate release in the locus coeruleus to activate descending inhibition in rats with chronic neuropathic hypersensitivity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; GABA Antagonists; gamma-Aminobutyric Acid; Glutami | 2018 |
NMDA Receptor Activation Underlies the Loss of Spinal Dorsal Horn Neurons and the Transition to Persistent Pain after Peripheral Nerve Injury.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Chronic Pain; Down-Regulation; gamma- | 2018 |
[Effects of HCN2 in the development of peripheral neuropathic pain in rats].
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; | 2017 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Biomarkers; Cluster Analysis; Computer Simulation; Diabe | 2018 |
Tropomyosin Receptor Kinase B Receptor Activation in the Locus Coeruleus Restores Impairment of Endogenous Analgesia at a Late Stage Following Nerve Injury in Rats.
Topics: Analgesics; Animals; Disease Models, Animal; Flavones; gamma-Aminobutyric Acid; Glutamic Acid; Hyper | 2019 |
Neurochemical effects of motor cortex stimulation in the periaqueductal gray during neuropathic pain.
Topics: Analgesia; Animals; Bicuculline; Deep Brain Stimulation; Efferent Pathways; GABA Antagonists; gamma- | 2019 |
Peripheral nerve injury in rats induces alternations in choice behavior associated with food reinforcement.
Topics: Animals; Choice Behavior; Disease Models, Animal; Food; gamma-Aminobutyric Acid; Hyperalgesia; Ligat | 2019 |
Nerve injury drives a heightened state of vigilance and neuropathic sensitization in
Topics: Animals; Arousal; Biomarkers; Cell Death; Drosophila; GABAergic Neurons; gamma-Aminobutyric Acid; Hy | 2019 |
Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Topics: Aged; Analgesics; Belgium; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationship, D | 2013 |
The antinociceptive effect of reversible monoamine oxidase-A inhibitors in a mouse neuropathic pain model.
Topics: Analgesics; Analysis of Variance; Animals; Anisoles; Disease Models, Animal; Dose-Response Relations | 2013 |
Systemic pregabalin attenuates facial hypersensitivity and noxious stimulus-evoked release of glutamate in medullary dorsal horn in a rodent model of trigeminal neuropathic pain.
Topics: Analgesics; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Data Interpretation | 2013 |
Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain.
Topics: Amines; Analgesics; Anesthesia; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarb | 2013 |
Topical medications for the effective management of neuropathic orofacial pain.
Topics: Administration, Topical; Amines; Analgesics, Non-Narcotic; Anesthetics, Local; Anti-Inflammatory Age | 2013 |
Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Topics: Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Femal | 2013 |
Treatment of neuropathic pain in acute intermittent porphyria with gabapentin.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2013 |
A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain.
Topics: Animals; Behavior, Animal; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2013 |
Neuropathic abuses.
Topics: Analgesics; Drug Industry; gamma-Aminobutyric Acid; Humans; Low Back Pain; Medicalization; Neuralgia | 2013 |
Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment.
Topics: Analgesics; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Epilepsy; Female; gamma-Aminobu | 2014 |
Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain.
Topics: 3T3-L1 Cells; Analgesics; Animals; Antioxidants; Cell Death; Diabetes Mellitus, Experimental; Diabet | 2013 |
Gabapentin-induced pharmacodynamic effects in the spinal nerve ligation model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2014 |
Effect of antioxidant treatment on spinal GABA neurons in a neuropathic pain model in the mouse.
Topics: Action Potentials; Animals; Antioxidants; Behavior, Animal; Cell Count; Cyclic N-Oxides; Dose-Respon | 2013 |
[Pregabalin (Lyrica)].
Topics: Analgesics; Animals; Calcium Channels; Chronic Pain; gamma-Aminobutyric Acid; Humans; Mice; Neuralgi | 2013 |
Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.
Topics: Adult; Aged; Analgesics; Disease Progression; Drug Therapy, Combination; Female; gamma-Aminobutyric | 2013 |
Effects of gabapentin on thermal sensitivity following spinal nerve ligation or spinal cord compression.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Conditioning, Operant; Cyclohexanecarboxylic Acids; D | 2013 |
[Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic | 2013 |
Neuropathic pain following sagittal split ramus osteotomy of the mandible: prevalence, risk factors, and clinical course.
Topics: Adult; Age Factors; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cohort Studies; Cyclo | 2013 |
[Lacosamide as an alternative in the treatment of post-surgery neuropathic pain in an allergic patient].
Topics: Acetamides; Adult; Amines; Analgesics; Anticonvulsants; Brachial Plexus Neuropathies; Contraindicati | 2013 |
Successful management of postoperative pain with pregabalin after thoracotomy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Intercostal Ner | 2014 |
Pregabalin alters nociceptive behavior and expression level of P2X3 receptor in the spinal dorsal horn in a rat model induced by chronic compression of the dorsal root ganglion.
Topics: Animals; Behavior, Animal; Blotting, Western; Fluorescent Antibody Technique; gamma-Aminobutyric Aci | 2013 |
Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats.
Topics: Administration, Oral; Amines; Analgesics; Animals; Cell Movement; Constriction, Pathologic; Cyclohex | 2013 |
The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice.
Topics: Amines; Analgesics; Animals; Antibodies; Chemokines; Cyclohexanecarboxylic Acids; Cyclooxygenase Inh | 2014 |
Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Health Care Costs; Humans; Male; Middle Ag | 2013 |
Spinal morphine but not ziconotide or gabapentin analgesia is affected by alternative splicing of voltage-gated calcium channel CaV2.2 pre-mRNA.
Topics: Alternative Splicing; Amines; Analgesia; Animals; Calcium Channels, N-Type; Cyclohexanecarboxylic Ac | 2013 |
The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclohexanes; Female; | 2013 |
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Topics: Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Cranial Nerve Injuries; Cyclohexanecarbox | 2014 |
Astrocytic activation in the anterior cingulate cortex is critical for sleep disorder under neuropathic pain.
Topics: Animals; Astrocytes; Cell Membrane; Cells, Cultured; Extracellular Space; GABA Plasma Membrane Trans | 2014 |
Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats.
Topics: Analgesics; Animals; Antineoplastic Agents; Calcitonin; Cold Temperature; gamma-Aminobutyric Acid; H | 2014 |
Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms.
Topics: Amines; Amino Acid Transport System X-AG; Animals; Astrocytes; Cyclohexanecarboxylic Acids; Disease | 2014 |
Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Chronic Pain; Drug Tolerance; Drug-Related Side Effects and Adverse | 2014 |
Gabapentin enhances the morphine anti-nociceptive effect in neuropathic pain via the interleukin-10-heme oxygenase-1 signalling pathway in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Heme | 2014 |
Pregabalin: cardiac adverse effects.
Topics: Aged; Analgesics; Female; gamma-Aminobutyric Acid; Heart Diseases; Humans; Male; Middle Aged; Neural | 2014 |
Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice.
Topics: 4-Butyrolactone; Analgesics; Animals; Antineoplastic Agents; gamma-Aminobutyric Acid; Hot Temperatur | 2014 |
Face-to-face comparison of the predictive validity of two models of neuropathic pain in the rat: analgesic activity of pregabalin, tramadol and duloxetine.
Topics: Analgesics; Animals; Cold Temperature; Disease Models, Animal; Duloxetine Hydrochloride; gamma-Amino | 2014 |
Silicon-containing GABA derivatives, silagaba compounds, as orally effective agents for treating neuropathic pain without central-nervous-system-related side effects.
Topics: Administration, Oral; Analgesics; Animals; Brain; Disease Models, Animal; Dose-Response Relationship | 2014 |
Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Female; Gabapentin; gamma-Amin | 2015 |
Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy.
Topics: Amines; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experim | 2014 |
Nummular headache in a patient with ipsilateral occipital neuralgia--a case report.
Topics: Amines; Analgesics; Anesthetics, Local; Bupivacaine; Comorbidity; Cyclohexanecarboxylic Acids; Femal | 2014 |
Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathi | 2014 |
Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy.
Topics: Amines; Analgesics; Animals; Biomarkers; Cyclohexanecarboxylic Acids; Dopamine; Gabapentin; gamma-Am | 2014 |
Antiallodynic action of 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), a betaine/GABA transporter inhibitor.
Topics: Animals; Betaine; CHO Cells; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; G | 2014 |
Menin regulates spinal glutamate-GABA balance through GAD65 contributing to neuropathic pain.
Topics: Animals; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Male; Mice; Mice, Inbred C | 2014 |
Novel use of perineural pregabalin infusion for analgesia in a rat neuropathic pain model.
Topics: Analgesics; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; gamma-Aminobutyric | 2014 |
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Benzoates; Chronic Pain; Conditioning, Psychological; Cyclohexanecarbox | 2014 |
Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2015 |
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
Topics: Administration, Oral; Amines; Analgesics; Animals; Biological Availability; Chemistry Techniques, Sy | 2014 |
Effect of histone deacetylase inhibitor JNJ-26481585 in pain.
Topics: Amines; Animals; Antineoplastic Agents; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; g | 2015 |
Agrin requires specific proteins to selectively activate γ-aminobutyric acid neurons for pain suppression.
Topics: Adenoviridae; Agrin; Animals; Disease Models, Animal; Excitatory Amino Acid Agonists; gamma-Aminobut | 2014 |
Nerve regenerative effects of GABA-B ligands in a model of neuropathic pain.
Topics: Animals; Baclofen; gamma-Aminobutyric Acid; Gene Expression; Humans; Hyperalgesia; Ligands; Myelin P | 2014 |
Transdermal administration of aqueous pregabalin solution as a potential treatment option for patients with neuropathic pain to avoid central nervous system-mediated side effects.
Topics: Administration, Cutaneous; Analgesics; Animals; Central Nervous System; Dizziness; Drug-Related Side | 2014 |
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Topics: Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cyclohexanecarboxyli | 2014 |
Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain.
Topics: Amines; Animals; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Fluorodeoxyglucose F18; | 2014 |
Curative effect research on curing intercostal neuralgia through paravertebral nerve block combined with pregabalin.
Topics: Adult; Aged; Combined Modality Therapy; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2014 |
Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report.
Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Mental Disorders; Neuralgia; Pregabalin; | 2014 |
Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2015 |
One-year follow-up for the therapeutic efficacy of pregabalin in patients with leg symptoms caused by lumbar spinal stenosis.
Topics: Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; Female; Follow | 2014 |
["Neuropathic backaches require different management"].
Topics: Analgesics; Back Pain; Combined Modality Therapy; Diagnosis, Differential; gamma-Aminobutyric Acid; | 2014 |
[Pregabalin improves pain and important comorbidities].
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Intervertebral Disc Degeneration; Nerve Compression Syn | 2014 |
Add-on treatment with pregabalin for patients with uncontrolled neuropathic pain who have been referred to pain clinics.
Topics: Adult; Aged; Analgesics; Cohort Studies; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; | 2014 |
[Interview with Prof. Dr. Ralf Baron. Pain: toward causality oriented therapy].
Topics: Analgesics; Cooperative Behavior; gamma-Aminobutyric Acid; General Practice; Humans; Interdisciplina | 2014 |
Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gaba | 2015 |
The role of the GABA-A receptor of the adjacent intact dorsal root ganglion neurons in rats with neuropathic pain.
Topics: Animals; Biophysics; Cell Size; Cells, Cultured; Disease Models, Animal; Electric Stimulation; GABA- | 2014 |
Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Drug Synergism; Drug Therapy, Combination; | 2015 |
Burst and Tonic Spinal Cord Stimulation Differentially Activate GABAergic Mechanisms to Attenuate Pain in a Rat Model of Cervical Radiculopathy.
Topics: Animals; Behavior, Animal; GABA Antagonists; gamma-Aminobutyric Acid; Hyperalgesia; Male; Neuralgia; | 2015 |
Comprehensive analysis of the GABAergic system gene expression profile in the anterior cingulate cortex of mice with Paclitaxel-induced neuropathic pain.
Topics: Animals; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; GABA Plasma Membra | 2015 |
Differences in cisplatin-induced mechanical allodynia in male and female mice.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Cisplatin; Cyclohexanecarboxylic Acids; Disease | 2015 |
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice.
Topics: Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; | 2015 |
Peripheral neuropathies: new recommendations for neuropathic pain pharmacotherapy.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Cyclohexanecarboxylic Acids; Gab | 2015 |
Increased expression of HCN2 channel protein in L4 dorsal root ganglion neurons following axotomy of L5- and inflammation of L4-spinal nerves in rats.
Topics: Amines; Animals; Axotomy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Excitatory Amino Acid | 2015 |
Blocking the GABA transporter GAT-1 ameliorates spinal GABAergic disinhibition and neuropathic pain induced by paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Disease Models, Animal; GABA Plasma M | 2015 |
Antiallodynic effect of tianeptine via modulation of the 5-HT7 receptor of GABAergic interneurons in the spinal cord of neuropathic rats.
Topics: Analgesics; Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hyperalges | 2015 |
Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice.
Topics: Amines; Analgesics; Animals; Cerebral Cortex; Cyclohexanecarboxylic Acids; Electroencephalography; G | 2015 |
Gabapentin alleviates affective pain after traumatic nerve injury.
Topics: Affect; Amines; Analgesics; Animals; Conditioning, Psychological; Cyclohexanecarboxylic Acids; Gabap | 2015 |
Pregabalin to treat ciguatera fish poisoning.
Topics: Aged; Analgesics; Animals; Ciguatera Poisoning; Female; Fishes; gamma-Aminobutyric Acid; Humans; Mid | 2015 |
Psychotic and depressive symptoms after gabapentin treatment.
Topics: Amines; Cyclohexanecarboxylic Acids; Depression; Excitatory Amino Acid Antagonists; Female; Gabapent | 2015 |
Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States.
Topics: Adult; Aged; Amines; Antidepressive Agents; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Dulo | 2015 |
Pregabalin is only partially effective for neuropathic pain.
Topics: Analgesics; Drug Industry; gamma-Aminobutyric Acid; Humans; Neuralgia; Patents as Topic; Pregabalin; | 2015 |
A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin.
Topics: Administration, Topical; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 2015 |
[The Analgesia of Oxymatrine Affecting Calcium Channel and GABA Release].
Topics: Alkaloids; Analgesia; Animals; Calcium; Calcium Channels; Disease Models, Animal; gamma-Aminobutyric | 2015 |
Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population?
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Prescriptions; Female; Gabapentin; gamma | 2015 |
Effect of a Novel, Orally Active Matrix Metalloproteinase-2 and -9 Inhibitor in Spinal and Trigeminal Rat Models of Neuropathic Pain.
Topics: Administration, Oral; Amines; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapent | 2015 |
Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model.
Topics: Amines; Analgesics; Animals; Carcinogenesis; Cells, Cultured; Cyclohexanecarboxylic Acids; Disease M | 2016 |
Treating Chiari-like malformation and syringomyelia in dogs.
Topics: Amines; Analgesics; Animals; Arnold-Chiari Malformation; Cyclohexanecarboxylic Acids; Dog Diseases; | 2015 |
Gabapentin attenuates neuropathic pain and improves nerve myelination after chronic sciatic constriction in rats.
Topics: Amines; Animals; Anticonvulsants; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids.
Topics: Amines; Animals; Cognition; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gabapent | 2015 |
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera | 2016 |
Peripheral Neuritis Trauma in Pigs: A Neuropathic Pain Model.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcitonin Gene-Re | 2016 |
Trigeminal neuropathic pain as a complication of anterior temporal lobectomy: report of 2 cases.
Topics: Amines; Analgesics; Anterior Temporal Lobectomy; Cyclohexanecarboxylic Acids; Drug Resistant Epileps | 2016 |
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.
Topics: Amines; Analgesics; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Data Interp | 2015 |
Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation.
Topics: Administration, Topical; Adult; Aged; Ambroxol; Amines; Anesthetics, Local; Cyclohexanecarboxylic Ac | 2015 |
Gabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α(2)δ-1 Subunit in Rats with Central Post-Stroke Pain Hypersensitivity.
Topics: Amines; Analgesics; Animals; Blotting, Western; Calcium Channels; Cyclohexanecarboxylic Acids; Disea | 2016 |
Antinociceptive Interaction of Tramadol with Gabapentin in Experimental Mononeuropathic Pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Rela | 2016 |
Auriculotemporal Neuralgia: Eight New Cases Report.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapentin; gamma | 2016 |
[Postmastectomy pain syndrome in our region: characteristics, treatment, and experience with gabapentin].
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans | 2016 |
Inhibition of the kinase WNK1/HSN2 ameliorates neuropathic pain by restoring GABA inhibition.
Topics: Animals; Disease Models, Animal; Exons; gamma-Aminobutyric Acid; Hyperalgesia; K Cl- Cotransporters; | 2016 |
Improvements in impaired GABA and GAD65/67 production in the spinal dorsal horn contribute to exercise-induced hypoalgesia in a mouse model of neuropathic pain.
Topics: Animals; Behavior, Animal; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate Decarboxylase; | 2016 |
Antinociceptive Interactions Between Meloxicam and Gabapentin in Neuropathic Pain Depend on the Ratio used in Combination in Rats.
Topics: Amines; Analgesics; Animals; Area Under Curve; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2016 |
Macular Edema after Gabapentin.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fluorescein Angiography; Gabapentin; gam | 2016 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico | 2016 |
Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain.
Topics: Animals; Chlorides; gamma-Aminobutyric Acid; Ganglia, Spinal; Homeostasis; Injections, Spinal; K Cl- | 2016 |
Reductions in tonic GABAergic current in substantia gelatinosa neurons and GABA
Topics: Animals; Constriction; Disease Models, Animal; gamma-Aminobutyric Acid; Lumbar Vertebrae; Mice; Neur | 2016 |
Medial plantar nerve ligation as a novel model of neuropathic pain in mice: pharmacological and molecular characterization.
Topics: Activating Transcription Factor 3; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease | 2016 |
Vitamin C enhances the analgesic effect of gabapentin on rats with neuropathic pain.
Topics: Amines; Analgesics; Animals; Ascorbic Acid; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapentin; | 2016 |
mir-500-Mediated GAD67 Downregulation Contributes to Neuropathic Pain.
Topics: Action Potentials; Animals; Antagomirs; Antineoplastic Agents, Phytogenic; Disease Models, Animal; D | 2016 |
The Antinociceptive Effects of Tramadol and/or Gabapentin on Rat Neuropathic Pain Induced by a Chronic Constriction Injury.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2016 |
Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drugs, Generic; Female; Gabapentin; gamma-Ami | 2018 |
Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain.
Topics: Amines; Animals; Behavior, Animal; Cathepsins; Cyclohexanecarboxylic Acids; Dipeptides; Disease Mode | 2016 |
Chronic pregabalin treatment decreases excitability of dentate gyrus and accelerates maturation of adult-born granule cells.
Topics: Aging; Animals; Calcium Channels; Cytoplasmic Granules; Dentate Gyrus; Epilepsy; gamma-Aminobutyric | 2017 |
Potential Contribution of Antioxidant Mechanism in the Defensive Effect of Lycopene Against Partial Sciatic Nerve Ligation Induced Behavioral, Biochemical and Histopathological Modification in Wistar Rats.
Topics: Amines; Animals; Antioxidants; Carotenoids; Catalase; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2016 |
Suppressed GABAergic signaling in the zona incerta causes neuropathic pain in a thoracic hemisection spinal cord injury rat model.
Topics: Action Potentials; Animals; Bicuculline; GABA Agonists; GABA-A Receptor Antagonists; gamma-Aminobuty | 2016 |
Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
Topics: Adult; Aged; Amines; Analgesics; Comoros; Cyclohexanecarboxylic Acids; Electronic Health Records; Fe | 2017 |
A rodent model of HIV protease inhibitor indinavir induced peripheral neuropathy.
Topics: Amines; Analgesics; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Cyclohexanec | 2017 |
Neuroprotective Effect of Genistein in Peripheral Nerve Injury.
Topics: Amines; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyr | 2017 |
6-Methoxyflavanone attenuates mechanical allodynia and vulvodynia in the streptozotocin-induced diabetic neuropathic pain.
Topics: Amines; Animals; Computer Simulation; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Female; Fl | 2016 |
Vendor-derived differences in injury-induced pain phenotype and pharmacology of Sprague-Dawley rats: Does it matter?
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Freund's Adjuvant; Gabapentin; gamma-Amino | 2017 |
Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model.
Topics: Administration, Topical; Amines; Analgesics; Animals; Constriction, Pathologic; Cyclohexanecarboxyli | 2017 |
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.
Topics: Amides; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapentin | 2017 |
Effects of pregabalin on spinal d-serine content and NMDA receptor-mediated synaptic transmission in mice with neuropathic pain.
Topics: Animals; Disease Models, Animal; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Male; | 2017 |
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Amines; Animals; Antineoplastic Agents; Constri | 2017 |
Formalin injection produces long-lasting hypersensitivity with characteristics of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Cyclohexanecarboxylic Acids; Female; Formaldehyd | 2017 |
Changing general medical practices in the management of neuropathic pain
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Duloxetine Hydrochloride; Female; Gabapentin; gamm | 2016 |
An Improved Rodent Model of Trigeminal Neuropathic Pain by Unilateral Chronic Constriction Injury of Distal Infraorbital Nerve.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Functional Lateral | 2017 |
Donepezil, an Acetylcholinesterase Inhibitor, Can Attenuate Gabapentinoid-Induced Somnolence in Patients with Neuropathic Pain: A Retrospective Chart Review.
Topics: Adult; Aged; Aged, 80 and over; Amines; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Diso | 2017 |
Neutrophils Infiltrate the Spinal Cord Parenchyma of Rats with Experimental Diabetic Neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2017 |
Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA).
Topics: Accidents, Traffic; Adult; Amines; Carbamazepine; Conjunctiva; Cyclohexanecarboxylic Acids; Facial P | 2008 |
Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin.
Topics: Amines; Analgesics; Animals; Anxiety; Cyclohexanecarboxylic Acids; Disease Models, Animal; Gabapenti | 2008 |
Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection.
Topics: Analgesics; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response R | 2008 |
Intrathecal clonidine suppresses phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Anticonvulsant | 2008 |
Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters.
Topics: Animals; Diabetes Mellitus, Experimental; gamma-Aminobutyric Acid; Hyperalgesia; Hyperesthesia; K Cl | 2008 |
Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin.
Topics: Animals; Brain Stem; gamma-Aminobutyric Acid; Long-Term Potentiation; Male; Neuralgia; Neurons; Preg | 2008 |
Diagnosis and treatment of glossopharyngeal and vagal neuropathies in a patient with laryngopharyngeal reflux.
Topics: gamma-Aminobutyric Acid; Gastroesophageal Reflux; Glossopharyngeal Nerve; Humans; Hypopharynx; Male; | 2008 |
Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain.
Topics: Amines; Analgesics; Animal Diseases; Animals; Anxiety; Behavior, Animal; Cyclohexanecarboxylic Acids | 2008 |
Efficacy and safety of pregabalin in neuropathic pain treatment: a still unreported adverse effect.
Topics: Adult; Analgesics; Bronchial Spasm; Female; gamma-Aminobutyric Acid; Humans; Hyperesthesia; Hypesthe | 2008 |
Improvement in psoriasis following treatment with gabapentin and pregabalin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; | 2008 |
Rash associated with pregabalin use.
Topics: Administration, Oral; Adult; Analgesics; Anti-Allergic Agents; Diphenhydramine; Drug Eruptions; Fema | 2008 |
[Gabapentin for neurophatic pain in children: a case report].
Topics: Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gaba | 2008 |
Gabapentin acts within the locus coeruleus to alleviate neuropathic pain.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Locus Coeruleus; | 2008 |
Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug-Related Side Effects and Adverse | 2008 |
Expert opinion. Supraorbital neuralgia.
Topics: Analgesics; gamma-Aminobutyric Acid; Head Injuries, Closed; Humans; Male; Middle Aged; Migraine Diso | 2009 |
Protective effects of gabapentin on allodynia and alpha 2 delta 1-subunit of voltage-dependent calcium channel in spinal nerve-ligated rats.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2009 |
The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin.
Topics: Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Calcium Channels; Calcium Channels | 2009 |
Gabapentin versus tricyclics for neuropathic pain.
Topics: Amines; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyri | 2009 |
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Synergism; Gabapent | 2009 |
Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure.
Topics: Adult; Analgesics; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Humans; Kidney | 2009 |
Clinical feasibility for cell therapy using human neuronal cell line to treat neuropathic behavioral hypersensitivity following spinal cord injury in rats.
Topics: Animals; Behavior, Animal; Cell Line; Cell- and Tissue-Based Therapy; Excitatory Amino Acid Agonists | 2009 |
Gabapentin-induced delirium and dependence.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am | 2009 |
Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin.
Topics: Acetaminophen; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 2009 |
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan; | 2009 |
Neuropathic pain treatment: a further step forward.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Effects of a Medicaid prior authorization policy for pregabalin.
Topics: Adult; Analgesics; Diabetic Neuropathies; Fee-for-Service Plans; Female; gamma-Aminobutyric Acid; Ga | 2009 |
Synthesis and in vivo evaluation of bicyclic gababutins.
Topics: Amines; Amino Acids; Animals; Blood-Brain Barrier; Bridged Bicyclo Compounds; CHO Cells; Cricetinae; | 2010 |
Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury.
Topics: Animals; Apoptosis; Caspase 3; Cell Count; Disease Models, Animal; Down-Regulation; GABA Agonists; G | 2010 |
[Pregabalin--profile of efficacy and tolerability in neuropathic pain].
Topics: Analgesics; Diabetic Neuropathies; gamma-Aminobutyric Acid; Humans; Neuralgia; Neuralgia, Postherpet | 2009 |
Treatments for neuropathic pain differentially affect delayed matching accuracy by macaques: effects of amitriptyline and gabapentin.
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Animals; Cyclohexanecarboxylic Acids; D | 2010 |
Chemical composition and evaluation of the anti-hypernociceptive effect of the essential oil extracted from the leaves of Ugni myricoides on inflammatory and neuropathic models of pain in mice.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Bicyclic Monoterpenes; Carr | 2010 |
Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Health Status; Humans; Middle Aged; Multic | 2010 |
Treatment of post-burn neuropathic pain: evaluation of pregablin.
Topics: Analgesics; Burns; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Humans; Male; | 2010 |
Reporting of trials of gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2010 |
Why pregabalin?
Topics: Analgesics; Cost-Benefit Analysis; gamma-Aminobutyric Acid; Humans; Neuralgia; Practice Guidelines a | 2010 |
A tropomyosine receptor kinase inhibitor blocks spinal neuroplasticity essential for the anti-hypersensitivity effects of gabapentin and clonidine in rats with peripheral nerve injury.
Topics: Acetylcholine; Amines; Analgesics; Animals; Carbazoles; Choline O-Acetyltransferase; Clonidine; Cycl | 2011 |
[Neuropathic pain in children].
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive A | 2010 |
A case of unilateral burning mouth syndrome of neuropathic origin.
Topics: Aged; Analgesics; Anesthesia, Dental; Biopsy; Burning Mouth Syndrome; gamma-Aminobutyric Acid; Human | 2011 |
Intrathecal gabapentin and clonidine synergistically inhibit allodynia in spinal nerve-ligated rats.
Topics: Amines; Animals; Clonidine; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relat | 2010 |
Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.
Topics: Amines; Analgesics; Animals; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Disease Models, | 2010 |
A novel rat forelimb model of neuropathic pain produced by partial injury of the median and ulnar nerves.
Topics: Amines; Analgesics; Animals; Behavior, Animal; CD11b Antigen; Cold Temperature; Cyclohexanecarboxyli | 2011 |
GABAergic pathway in a rat model of chronic neuropathic pain: modulation after intrathecal transplantation of a human neuronal cell line.
Topics: Animals; Cell Line; Chronic Disease; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate Deca | 2011 |
Compression of the superficial branch of the radial nerve by calcinosis cutis causing neuropathic pain.
Topics: Analgesics; Calcinosis; Cyclooxygenase 2 Inhibitors; Etoricoxib; gamma-Aminobutyric Acid; Humans; Ma | 2010 |
Agrin downregulation induced by nerve injury contributes to neuropathic pain.
Topics: Agrin; Analysis of Variance; Animals; Blotting, Western; Down-Regulation; gamma-Aminobutyric Acid; I | 2010 |
Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain.
Topics: Amines; Animals; Calcium Channels; Circadian Rhythm; Cyclohexanecarboxylic Acids; Disease Models, An | 2010 |
Effects of gabapentin on brain hyperactivity related to pain and sleep disturbance under a neuropathic pain-like state using fMRI and brain wave analysis.
Topics: Amines; Analgesics; Animals; Axotomy; Brain; Brain Mapping; Brain Waves; Cyclohexanecarboxylic Acids | 2011 |
Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2011 |
A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
Topics: Adult; Aged; Analgesics; Cost of Illness; Costs and Cost Analysis; Female; gamma-Aminobutyric Acid; | 2011 |
Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release.
Topics: Analysis of Variance; Animals; Bicuculline; Cyclic N-Oxides; Disease Models, Animal; Dose-Response R | 2011 |
Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Topics: Adolescent; Adult; Analgesics; Cohort Studies; Diabetic Neuropathies; Duloxetine Hydrochloride; Fema | 2011 |
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Child; Child, Preschool; | 2011 |
Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Child; Cohort Studies; Data Collection; Dose | 2011 |
[Pitfalls in the treatment of neuropathic pain in patients with cancer].
Topics: Aged; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2011 |
Attenuating effect of hydroalcoholic extract of Acorus calamus in vincristine-induced painful neuropathy in rats.
Topics: Acorus; Animals; Calcium; Female; gamma-Aminobutyric Acid; Male; Neuralgia; Peroxidase; Plant Extrac | 2011 |
Attenuating effect of Acorus calamus extract in chronic constriction injury induced neuropathic pain in rats: an evidence of anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory effects.
Topics: Acorus; Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Behavior, Animal; Calcium; Cons | 2011 |
Differential GABAergic disinhibition during the development of painful peripheral neuropathy.
Topics: Animals; Cell Count; Disease Progression; gamma-Aminobutyric Acid; K Cl- Cotransporters; Male; Neura | 2011 |
GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain.
Topics: Analgesics, Opioid; Animals; gamma-Aminobutyric Acid; Inhibitory Postsynaptic Potentials; Male; Mini | 2011 |
Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; gamma-Am | 2011 |
Possible heart failure associated with pregabalin use: case report.
Topics: Amines; Analgesics; Back Pain; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Edema; Female; | 2011 |
Pregabalin-induced hepatotoxicity.
Topics: Analgesics; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; gamma-Aminobut | 2011 |
Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Dopamine Uptake Inhibitors; Duloxetine Hydrochloride; Fe | 2011 |
Pregabalin assay in a patient with widespread neuropathic pain and late onset gluten intolerance.
Topics: Adult; Analgesics; Animals; Celiac Disease; gamma-Aminobutyric Acid; Humans; Male; Neuralgia; Pregab | 2011 |
Beneficial response to gabapentin portraying with interval change of brain SPECT imaging in a case with failed back surgery syndrome.
Topics: Adult; Amines; Analgesics; Cerebral Cortex; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids | 2011 |
Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2011 |
Pulsed radiofrequency modulation for lingual neuralgia.
Topics: Amines; Carbamazepine; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Excitatory Amino Acid An | 2012 |
Reversible post-pregabalin peripheral edema in a spinal cord injury patient.
Topics: Adult; Analgesics; Edema; gamma-Aminobutyric Acid; Humans; Lower Extremity; Male; Neuralgia; Paraple | 2012 |
Pregabalin modulation of spinal and brainstem visceral nociceptive processing.
Topics: Afferent Pathways; Analgesics; Animals; Brain Stem; Disease Models, Animal; gamma-Aminobutyric Acid; | 2011 |
Manual acupuncture inhibits mechanical hypersensitivity induced by spinal nerve ligation in rats.
Topics: Acupuncture Points; Acupuncture Therapy; Amines; Analgesics; Analysis of Variance; Animals; Cyclohex | 2011 |
Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.
Topics: Aged; Analgesia; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Motor Activ | 2011 |
Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
Topics: Amines; Amitriptyline; Analgesics; Animals; Benzoxazines; Chronic Disease; Constriction; Cyclohexane | 2011 |
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans; | 2011 |
A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
Topics: Analgesics; Cost-Benefit Analysis; Female; gamma-Aminobutyric Acid; Humans; Male; Neuralgia; Pain, I | 2012 |
Decreased intracellular GABA levels contribute to spinal cord stimulation-induced analgesia in rats suffering from painful peripheral neuropathy: the role of KCC2 and GABA(A) receptor-mediated inhibition.
Topics: Analgesia; Animals; Chronic Pain; Disease Models, Animal; Electric Stimulation Therapy; gamma-Aminob | 2012 |
Biphasic effects of chronic intrathecal gabapentin administration on the expression of protein kinase C gamma in the spinal cord of neuropathic pain rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dizocilpine Maleate; Gabapentin; gamma-Ami | 2011 |
Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states.
Topics: Animals; Behavior, Animal; Blotting, Western; Calcium Channels; Calcium Channels, L-Type; Central Ne | 2012 |
Antinociceptive effect of Butea monosperma on vincristine-induced neuropathic pain model in rats.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Behavior, Animal; Butea; Calci | 2013 |
[Medical treatment including pregabalin and radiation therapy provided remarkable relief for neuropathic pain by brachial plexus invasion in a patient with esophageal cancer].
Topics: Analgesics; Brachial Plexus; Esophageal Neoplasms; gamma-Aminobutyric Acid; Humans; Magnetic Resonan | 2012 |
Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs.
Topics: Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Disease Models, Animal; | 2012 |
Analgesic effect of gabapentin in a rat model for chronic constrictive injury.
Topics: Amines; Analgesics; Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 2; | 2011 |
The combined predictive capacity of rat models of algogen-induced and neuropathic hypersensitivity to clinically used analgesics varies with nociceptive endpoint and consideration of locomotor function.
Topics: Amines; Analgesics; Animals; Capsaicin; Cyclohexanecarboxylic Acids; Disease Models, Animal; Duloxet | 2012 |
[Retrospective evaluation of pregabalin for cancer-related neuropathic pain].
Topics: Aged; Analgesics; Disorders of Excessive Somnolence; Female; gamma-Aminobutyric Acid; Humans; Male; | 2012 |
The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model.
Topics: Administration, Oral; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Cyclohexanecarb | 2012 |
Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model.
Topics: Amines; Analgesics; Animals; Calcium Channels; CD11b Antigen; Cyclohexanecarboxylic Acids; Disease M | 2012 |
[Lyrical tragedy].
Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Neuralgia; Pregabalin; Risk Factors; S | 2012 |
Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2012 |
Evaluation of aqueous and ethanolic extracts of saffron, Crocus sativus L., and its constituents, safranal and crocin in allodynia and hyperalgesia induced by chronic constriction injury model of neuropathic pain in rats.
Topics: Acetone; Amines; Analgesics; Animals; Behavior, Animal; Carotenoids; Constriction; Crocus; Cyclohexa | 2012 |
A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
Topics: Adult; Aged; Analgesics; Cost-Benefit Analysis; Female; gamma-Aminobutyric Acid; Health Care Costs; | 2012 |
Study of emotional and cognitive impairments in mononeuropathic rats: effect of duloxetine and gabapentin.
Topics: Affective Symptoms; Amines; Analgesics; Animals; Antidepressive Agents; Cognition; Cognition Disorde | 2012 |
A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.
Topics: Analgesics; Clinical Trials as Topic; Cost-Benefit Analysis; gamma-Aminobutyric Acid; Health Service | 2012 |
[About the neuropathic component of back pain].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chroni | 2012 |
The immunomodulatory effect of pregabalin on spleen cells in neuropathic mice.
Topics: Animals; Cell Proliferation; gamma-Aminobutyric Acid; Immunologic Factors; Male; Mice; Mice, Inbred | 2012 |
GABA, but not opioids, mediates the anti-hyperalgesic effects of 5-HT7 receptor activation in rats suffering from neuropathic pain.
Topics: Analgesics, Opioid; Animals; gamma-Aminobutyric Acid; Hyperalgesia; Immersion; Immunohistochemistry; | 2012 |
Neuropathic truncal pain--a case series.
Topics: Abdominal Pain; Adolescent; Adult; Amines; Analgesics; Anesthetics, Local; Antidepressive Agents; Ch | 2012 |
Asymmetric time-dependent activation of right central amygdala neurones in rats with peripheral neuropathy and pregabalin modulation.
Topics: Amygdala; Animals; Evoked Potentials; gamma-Aminobutyric Acid; Male; Neuralgia; Neuronal Plasticity; | 2012 |
Substance misuse of gabapentin.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2012 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |
Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain.
Topics: Analgesics; Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug S | 2012 |
Patterns of nerve injury and neuropathic pain in ischemic neuropathy after ligation-reperfusion of femoral artery in mice.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Femoral Artery; Gaba | 2012 |
Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia.
Topics: 2-Aminopurine; Amines; Analgesics; Antiviral Agents; Comorbidity; Cyclohexanecarboxylic Acids; Famci | 2012 |
The effect of intrathecal gabapentin on neuropathic pain is independent of the integrity of the dorsolateral funiculus in rats.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Injec | 2012 |
Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats.
Topics: Administration, Topical; Analysis of Variance; Animals; Diclofenac; Facial Pain; gamma-Aminobutyric | 2012 |
Long-term outcome of Cavalier King Charles spaniel dogs with clinical signs associated with Chiari-like malformation and syringomyelia.
Topics: Amines; Analgesics; Animals; Arnold-Chiari Malformation; Breeding; Carbazoles; Cohort Studies; Cyclo | 2012 |
Pre- and post-synaptic switches of GABA actions associated with Cl- homeostatic changes are induced in the spinal nucleus of the trigeminal nerve in a rat model of trigeminal neuropathic pain.
Topics: Animals; Chlorides; Disease Models, Animal; gamma-Aminobutyric Acid; HEK293 Cells; Homeostasis; Huma | 2013 |
Peripheral edema with pregabalin.
Topics: Aged; Analgesics; Diagnosis, Differential; Edema; Female; gamma-Aminobutyric Acid; Humans; Neuralgia | 2013 |
Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord.
Topics: Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Humans; Mice; Mice, Inbred ICR; Mi | 2012 |
[Case of acute exacerbation of neuropathic cancer pain rapidly relieved by simultaneous oral intake of immediate release oxycodone and pregabalin].
Topics: Acute Disease; Administration, Oral; Adult; Bone Neoplasms; Drug Combinations; gamma-Aminobutyric Ac | 2012 |
Effects of oxymatrine on the neuropathic pain induced by chronic constriction injury in mice.
Topics: Alkaloids; Animals; Chronic Disease; Constriction; Disease Models, Animal; Dose-Response Relationshi | 2012 |
Optimised protocol design for the screening of analgesic compounds in neuropathic pain.
Topics: Amines; Analgesics; Animals; Cohort Studies; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug | 2012 |
Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Evaluation, Prec | 2012 |
Relief of hypersensitivity after nerve injury from systemic donepezil involves spinal cholinergic and γ-aminobutyric acid mechanisms.
Topics: Animals; Atropine; Bicuculline; Cholinergic Agents; Cholinesterase Inhibitors; Disease Models, Anima | 2013 |
Antioxidants and gabapentin prevent heat hypersensitivity in a neuropathic pain model.
Topics: Amines; Animals; Antioxidants; Calcium Channels; Catalase; Cyclohexanecarboxylic Acids; Drug Combina | 2013 |
Intrathecal ketamine and pregabalin at sub-effective doses synergistically reduces neuropathic pain without motor dysfunction in mice.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; gamma-Aminobutyric Acid; Hyperalgesia; | 2013 |
Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohe | 2013 |
Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
Topics: Adult; Aged; Ambulatory Care; Analgesics; Cost Savings; Cost-Benefit Analysis; Female; Follow-Up Stu | 2013 |
Combined antiallodynic effect of Neurotropin® and pregabalin in rats with L5-spinal nerve ligation.
Topics: Administration, Oral; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid | 2013 |
Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Cyclohexanecarboxylic Acids; Cytokines; D | 2013 |
Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.
Topics: Animals; Blotting, Western; Cell Death; Disease Models, Animal; Excitatory Postsynaptic Potentials; | 2002 |
Gabapentin in the treatment of SUNCT syndrome.
Topics: Acetates; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Am | 2002 |
SUNCT responsive to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Conjunctiva; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2002 |
[Neuropathic pain. Often mishandled for years].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2002 |
Gabbing about gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; gamma-Ami | 2003 |
[Case report on a patient with SUNCT-syndrome].
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Functional Laterality; Gabapentin | 2003 |
Patient pages. Treatment of postherpetic neuralgia.
Topics: Administration, Topical; Adult; Chickenpox; Chickenpox Vaccine; Child; gamma-Aminobutyric Acid; Gels | 2003 |
Comment on: Serpell et al., gabapentin in neuropathic pain syndromes: a randomised double-blind, placebo controlled trial (Pain 2002; 99: 557-66).
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; ga | 2003 |
Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Gabapentin; | 2003 |
Great auricular neuralgia: a case report.
Topics: Acetates; Aged; Amines; Analgesics; Cervical Vertebrae; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2003 |
[Efficacy and tolerability of gabapentin in the treatment of patients with neuropathic pain. Results of an observational study involving 5620 patients].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 2003 |
Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn.
Topics: Animals; Denervation; Disease Models, Animal; Excitatory Amino Acid Antagonists; Excitatory Postsyna | 2003 |
Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cycloh | 2003 |
Conquering peripheral neuropathic pain.
Topics: Acetates; Amines; Analgesics; Anesthetics, Local; Antidepressive Agents, Tricyclic; Cyclohexanecarbo | 2004 |
Pharmacological characterisation of the rat brachial plexus avulsion model of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Analysis of Variance; Animals; Brachial Plexus; Brachial Plexus Neurop | 2004 |
Treatment of postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Age Factors; Aged; Amines; Analgesics; Analgesics, Opioid; Antidepressive | 2004 |
Oxcarbazepine (Trileptal) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2004 |
[Peripheral neuropathic pain and epilepsy].
Topics: Analgesics; Anticonvulsants; Clinical Trials as Topic; Epilepsies, Partial; gamma-Aminobutyric Acid; | 2004 |
[Reducing pain by new forms of therapy].
Topics: Analgesics; Anticonvulsants; Calcium Channels; Drug Therapy, Combination; gamma-Aminobutyric Acid; H | 2004 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Psychometric properties of the Medical Outcomes Study Sleep measure.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Clinical Trials as Topic; Female; gamma-Aminobutyri | 2005 |
Pregabalin for painful neuropathy.
Topics: Anticonvulsants; Diabetic Neuropathies; gamma-Aminobutyric Acid; Humans; Neuralgia; Peripheral Nervo | 2005 |
[Questions to the Drug Committee about administration of Lyrica].
Topics: Anticonvulsants; Denmark; Drug and Narcotic Control; gamma-Aminobutyric Acid; Humans; Neuralgia; Pai | 2005 |
Combination therapy for neuropathic pain--which drugs, which combination, which patients?
Topics: Amines; Analgesia; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2005 |
Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Diterpenes; Gabape | 2005 |
Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain.
Topics: Amines; Amitriptyline; Analgesics; Animals; Behavior, Animal; Benzoxazines; Blotting, Western; Cyclo | 2005 |
Gene transfer of glutamic acid decarboxylase reduces neuropathic pain.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Gene Transfer Techniques; Genetic Therapy; | 2005 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2005 |
Treatment of peripheral neuropathic pain: a simulation model.
Topics: Anticonvulsants; Cohort Studies; Decision Support Techniques; gamma-Aminobutyric Acid; Humans; Model | 2006 |
Morphine, gabapentin, or their combination for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Nephropathies; Drug Therapy, Combination; | 2005 |
Gabapentin in dermatology.
Topics: Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Lyme Neuro | 2005 |
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Amines; Analgesics; Animals; Aspartic Acid; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory | 2005 |
Occipital neuralgia secondary to respiratory tract infection.
Topics: Amines; Amitriptyline; Analgesics, Non-Narcotic; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnos | 2005 |
Pregabalin associated asterixis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Analgesics; Dyskinesia, Drug-Induced; Female; gamma-Amino | 2005 |
Pregabalin (lyrica) for neuropathic pain and epilepsy.
Topics: Costs and Cost Analysis; Drug Interactions; Epilepsy; gamma-Aminobutyric Acid; Humans; Neuralgia; Pr | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Spinal nerve ligation does not alter the expression or function of GABA(B) receptors in spinal cord and dorsal root ganglia of the rat.
Topics: Animals; Baclofen; Denervation; Disease Models, Animal; GABA Agonists; gamma-Aminobutyric Acid; Gang | 2006 |
Economic evaluation of oral treatments for neuropathic pain.
Topics: Administration, Oral; Amines; Amitriptyline; Analgesics; Carbamazepine; Cohort Studies; Cost-Benefit | 2006 |
Experience with gabapentin for neuropathic pain in adolescents: report of five cases.
Topics: Adolescent; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2006 |
Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.
Topics: Aged; Amines; Amitriptyline; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; | 2006 |
Abnormal blink reflex studies in a patient with supraorbital neuralgia.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Blinking; Cyclohexanecarboxylic | 2006 |
Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclohexanols; Dose-Response Relationship, | 2006 |
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met | 2006 |
Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients.
Topics: Adolescent; Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neu | 2006 |
Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Calcium Channels; | 2007 |
Cognitive function impairment in patients with neuropathic pain under standard conditions of care.
Topics: Adult; Aged; Amines; Analgesics; Cognition Disorders; Cohort Studies; Cyclohexanecarboxylic Acids; F | 2007 |
[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy].
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Clomipramine; Cyclohexanecarboxylic A | 2006 |
Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; gamma-Aminobutyric Ac | 2007 |
[3H] pregabalin binding is increased in ipsilateral dorsal horn following chronic constriction injury.
Topics: Afferent Pathways; Analgesics; Animals; Binding, Competitive; Calcium Channel Blockers; Calcium Chan | 2007 |
The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain.
Topics: Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal | 2007 |
Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain.
Topics: Acetamides; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cyclohex | 2007 |
Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Duloxetine Hydrochloride; Ga | 2007 |
Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain.
Topics: Aged; Anticonvulsants; gamma-Aminobutyric Acid; Heart Failure; Humans; Male; Middle Aged; Neuralgia; | 2007 |
Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain.
Topics: Adenoviridae; Animals; gamma-Aminobutyric Acid; Genetic Therapy; Glutamate Decarboxylase; Isoenzymes | 2007 |
Vagoglossopharyngeal neuralgia: a rare case of sincope responding to pregabalin.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Glossopharyngeal Nerve Diseases; Humans; Male; Middle Aged | 2007 |
[Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions].
Topics: Analgesics; Calcium Channels; Central Nervous System; Clinical Trials as Topic; gamma-Aminobutyric A | 2007 |
[Gabapentin mitigates neuropathic pain in cancer patients--a case report].
Topics: Adenocarcinoma; Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2007 |
Gabapentin for the treatment of neuropathic pain in a pregnant horse.
Topics: Amines; Analgesics; Animals; Colic; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2007 |
Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Hyperalgesia; Male; Mi | 2008 |
[Pregabalin in the treatment of neuropathic pain].
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain; Pregabalin | 2007 |
A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury.
Topics: Animals; Behavior, Animal; gamma-Aminobutyric Acid; Ganglia, Spinal; Gene Transfer Techniques; Genet | 2008 |
Gabapentin and sexual dysfunction: report of two cases.
Topics: Adolescent; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2008 |
Hemichorea associated with gabapentin therapy with hypoperfusion in contralateral basal ganglion - a case of a paraplegic patient with neuropathic pain.
Topics: Adult; Amines; Analgesics; Basal Ganglia; Cerebrovascular Circulation; Chorea; Cyclohexanecarboxylic | 2008 |
Patient compliance with neuropathic pain treatment.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2008 |
Ronald Tasker Award: Intrathecal transplantation of a human neuronal cell line for the treatment of neuropathic pain in a spinal cord injury model.
Topics: Animals; Carcinoma, Embryonal; Cell Line, Tumor; gamma-Aminobutyric Acid; Glycine; Injections, Spina | 2007 |
Gabapentin as a novel treatment for postherpetic neuralgia.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amin | 1996 |
Release of gamma-aminobutyric acid in the dorsal horn and suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats.
Topics: Animals; Chromatography, High Pressure Liquid; Electric Stimulation Therapy; Electrodes, Implanted; | 1996 |
Psychomotor agitation following gabapentin use in brain injury.
Topics: Acetates; Adult; Akathisia, Drug-Induced; Amines; Analgesics; Brain Injuries; Cyclohexanecarboxylic | 1997 |
Spinal bicuculline produces hypersensitivity of dorsal horn neurons: effects of excitatory amino acid antagonists.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Bicuculline; Blood Press | 1998 |
[Treatment of neuropathic pain with gabapentin ++].
Topics: Acetates; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 1998 |
The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 1998 |
Symptomatic treatment of painful neuropathy.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 1998 |
[Use of gabapentin in glossopharyngeal neuralgia].
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobut | 1999 |
Gabapentin for postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 1999 |
A single intrathecal injection of GABA permanently reverses neuropathic pain after nerve injury.
Topics: Animals; Cold Temperature; Drug Administration Schedule; Female; gamma-Aminobutyric Acid; Hyperalges | 1999 |
Neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Drug The | 1999 |
Using gabapentin to treat neuropathic pain.
Topics: Acetates; Adult; Amines; Analgesics; Anticonvulsants; Costs and Cost Analysis; Cyclohexanecarboxylic | 1999 |
Gabapentin-induced anorgasmia.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 1999 |
Gabapentin vs amitriptyline for the treatment of peripheral neuropathy.
Topics: Acetates; Amines; Amitriptyline; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Drug Adminis | 2000 |
Amino acids in spinal dorsal horn of patients during surgery for neuropathic pain or spasticity.
Topics: Amino Acids; Aspartic Acid; Chromatography, High Pressure Liquid; Extracellular Space; Feasibility S | 2000 |
Herpes zoster.
Topics: Acetates; Acute Disease; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2000 |
Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Calcium Channels; Cyclohexanecarboxylic Acids; Disease Models | 2000 |
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2000 |
SUNCT syndrome responsive to gabapentin (Neurontin).
Topics: Acetates; Amines; Analgesics; Conjunctival Diseases; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2000 |
[Treatment of chronic and neuropathic pain. Established amitriptyline and the new gabapentin].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; | 2000 |
The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat.
Topics: Acetates; Amines; Analgesics; Animals; Baclofen; Cyclohexanecarboxylic Acids; Electric Stimulation; | 2001 |
Three-month follow-up of shoulder-hand syndrome induced by phenobarbital and treated with gabapentin.
Topics: Acetaminophen; Acetates; Amines; Analgesics; Anticonvulsants; Arthralgia; Cyclohexanecarboxylic Acid | 2001 |
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats.
Topics: Acetates; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Res | 2001 |
[Pharmacotherapy for neuropathic pain caused by injury to the afferent nerve fibers].
Topics: Acetates; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; | 2001 |
Gabapentin therapy for genitofemoral and ilioinguinal neuralgia.
Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Femoral Neuropathy; Gabapen | 2001 |
Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin.
Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |
Gabapentin: resistant neuropathic pain and malignancy.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Resistance; Gabapentin; gamma | 2001 |